https://lymphoma-stg.clarovantdigital.com/library/is-early-hematopoietic-stem-cell-transplantation-necessary-in-mantle-cell-lymphoma/2025-12-09T22:32:25+00:00https://lymphoma-stg.clarovantdigital.com/library/romidepsin-for-the-treatment-of-relapsed-refractory-peripheral-t-cell-lymphoma-pivotal-study-update-demonstrates-durable-responses/2025-12-09T22:27:36+00:00https://lymphoma-stg.clarovantdigital.com/library/idelalisib-and-rituximab-in-relapsed-chronic-lymphocytic-leukemia/2025-12-09T22:23:59+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-plus-chlorambucil-in-patients-with-cll-and-coexisting-conditions/2025-12-09T22:20:05+00:00https://lymphoma-stg.clarovantdigital.com/library/event-free-survival-at-24-months-is-a-robust-end-point-for-disease-related-outcome-in-diffuse-large-b-cell-lymphoma-treated-with-immunochemotherapy/2025-12-09T22:12:15+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-place-of-residence-and-treatment-on-survival-outcomes-in-patients-with-diffuse-large-b-cell-lymphoma-in-british-columbia/2025-12-09T22:08:48+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-for-hodgkin-lymphoma-patients-failing-autologous-or-autologous-and-allogeneic-stem-cell-transplantation/2025-12-09T22:05:08+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-phase-ii-study-of-mogamulizumab-kw-0761-a-defucosylated-anti-cc-chemokine-receptor-4-antibody-in-patients-with-relapsed-peripheral-t-cell-lymphoma-and-cutaneous-t-cell-lymphoma/2025-12-09T21:59:56+00:00https://lymphoma-stg.clarovantdigital.com/library/how-we-treat-richter-syndrome/2025-12-09T21:32:06+00:00https://lymphoma-stg.clarovantdigital.com/library/research-finds-first-line-therapy-response-linked-to-non-hodgkina%c2%80%c2%99s-lymphoma-survival/2025-12-09T21:10:44+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicentre-phase-ii-study-of-vorinostat-in-patients-with-relapsed-or-refractory-indolent-b-cell-non-hodgkin-lymphoma-and-mantle-cell-lymphoma/2025-04-14T21:23:11+00:00https://lymphoma-stg.clarovantdigital.com/library/bone-marrow-fdg-pet-ct-cannot-replace-bone-marrow-biopsy-in-diffuse-large-b-cell-lymphoma/2025-12-09T20:43:48+00:00https://lymphoma-stg.clarovantdigital.com/library/bulky-aggressive-b-cell-lymphoma-to-radiate-or-not-to-radiatea%c2%80%c2%94that-is-the-question/2025-12-09T20:41:06+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-versus-a-watch-and-wait-approach-in-patients-with-advanced-stage-asymptomatic-non-bulky-follicular-lymphoma-an-open-label-randomised-phase-3-trial/2024-12-19T19:32:31+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-multiple-primary-malignancies-following-treatment-of-hodgkin-lymphoma/2025-12-09T20:07:00+00:00https://lymphoma-stg.clarovantdigital.com/library/what-is-the-value-of-the-routine-use-of-patient-reported-outcome-measures-toward-improvement-of-patient-outcomes-processes-of-care-and-health-service-outcomes-in-cancer-care-a-systematic-review-of/2025-12-09T20:02:59+00:00https://lymphoma-stg.clarovantdigital.com/library/fdg-pet-in-cll-today/2025-12-09T20:00:17+00:00https://lymphoma-stg.clarovantdigital.com/library/psychological-and-behavioral-approaches-to-cancer-pain-management/2025-05-23T20:30:04+00:00https://lymphoma-stg.clarovantdigital.com/library/physical-activity-in-relation-to-risk-of-hematologic-cancers-a-systematic-review-and-meta-analysis/2025-12-09T19:56:39+00:00https://lymphoma-stg.clarovantdigital.com/library/active-idiotypic-vaccination-versus-control-immunotherapy-for-follicular-lymphoma/2025-12-09T19:54:14+00:00https://lymphoma-stg.clarovantdigital.com/library/time-has-come-for-immunotherapy-in-ptcl/2025-12-09T19:52:11+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-low-dose-alemtuzumab-with-fludarabine-and-cyclophosphamide-prolongs-progression-free-survival-in-high-risk-cll/2025-12-09T19:43:03+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-versus-ofatumumab-in-previously-treated-chronic-lymphoid-leukemia/2025-12-09T19:40:16+00:00https://lymphoma-stg.clarovantdigital.com/library/eradication-of-bone-marrow-minimal-residual-disease-may-prompt-early-treatment-discontinuation-in-cll/2025-12-09T19:34:45+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-bendamustine-in-combination-with-fludarabine-in-primary-chronic-lymphocytic-leukemia-cells/2025-12-09T19:30:30+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-dacetuzumab-sgn-40-in-patients-with-relapsed-diffuse-large-b-cell-lymphoma-dlbcl-and-correlative-analyses-of-patient-specific-factors/2025-12-09T19:28:30+00:00https://lymphoma-stg.clarovantdigital.com/library/a-new-prognostic-score-for-cll/2025-12-09T19:25:11+00:00https://lymphoma-stg.clarovantdigital.com/library/a-prospective-study-of-mediastinal-gray-zone-lymphoma/2025-12-09T19:22:22+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-lymphoma-in-patients-with-inflammatory-bowel-disease-treated-with-azathioprine-and-6-mercaptopurine/2025-12-09T19:19:57+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-on-prognostic-factors-and-treatment-in-peripheral-t-cell-lymphomas-a-study-from-the-swedish-lymphoma-registry/2025-12-09T19:14:39+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-diabetes-mellitus-in-long-term-survivors-of-hodgkin-lymphoma/2025-12-09T19:11:55+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-combined-with-r-chop-overcomes-negative-prognostic-impact-of-nona%c2%80%c2%93germinal-center-b-cell-phenotype-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-a-phase-ii-study/2025-12-09T18:48:30+00:00https://lymphoma-stg.clarovantdigital.com/library/vitamin-d-deficiency-impairs-rituximab-mediated-cellular-cytotoxicity-and-outcome-of-patients-with-diffuse-large-b-cell-lymphoma-treated-with-but-not-without-rituximab/2025-12-09T18:27:01+00:00https://lymphoma-stg.clarovantdigital.com/library/recommendations-for-initial-evaluation-staging-and-response-assessment-of-hodgkin-and-non-hodgkin-lymphoma-the-lugano-classification/2026-01-02T14:45:08+00:00https://lymphoma-stg.clarovantdigital.com/library/precision-treatment-of-distinct-molecular-subtypes-of-diffuse-large-b-cell-lymphoma-ascribing-treatment-based-on-the-molecular-phenotype/2025-12-09T18:10:22+00:00https://lymphoma-stg.clarovantdigital.com/library/utility-of-routine-post-therapy-surveillance-imaging-in-diffuse-large-b-cell-lymphoma-2/2025-12-19T21:07:08+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-comparative-effectiveness-in-elderly-diffuse-large-b-cell-lymphoma-patients-a-surveillance-epidemiology-and-end-results-medicare-analysis/2025-12-09T16:49:01+00:00https://lymphoma-stg.clarovantdigital.com/library/exercise-and-risk-of-major-cardiovascular-events-in-adult-survivors-of-childhood-hodgkin-lymphoma/2025-12-09T16:46:05+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-burkitt-lymphoma-in-adults/2025-12-09T16:39:09+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-hematopoietic-stem-cell-transplantation-for-relapsed-and-refractory-hodgkin-lymphoma/2025-12-09T16:36:37+00:00https://lymphoma-stg.clarovantdigital.com/library/optimization-of-rituximab-for-the-treatment-of-diffuse-large-b-cell-lymphoma-ii-extended-rituximab-exposure-time-in-the-smarte-r-chop-14-trial-of-the-german-high-grade-non-hodgkin-lymphoma-study-gr/2025-12-09T16:35:05+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-results-of-first-salvage-treatment-in-cll-patients-treated-initially-with-fcr-fludarabine-cyclophosphamide-rituximab/2025-12-09T16:30:19+00:00https://lymphoma-stg.clarovantdigital.com/library/biosimilars-the-science-of-extrapolation/2025-12-09T16:27:50+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin/2025-12-09T16:26:15+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-optimizing-outcome-in-the-context-of-clinical-and-biologic-heterogeneity/2025-12-08T21:51:51+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-mediastinal-b-cell-lymphoma-and-mediastinal-gray-zone-lymphoma-do-they-require-a-unique-therapeutic-approach/2025-12-08T21:49:00+00:00https://lymphoma-stg.clarovantdigital.com/library/managing-high-risk-cll-during-transition-to-a-new-treatment-era-stem-cell-transplantation-or-novel-agents/2025-12-05T21:39:33+00:00https://lymphoma-stg.clarovantdigital.com/library/transplant-for-cll-still-an-option/2025-12-05T21:38:30+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-evolving-management-strategies/2025-12-05T21:28:24+00:00https://lymphoma-stg.clarovantdigital.com/library/transformed-follicular-non-hodgkin-lymphoma/2025-12-05T21:25:57+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-demonstrates-objective-responses-in-a-phase-2-study-of-relapsed-refractory-dlbcl-with-variable-cd30-expression/2025-12-05T21:23:45+00:00https://lymphoma-stg.clarovantdigital.com/library/ibritumomab-consolidation-after-3-cycles-of-chop-plus-radiotherapy-in-high-risk-limited-stage-aggressive-b-cell-lymphoma-swog-s0313/2025-12-05T21:22:08+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1-2-study-of-mogamulizumab-a-defucosylated-anti-ccr4-antibody-in-previously-treated-patients-with-cutaneous-t-cell-lymphoma/2025-12-05T21:17:40+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-second-malignancies-in-patients-with-early-stage-classical-hodgkins-lymphoma-treated-in-a-modern-era/2025-12-05T21:12:19+00:00https://lymphoma-stg.clarovantdigital.com/library/surveillance-until-rituximab-retreatment-does-not-increase-anxiety-in-non-hodgkin-lymphoma/2025-12-05T20:31:21+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-t-cells-that-express-an-anti-cd19-chimeric-antigen-receptor-induce-remissions-of-b-cell-malignancies-that-progress-after-allogeneic-hematopoietic-stem-cell-transplantation-without-causing-g/2025-12-05T20:11:58+00:00https://lymphoma-stg.clarovantdigital.com/library/eliminating-minimal-residual-disease-as-a-therapeutic-end-point-working-toward-cure-for-patients-with-cll/2025-12-05T19:08:55+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-relapsed-classical-hodgkin-lymphoma-after-autologous-stem-cell-transplant/2025-12-05T19:07:09+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-selection-and-outcomes-in-early-stage-classical-hodgkin-lymphoma-analysis-of-the-national-cancer-data-base/2025-12-05T18:48:57+00:00https://lymphoma-stg.clarovantdigital.com/library/abnormal-exercise-response-in-long-term-survivors-of-hodgkin-lymphoma-treated-with-thoracic-irradiation-evidence-of-cardiac-autonomic-dysfunction-and-impact-on-outcomes/2025-05-27T16:39:57+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-in-patients-with-hodgkin-lymphoma-and-a-failed-allogeneic-stem-cell-transplantation-results-from-a-named-patient-program-at-four-italian-centers/2025-12-05T18:42:14+00:00https://lymphoma-stg.clarovantdigital.com/library/fdg-pet-ct-in-follicular-lymphoma-a-case-based-evidence-review/2025-12-05T18:36:45+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-remissions-in-a-pivotal-phase-2-study-of-brentuximab-vedotin-in-relapsed-or-refractory-hodgkin-lymphoma/2025-12-04T21:56:27+00:00https://lymphoma-stg.clarovantdigital.com/library/very-low-utility-of-surveillance-imaging-in-early-stage-classic-hodgkin-lymphoma-treated-with-a-combination-of-doxorubicin-bleomycin-vinblastine-and-dacarbazine-and-radiation-therapy/2025-12-04T21:11:07+00:00https://lymphoma-stg.clarovantdigital.com/library/farm-characteristics-allergy-symptoms-and-risk-of-non-hodgkin-lymphoid-neoplasms-in-the-agricultural-health-study/2025-12-04T21:07:54+00:00https://lymphoma-stg.clarovantdigital.com/library/increased-incidence-of-fractures-in-recipients-of-hematopoietic-stem-cell-transplantation/2025-12-04T21:04:41+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-g-plus-fludarabine-cyclophosphamide-g-fc-or-bendamustine-g-b-in-the-initial-therapy-of-cll-patients-the-phase-1b-galton-trial/2025-12-04T21:00:58+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comparative-study-of-molecular-characteristics-of-diffuse-large-b-cell-lymphoma-from-patients-with-and-without-human-immunodeficiency-virus-infection/2025-12-04T20:54:28+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-chronic-lymphocytic-leukemia-after-discontinuing-ibrutinib/2025-12-04T20:48:53+00:00https://lymphoma-stg.clarovantdigital.com/library/population-based-study-on-the-impact-of-the-familial-form-of-waldenstra%c2%b6m-macroglobulinemia-on-overall-survival/2025-12-04T20:46:28+00:00https://lymphoma-stg.clarovantdigital.com/library/hope-for-high-risk-chronic-lymphocytic-leukemia-relapsing-after-allogeneic-stem-cell-transplantation/2025-12-04T20:26:22+00:00https://lymphoma-stg.clarovantdigital.com/library/an-open-label-phase-2-trial-of-entospletinib-gs-9973-a-selective-spleen-tyrosine-kinase-inhibitor-in-chronic-lymphocytic-leukemia/2025-12-04T20:23:18+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-lenalidomide-and-rituximab-overcomes-rituximab-resistance-in-patients-with-indolent-b-cell-and-mantle-cell-lymphomas/2025-12-04T19:42:13+00:00https://lymphoma-stg.clarovantdigital.com/library/the-biology-and-treatment-of-plasmablastic-lymphoma/2026-09-02T16:13:35+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-iii-trial-comparing-abvd-plus-radiotherapy-with-the-stanford-v-regimen-in-patients-with-stages-i-or-ii-locally-extensive-bulky-mediastinal-hodgkin-lymphoma/2025-05-27T16:35:02+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-fdg-pet-prior-to-autologous-stem-cell-transplantation-for-relapsed-and-refractory-diffuse-large-b-cell-lymphoma/2025-12-04T19:36:41+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-of-treatment-naa%c2%afve-and-previously-treated-patients-with-cll-and-sll-receiving-single-agent-ibrutinib-2/2025-12-04T19:34:10+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-in-non-hodgkin-lymphoma-biological-perspectives-and-therapeutic-opportunities/2025-12-04T19:28:52+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-disease-after-hodgkin-lymphoma-treatment/2025-12-04T19:26:23+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-re-up-strategy-is-drug-sparing-therapy/2025-12-04T19:24:02+00:00https://lymphoma-stg.clarovantdigital.com/library/the-bruton-tyrosine-kinase-inhibitor-ibrutinib-with-chemoimmunotherapy-in-patients-with-chronic-lymphocytic-leukemia/2025-12-04T18:44:34+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-idelalisib-and-rituximab-are-unacceptably-toxic-in-patients-with-relapsed-refractory-indolent-lymphoma/2025-12-04T15:32:26+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-rituximab-every-2-months-is-more-toxic-than-every-3-months-in-patients-with-non-hodgkin-lymphoma/2025-12-04T15:29:03+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-checkpoint-blockade-in-hematologic-malignancies/2025-12-04T15:27:14+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-mcl-patients-treated-with-single-agent-ibrutinib-updated-safety-and-efficacy-results/2025-12-04T15:16:21+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-intergroup-trial-of-alisertib-in-relapsed-and-refractory-peripheral-t-cell-lymphoma-and-transformed-mycosis-fungoides/2025-12-04T15:12:58+00:00https://lymphoma-stg.clarovantdigital.com/library/whole-genome-sequencing-reveals-oncogenic-mutations-in-mycosis-fungoides/2025-12-04T15:05:45+00:00https://lymphoma-stg.clarovantdigital.com/library/belinostat-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-results-of-the-pivotal-phase-ii-belief-cln-19-study/2025-12-04T00:13:10+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-bleomycin-and-vincristine-dose-reductions-in-patients-with-advanced-hodgkin-lymphoma-treated-with-beacopp/2025-12-04T00:08:49+00:00https://lymphoma-stg.clarovantdigital.com/library/romidepsin-for-the-treatment-of-peripheral-t-cell-lymphoma/2025-12-04T00:06:37+00:00https://lymphoma-stg.clarovantdigital.com/library/survivors-of-hodgkin-lymphoma-at-increased-risk-for-head-and-neck-cancer/2025-12-04T00:04:38+00:00https://lymphoma-stg.clarovantdigital.com/library/utility-of-baseline-18fdg-pet-ct-functional-parameters-in-defining-prognosis-of-primary-mediastinal-thymic-large-b-cell-lymphoma/2025-12-04T00:01:46+00:00https://lymphoma-stg.clarovantdigital.com/library/salvage-chemotherapy-and-autologous-stem-cell-transplantation-for-transformed-indolent-lymphoma/2025-12-03T23:59:34+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-transformed-follicular-lymphoma-in-the-modern-era/2025-12-03T23:57:29+00:00https://lymphoma-stg.clarovantdigital.com/library/early-relapse-of-follicular-lymphoma-after-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-defines-patients-at-high-risk-for-death/2025-12-03T23:54:43+00:00https://lymphoma-stg.clarovantdigital.com/library/a-new-and-validated-clinical-prognostic-model-epi-for-enteropathy-associated-t-cell-lymphoma/2025-12-03T23:52:44+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-maintenance-therapy-in-diffuse-large-b-cell-lymphoma/2025-12-03T23:50:25+00:00https://lymphoma-stg.clarovantdigital.com/library/heart-failure-and-asymptomatic-left-ventricular-systolic-dysfunction-in-lymphoma-survivors-treated-with-autologous-stem-cell-transplantation/2025-12-03T23:47:05+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-adapted-treatment-improves-outcome-of-patients-with-stages-i-ii-hodgkin-lymphoma/2025-12-03T23:42:03+00:00https://lymphoma-stg.clarovantdigital.com/library/amc-048-modified-codox-m-ivac-rituximab-is-safe-and-effective-for-hiv-associated-burkitt-lymphoma/2025-05-23T20:07:57+00:00https://lymphoma-stg.clarovantdigital.com/library/final-results-of-a-prospective-evaluation-of-the-predictive-value-of-interim-positron-emission-tomography-in-patients-with-diffuse-large-b-cell-lymphoma-treated-with-r-chop-14/2025-12-03T19:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/infused-autograft-lymphocyte-to-monocyte-ratio-and-survival-in-t-cell-lymphoma-post-autologous-peripheral-blood-hematopoietic-stem-cell-transplantation/2025-12-03T19:39:21+00:00https://lymphoma-stg.clarovantdigital.com/library/central-nervous-system-relapse-in-peripheral-t-cell-lymphomas-a-swedish-lymphoma-registry-study/2025-12-03T19:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/the-biology-and-management-of-systemic-anaplastic-large-cell-lymphoma/2025-12-03T19:32:33+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-investigator-initiated-study-of-brentuximab-vedotin-in-mycosis-fungoides-and-sazary-syndrome-with-variable-cd30-expression-level/2025-12-03T19:26:57+00:00https://lymphoma-stg.clarovantdigital.com/library/mechanisms-of-action-of-lenalidomide-in-b-cell-non-hodgkin-lymphoma/2025-12-03T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/the-mtorc1-inhibitor-everolimus-has-antitumor-activity-in-vitro-and-produces-tumor-responses-in-patients-with-relapsed-t-cell-lymphoma/2025-12-03T18:52:32+00:00https://lymphoma-stg.clarovantdigital.com/library/quality-of-life-of-patients-with-chronic-lymphocytic-leukaemia-in-the-netherlands/2025-12-03T18:47:28+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-treatment-of-cll-integrating-biology-and-functional-status/2025-12-03T18:42:42+00:00https://lymphoma-stg.clarovantdigital.com/library/a-drive-through-cellular-therapy-for-cll-in-2015-allogeneic-cell-transplantation-and-cars-2/2025-12-03T18:37:59+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-therapies-in-cll-mechanisms-of-resistance-and-strategies-for-management/2025-12-03T18:36:01+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-course-of-patients-with-stage-ia-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-report-from-the-german-hodgkin-study-group/2025-12-03T18:31:19+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-melanoma-among-survivors-of-non-hodgkin-lymphoma/2025-12-03T18:27:38+00:00https://lymphoma-stg.clarovantdigital.com/library/activity-with-ibrutinib-in-mantle-cell-lymphoma-patients-with-central-nervous-system-relapse/2025-12-02T22:12:21+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-rituximab-cyclophosphamide-doxorubicin-and-prednisone-with-bortezomib-vr-cap-or-vincristine-r-chop-for-non-gcb-dlbcl/2025-12-02T22:10:38+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-selection-and-survival-outcomes-in-early-stage-diffuse-large-b-cell-lymphoma-do-we-still-need-consolidative-radiotherapy/2025-05-27T16:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-a-phase-ii-trial-of-brentuximab-vedotin-for-cd30-cutaneous-t-cell-lymphoma-and-lymphomatoid-papulosis/2025-12-02T22:04:21+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-waldenstra%c2%b6m-macroglobulinemia/2025-12-02T22:00:02+00:00https://lymphoma-stg.clarovantdigital.com/library/extranodal-marginal-zone-lymphoma-of-mucosa-associated-lymphoid-tissue-of-the-salivary-glands/2025-12-02T21:56:39+00:00https://lymphoma-stg.clarovantdigital.com/library/combined-modality-therapy-for-early-stage-diffuse-large-b-cell-lymphoma-knowing-when-to-quit/2025-05-27T16:16:48+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-the-treatment-of-secondary-cns-lymphoma/2025-12-02T21:21:45+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-ii-trial-comparing-obinutuzumab-ga101-with-rituximab-in-patients-with-relapsed-cd20-indolent-b-cell-non-hodgkin-lymphoma/2025-12-02T21:18:30+00:00https://lymphoma-stg.clarovantdigital.com/library/high-doses-of-antimetabolites-followed-by-high-dose-sequential-chemoimmunotherapy-and-autologous-stem-cell-transplantation-in-patients-with-systemic-b-cell-lymphoma-and-secondary-cns-involvement/2025-12-02T21:07:03+00:00https://lymphoma-stg.clarovantdigital.com/library/time-trends-in-rates-of-hodgkin-lymphoma-histologic-subtypes-true-incidence-changes-or-evolving-diagnostic-practice/2025-12-02T20:56:20+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-activity-of-btk-inhibitor-ibrutinib-combined-with-ofatumumab-in-chronic-lymphocytic-leukemia/2025-12-02T20:47:46+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-trial-of-lenalidomide-alone-versus-lenalidomide-plus-rituximab-in-patients-with-recurrent-follicular-lymphoma-calgb-50401/2025-12-02T20:31:10+00:00https://lymphoma-stg.clarovantdigital.com/library/no-evidence-of-transmission-of-chronic-lymphocytic-leukemia-through-blood-transfusion/2025-12-02T20:14:46+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-lymphoma-of-bone-imaging-findings-to-improve-diagnosis-of-a-rarely-considered-disease-prior-to-biopsy/2025-12-02T20:13:12+00:00https://lymphoma-stg.clarovantdigital.com/library/cell-of-origin-of-transformed-follicular-lymphoma/2025-12-02T20:09:43+00:00https://lymphoma-stg.clarovantdigital.com/library/new-mutation-in-hairy-cell-leukemia/2025-12-02T19:30:11+00:00https://lymphoma-stg.clarovantdigital.com/library/some-hodgkin-lymphoma-patients-do-not-need-radiotherapy/2025-05-27T16:14:41+00:00https://lymphoma-stg.clarovantdigital.com/library/chemoimmunotherapy-for-relapsed-refractory-and-progressive-17p13-deleted-chronic-lymphocytic-leukemia-cll-combining-pentostatin-alemtuzumab-and-low-dose-rituximab-is-effective-and-tolerable-and-li/2025-12-02T19:21:41+00:00https://lymphoma-stg.clarovantdigital.com/library/cd38-in-hairy-cell-leukemia-is-a-marker-of-poor-prognosis-and-a-new-target-for-therapy/2025-12-02T19:18:22+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-mutant-braf-in-relapsed-or-refractory-hairy-cell-leukemia/2025-12-02T19:13:06+00:00https://lymphoma-stg.clarovantdigital.com/library/non-hodgkin-lymphoma-in-children-and-adolescents-progress-through-effective-collaboration-current-knowledge-and-challenges-ahead/2025-05-23T20:10:11+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-adapted-therapy-for-early-stage-extranodal-nasal-type-nk-t-cell-lymphoma-analysis-from-a-multicenter-study/2025-05-27T16:09:11+00:00https://lymphoma-stg.clarovantdigital.com/library/topical-resiquimod-can-induce-disease-regression-and-enhance-t-cell-effector-functions-in-cutaneous-t-cell-lymphoma/2025-12-02T19:08:29+00:00https://lymphoma-stg.clarovantdigital.com/library/histologic-transformation-in-marginal-zone-lymphomas/2025-12-02T19:05:54+00:00https://lymphoma-stg.clarovantdigital.com/library/temsirolimus-plus-bortezomib-safe-active-for-relapsed-refractory-b-cell-nhl/2025-12-02T19:03:41+00:00https://lymphoma-stg.clarovantdigital.com/library/cutaneous-lymphoma-international-consortium-study-of-outcome-in-advanced-stages-of-mycosis-fungoides-and-sazary-syndrome-effect-of-specific-prognostic-markers-on-survival-and-development-of-a-p/2025-12-02T18:47:58+00:00https://lymphoma-stg.clarovantdigital.com/library/routine-imaging-for-diffuse-large-b-cell-lymphoma-in-first-complete-remission-does-not-improve-post-treatment-survival/2025-12-02T18:45:45+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cutaneous-b-cell-lymphoma-management-and-patterns-of-recurrence-at-the-multimodality-cutaneous-lymphoma-clinic-of-the-ohio-state-university/2025-12-02T18:44:10+00:00https://lymphoma-stg.clarovantdigital.com/library/activity-of-ibrutinib-in-mantle-cell-lymphoma-patients-with-central-nervous-system-relapse/2025-12-02T18:40:30+00:00https://lymphoma-stg.clarovantdigital.com/library/precision-oncology-framework-for-investigation-of-exercise-as-treatment-for-cancer/2025-12-02T18:38:23+00:00https://lymphoma-stg.clarovantdigital.com/library/b-cell-non-hodgkin-lymphoma-linked-to-coxiella-burnetii/2025-12-02T18:35:36+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-ii-study-of-obinutuzumab-monotherapy-in-symptomatic-previously-untreated-chronic-lymphocytic-leukemia/2025-12-02T18:32:05+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-remissions-after-fcr-chemoimmunotherapy-in-previously-untreated-patients-with-cll/2025-12-02T18:29:27+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-prediction-of-durable-remission-after-first-line-fludarabine-cyclophosphamide-rituximab-in-chronic-lymphocytic-leukemia/2025-12-02T18:26:20+00:00https://lymphoma-stg.clarovantdigital.com/library/fludarabine-cyclophosphamide-and-rituximab-achieves-long-term-disease-free-survival-in-ighv-mutated-chronic-lymphocytic-leukemia/2025-12-02T18:21:33+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-in-transplant-naa%c2%afve-relapsed-refractory-hodgkin-lymphoma-experience-in-30-patients/2025-12-02T18:16:00+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-familial-classical-hodgkin-lymphoma-by-relationship-histology-age-and-sex-a-joint-study-from-five-nordic-countries/2025-12-01T22:09:44+00:00https://lymphoma-stg.clarovantdigital.com/library/presence-of-multiple-recurrent-mutations-confers-poor-trial-outcome-of-relapsed-refractory-cll/2025-12-01T22:02:05+00:00https://lymphoma-stg.clarovantdigital.com/library/partial-reconstitution-of-humoral-immunity-and-fewer-infections-in-patients-with-chronic-lymphocytic-leukemia-treated-with-ibrutinib/2025-12-01T21:57:42+00:00https://lymphoma-stg.clarovantdigital.com/library/expression-of-programmed-cell-death-ligand-1-is-associated-with-poor-overall-survival-in-patients-with-diffuse-large-b-cell-lymphoma/2025-12-01T21:55:44+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-rituximab-lenalidomide-promising-as-first-line-therapy/2025-12-01T21:46:57+00:00https://lymphoma-stg.clarovantdigital.com/library/abt-199-venetoclax-and-bcl-2-inhibitors-in-clinical-development/2025-12-01T21:43:13+00:00https://lymphoma-stg.clarovantdigital.com/library/delayed-efficacy-after-treatment-with-lenalidomide-or-thalidomide-in-patients-with-mucosa-associated-lymphoid-tissue-lymphoma/2025-12-01T21:33:00+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-in-children-and-adolescents-improving-the-therapeutic-index/2025-12-01T21:28:57+00:00https://lymphoma-stg.clarovantdigital.com/library/myc-ig-rearrangements-are-negative-predictors-of-survival-in-dlbcl-patients-treated-with-immunochemotherapy/2025-12-01T21:26:34+00:00https://lymphoma-stg.clarovantdigital.com/library/minimizing-cardiac-risks-with-contemporary-radiation-therapy-for-hodgkin-lymphoma/2025-05-27T14:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/complete-surgical-excision-is-essential-for-the-management-of-patients-with-breast-implanta%c2%80%c2%93associated-anaplastic-large-cell-lymphoma/2025-12-01T21:22:41+00:00https://lymphoma-stg.clarovantdigital.com/library/pregnancy-and-the-risk-of-relapse-in-patients-diagnosed-with-hodgkin-lymphoma/2025-12-01T21:19:24+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-and-survival-among-1594-patients-with-atl/2025-12-01T21:17:44+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-release-in-patients-with-cll-treated-with-obinutuzumab-and-possible-relationship-with-infusion-related-reactions/2025-12-01T21:13:51+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-frontline-brentuximab-vedotin-monotherapy-in-hodgkin-lymphoma-patients-aged-60-years-and-older/2025-11-28T19:56:15+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-trial-of-a-web-based-intervention-to-address-barriers-to-clinical-trials/2025-11-28T19:54:25+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-idelalisib-plus-rituximab-in-treatment-naa%c2%afve-older-patients-with-chronic-lymphocytic-leukemia/2024-04-28T19:58:44+00:00https://lymphoma-stg.clarovantdigital.com/library/differences-in-quality-of-life-between-bendamustine-rituximab-and-r-chop-r-cvp-in-patients-with-previously-untreated-advanced-indolent-non-hodgkin-lymphoma-or-mantle-cell-lymphoma/2025-11-26T21:54:05+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-impact-of-molecular-features-in-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma/2025-11-26T21:51:56+00:00https://lymphoma-stg.clarovantdigital.com/library/bleomycin-in-older-early-stage-favorable-hodgkin-lymphoma-patients-analysis-of-the-german-hodgkin-study-group-ghsg-hd10-and-hd13-trials/2025-11-26T21:47:19+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-dual-expression-of-myc-and-bcl2-by-immunohistochemistry-on-the-risk-of-cns-relapse-in-dlbcl/2025-11-26T21:44:55+00:00https://lymphoma-stg.clarovantdigital.com/library/should-ighv-status-and-fish-testing-be-performed-in-all-cll-patients-at-diagnosis-a-systematic-review-and-meta-analysis/2025-11-26T21:35:19+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-stem-cell-transplantation-in-hodgkin-lymphoma/2025-11-26T21:33:31+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-positron-emission-tomography-responsea%c2%80%c2%93adapted-therapy-in-advanced-stage-hodgkin-lymphoma/2025-11-26T21:30:53+00:00https://lymphoma-stg.clarovantdigital.com/library/re-examining-the-role-of-radiation-therapy-for-diffuse-large-b-cell-lymphoma-in-the-modern-era/2025-05-27T14:46:47+00:00https://lymphoma-stg.clarovantdigital.com/library/innovation-in-the-prognostication-of-chronic-lymphocytic-leukemia/2025-11-26T21:18:11+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-i-ii-multicenter-open-label-study-of-the-oral-histone-deacetylase-inhibitor-abexinostat-in-relapsed-refractory-lymphoma/2025-11-26T21:10:19+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-ki-67-index-cytology-and-growth-pattern-in-mantle-cell-lymphoma/2025-11-26T21:06:23+00:00https://lymphoma-stg.clarovantdigital.com/library/discordant-bone-marrow-involvement-in-non-hodgkin-lymphoma/2025-11-26T21:04:50+00:00https://lymphoma-stg.clarovantdigital.com/library/whole-exome-sequencing-in-relapsing-chronic-lymphocytic-leukemia-clinical-impact-of-recurrent-rps15-mutations/2025-11-26T21:03:20+00:00https://lymphoma-stg.clarovantdigital.com/library/braf-inhibition-in-hairy-cell-leukemia-with-low-dose-vemurafenib/2025-11-26T21:02:03+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-maintenance-for-a-maximum-of-5-years-after-single-agent-rituximab-induction-in-follicular-lymphoma/2025-11-26T20:56:20+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-idelalisib-and-entospletinib-pneumonitis-limits-combination-therapy-in-relapsed-refractory-cll-and-nhl/2025-11-26T20:52:26+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-trial-of-temsirolimus-for-relapsed-refractory-primary-cns-lymphoma/2025-11-26T20:48:41+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-in-survival-of-chronic-lymphocyticleukemia-patients-in-germany-and-the-usa-in-the-first-decade-of-the-twenty-first-century/2025-11-26T20:43:33+00:00https://lymphoma-stg.clarovantdigital.com/library/ofatumumab-and-lenalidomide-for-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia/2025-11-26T19:41:26+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-autologous-and-allogeneic-stem-cell-transplantation-in-the-management-of-indolent-b-cell-lymphoma/2025-11-26T19:38:10+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-the-bispecific-t-cell-engager-bite-antibody-blinatumomab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2025-11-26T21:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/valvular-dysfunction-in-lymphoma-survivors-treated-with-autologous-stem-cell-transplantation/2025-11-26T19:31:14+00:00https://lymphoma-stg.clarovantdigital.com/library/postibrutinib-outcomes-in-patients-with-mantle-cell-lymphoma/2025-11-26T19:15:38+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-ct-for-staging-and-early-response-results-from-the-response-adapted-therapy-in-advanced-hodgkin-lymphoma-study/2025-11-26T19:13:58+00:00https://lymphoma-stg.clarovantdigital.com/library/reduced-intensity-allogeneic-stem-cell-transplantation-for-follicular-lymphoma-relapsing-after-an-autologous-transplant-achieves-durable-long-term-disease-control/2025-11-26T18:46:19+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-results-of-the-hd2000-trial-comparing-abvd-versus-beacopp-versus-copp-ebv-cad-in-untreated-patients-with-advanced-hodgkin-lymphoma/2025-11-26T18:37:26+00:00https://lymphoma-stg.clarovantdigital.com/library/disruption-of-in-vivo-chronic-lymphocytic-leukemia-tumora%c2%80%c2%93microenvironment-interactions-by-ibrutinib/2025-11-26T18:31:54+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-autologous-stem-cell-transplantation-in-primary-central-nervous-system-lymphoma/2025-11-26T18:29:20+00:00https://lymphoma-stg.clarovantdigital.com/library/us-intergroup-trial-of-response-adapted-therapy-for-stage-iii-to-iv-hodgkin-lymphoma-using-early-interim-fluorodeoxyglucosea%c2%80%c2%93positron-emission-tomography-imaging/2025-11-26T18:22:48+00:00https://lymphoma-stg.clarovantdigital.com/library/being-married-helped-prolong-survival-in-cancer-patients/2025-07-24T17:54:22+00:00https://lymphoma-stg.clarovantdigital.com/library/reduced-dose-romidepsin-may-prolong-response-in-cutaneous-lymphoma/2025-07-24T17:52:05+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-on-the-role-of-gemcitabine-plus-romidepsin-gemro-regimen-in-the-treatment-of-relapsed-refractory-peripheral-t-cell-lymphoma-patients/2025-07-24T17:48:10+00:00https://lymphoma-stg.clarovantdigital.com/library/the-value-of-routine-bone-marrow-biopsy-in-patients-with-diffuse-large-b-cell-lymphoma-staged-with-pet-ct-a-danish-canadian-study/2025-07-24T17:19:08+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-renal-toxicity-after-rituximab-dhap-with-a-modified-cisplatin-application-scheme-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2025-07-24T17:13:09+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-a-hope-for-lymphoma-patients/2025-07-24T17:10:34+00:00https://lymphoma-stg.clarovantdigital.com/library/l-asparaginase-based-regimens-followed-by-allogeneic-hematopoietic-stem-cell-transplantation-improve-outcomes-in-aggressive-natural-killer-cell-leukemia/2026-09-02T16:12:54+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-as-initial-therapy-for-patients-with-chronic-lymphocytic-leukemia/2025-07-24T13:16:22+00:00https://lymphoma-stg.clarovantdigital.com/library/large-b-cell-transformation-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-40-year-experience-from-a-single-institution/2025-07-24T13:02:33+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-67-patients-treated-with-chemoradiotherapy-for-primary-thyroid-non-hodgkina%c2%80%c2%99s-lymphoma-in-osaka-medical-college/2024-12-20T19:20:55+00:00https://lymphoma-stg.clarovantdigital.com/library/at-the-heart-of-adolescent-and-young-adult-cancer-survivorship/2025-07-24T12:58:57+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-impact-of-clonal-and-subclonala-tp53a-sf3b1a-birc3a-notch1-anda-atmmutations-in-chronic-lymphocytic-leukemia/2025-07-24T12:54:46+00:00https://lymphoma-stg.clarovantdigital.com/library/the-spectrum-of-malt-lymphoma-at-different-sites-biological-and-therapeutic-relevance/2025-07-24T12:52:04+00:00https://lymphoma-stg.clarovantdigital.com/library/splenic-marginal-zone-lymphoma-from-genetics-to-management/2025-07-24T12:45:52+00:00https://lymphoma-stg.clarovantdigital.com/library/optimizing-therapy-for-nodal-marginal-zone-lymphoma/2025-07-24T12:42:04+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-evolving-therapeutic-strategies/2025-07-24T12:39:09+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-landscapes-of-relapsed-and-refractory-diffuse-large-b-cell-lymphomas/2025-07-24T12:35:28+00:00https://lymphoma-stg.clarovantdigital.com/library/toward-personalized-lymphoma-immunotherapy-identification-of-common-driver-mutations-recognized-by-patient-cd8t-cells/2025-07-24T12:22:18+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-of-chronic-lymphocytic-leukemia-in-senegal/2026-03-13T19:47:12+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-responsive-central-nervous-system-involvement-in-chronic-lymphocytic-leukemia/2025-04-14T20:49:46+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-treatment-of-low-risk-pediatric-lymphocyte-predominant-hodgkin-lymphoma-a-report-from-the-childrens-oncology-group/2025-07-23T21:13:28+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-double-blind-phase-iii-trial-of-enzastaurin-versus-placebo-in-patients-achieving-remission-after-first-line-therapy-for-high-risk-diffuse-large-b-cell-lymphoma/2025-07-23T21:03:07+00:00https://lymphoma-stg.clarovantdigital.com/library/myd88a-l265p-mutations-but-no-other-variants-identify-a-subpopulation-of-dlbcl-patients-of-activated-b-cell-origin-extranodal-involvement-and-poor-outcome/2025-07-23T20:55:25+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-the-risk-of-relapse-in-classical-hodgkin-lymphoma-at-event-free-survival-time-points-and-survival-comparison-with-the-general-population-in-british-columbia/2025-07-23T20:44:03+00:00https://lymphoma-stg.clarovantdigital.com/library/is-watch-and-wait-still-acceptable-for-patients-with-low-grade-follicular-lymphoma/2025-07-22T21:40:44+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-hematopoietic-cell-transplantation-for-hiv-related-lymphoma-results-of-the-bmt-ctn-0803-amc-071-trial/2025-07-22T21:35:21+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-and-outcomes-for-patients-with-follicular-lymphoma-who-had-histologic-transformation-after-response-to-first-line-immunochemotherapy-in-the-prima-trial/2025-07-22T20:51:59+00:00https://lymphoma-stg.clarovantdigital.com/library/next-generation-sequencing-in-diffuse-large-b-cell-lymphoma-highlights-molecular-divergence-and-therapeutic-opportunities-a-lysa-study/2025-07-22T20:45:22+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-panobinostat-with-or-without-rituximab-in-relapsed-diffuse-large-b-cell-lymphoma/2025-07-22T20:41:09+00:00https://lymphoma-stg.clarovantdigital.com/library/idelalisib-given-front-line-for-treatment-of-chronic-lymphocytic-leukemia-causes-frequent-immune-mediated-hepatotoxicity/2025-07-22T20:36:24+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-survival-and-durability-results-of-brentuximab-vedotin-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma/2025-07-22T18:26:45+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-chemoimmunotherapy-with-bendamustine-and-rituximab-versus-fludarabine-cyclophosphamide-and-rituximab-in-patients-with-advanced-chronic-lymphocytic-leukaemia-cll10-an-international-ope/2024-04-28T19:54:29+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-mycosis-fungoides-and-sazary-syndrome/2025-07-22T18:02:15+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-bendamustine-rituximab-in-untreated-mantle-cell-lymphoma-65-years-the-nordic-lymphoma-group-phase-iii-trial-nlg-mcl4/2025-07-22T17:50:40+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-epstein-barr-virus-infection-leading-to-classical-hodgkin-lymphoma/2025-07-22T17:48:13+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-in-combination-with-gemcitabine-and-vinorelbine-is-an-effective-regimen-as-induction-chemotherapy-before-autologous-stem-cell-transplantation-for-relapsed-or-refractory-hodgkin-lymphoma/2025-07-22T17:29:58+00:00https://lymphoma-stg.clarovantdigital.com/library/programmed-death-1-blockade-with-pembrolizumab-in-patients-with-classical-hodgkin-lymphoma-after-brentuximab-vedotin-failure/2025-07-22T17:23:14+00:00https://lymphoma-stg.clarovantdigital.com/library/idelalisib-in-the-management-of-lymphoma/2025-03-04T19:19:02+00:00https://lymphoma-stg.clarovantdigital.com/library/complex-karyotypes-anda-krasa-anda-pot1a-mutations-impact-outcome-in-cll-after-chlorambucil-based-chemotherapy-or-chemoimmunotherapy/2025-12-15T21:09:13+00:00https://lymphoma-stg.clarovantdigital.com/library/speed-bumps-on-the-road-to-a-chemotherapy-free-world-for-lymphoma-patients/2025-07-22T16:14:47+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-and-avd-followed-by-involved-site-radiotherapy-in-early-stage-unfavorable-risk-hodgkin-lymphoma/2025-07-22T16:04:55+00:00https://lymphoma-stg.clarovantdigital.com/library/cns-international-prognostic-index-a-risk-model-for-cns-relapse-in-patients-with-diffuse-large-b-cell-lymphoma-treated-with-r-chop/2025-07-17T20:41:06+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-cll-patients-treated-with-sequential-kinase-inhibitor-therapy-a-real-world-experience/2025-07-17T20:36:43+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-is-it-a-valid-treatment-option-2/2025-07-17T20:18:53+00:00https://lymphoma-stg.clarovantdigital.com/library/economic-evaluation-of-obinutuzumab-in-combination-with-chlorambucil-in-first-line-treatment-of-patients-with-chronic-lymphocytic-leukemia-in-spain/2025-07-17T20:08:33+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-metabolic-tumor-volume-predicts-outcome-in-higha%c2%80%c2%93tumor-burden-follicular-lymphoma-a-pooled-analysis-of-three-multicenter-studies/2025-07-17T20:04:49+00:00https://lymphoma-stg.clarovantdigital.com/library/brafa-v600e-mutation-in-hairy-cell-leukemia-from-bench-to-bedside/2025-07-17T20:02:18+00:00https://lymphoma-stg.clarovantdigital.com/library/atypicala-pneumocystis-jiroveciia-pneumonia-in-previously-untreated-patients-with-cll-on-single-agent-ibrutinib/2025-07-17T19:56:01+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-double-hit-and-double-expressor-phenotypes-in-relapsed-aggressive-b-cell-lymphomas-treated-with-autologous-hematopoietic-stem-cell-transplantation/2025-07-17T19:47:41+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-a-web-based-cognitive-rehabilitation-program-in-cancer-survivors-reporting-cognitive-symptoms-after-chemotherapy/2025-07-17T19:39:48+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-recommendations-from-the-eighth-international-workshop-on-waldenstra%c2%b6ma%c2%80%c2%99s-macroglobulinemia/2025-07-17T19:13:19+00:00https://lymphoma-stg.clarovantdigital.com/library/economic-burden-of-chronic-lymphocytic-leukemia-in-the-era-of-oral-targeted-therapies-in-the-united-states/2025-12-19T18:52:48+00:00https://lymphoma-stg.clarovantdigital.com/library/prevention-and-monitoring-of-cardiac-dysfunction-in-survivors-of-adult-cancers-american-society-of-clinical-oncology-clinical-practice-guideline/2025-12-19T18:52:06+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-mutation-that-makes-the-body-turn-life-saving-immune-cells-into-a-rare-and-dangerous-cancer/2020-05-20T10:24:29+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-rituximab-plus-lenalidomide-for-mucosa-associated-lymphoid-tissue-lymphoma-malt-lymphoma/2025-07-17T18:59:56+00:00https://lymphoma-stg.clarovantdigital.com/library/interferon-free-antiviral-treatment-in-b-cell-lymphoproliferative-disorders-associated-with-hepatitis-c-virus-infection/2025-07-17T18:52:45+00:00https://lymphoma-stg.clarovantdigital.com/library/doing-the-same-thing-over-and-over-again-but-expecting-different-results-ita%c2%80%c2%99s-time-to-move-on/2025-12-15T20:56:20+00:00https://lymphoma-stg.clarovantdigital.com/library/immunomodulatory-effect-of-vitamin-d-after-allogeneic-stem-cell-transplantation-results-of-a-prospective-multicenter-clinical-trial/2025-07-16T20:32:01+00:00https://lymphoma-stg.clarovantdigital.com/library/myd88-mutation-is-associated-with-an-unfavorable-outcome-of-primary-diffuse-large-b-cell-lymphoma/2025-07-16T20:29:23+00:00https://lymphoma-stg.clarovantdigital.com/library/beac-and-beam-high-dose-chemotherapy-in-patients-with-mantle-cell-lymphoma-undergoing-autologous-stem-cell-transplantation-are-efficacious-with-comparable-toxicity/2025-07-16T20:23:49+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-factors-of-cll-patients-undergoing-reduced-intensity-allogeneic-hematopoietic-stem-cell-transplantation-in-the-immunochemotherapy-era/2025-07-16T20:21:46+00:00https://lymphoma-stg.clarovantdigital.com/library/high-rate-of-long-term-complete-remission-for-patients-with-chronic-lymphocytic-leukemia-cll-who-relapse-after-allogeneic-stem-cell-transplantation-and-receive-salvage-with-donor-lymphocyte-infusion/2025-07-16T20:19:31+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-patients-with-peripheral-t-cell-lymphoma-undergoing-allogeneic-stem-cell-in-british-columbia/2025-07-16T20:17:01+00:00https://lymphoma-stg.clarovantdigital.com/library/salvage-high-dose-melphalane-and-autologous-peripheral-blood-stem-cell-transplantation-for-diffuse-large-b-cell-lymphoma-refractory-to-2nd-or-3rd-line-treatment/2025-12-15T20:55:36+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-of-the-effect-of-hematopoietic-stem-cell-transplantation-in-the-treatment-of-98-cases-of-t-cell-lymphoma/2025-07-16T20:04:40+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-survival-and-absence-of-late-relapses-in-patients-who-underwent-allogeneic-stem-cell-transplantation-for-advanced-cutaneous-t-cell-lymphoma/2026-01-16T15:03:07+00:00https://lymphoma-stg.clarovantdigital.com/library/single-centre-experience-of-managing-patients-with-double-hit-lymphoma/2025-07-16T19:57:25+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-cell-transplantation-for-lymphoma-baseline-and-post-transplant-prognostic-factors/2025-07-16T19:49:18+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comparison-study-between-allogeneic-and-autologous-hematopoietic-stem-cell-transplant-for-high-risk-peripheral-t-cell-lymphomas-ptcl/2025-07-16T19:22:19+00:00https://lymphoma-stg.clarovantdigital.com/library/high-dose-telmisartan-for-prevention-of-acute-graft-vs-host-disease/2025-07-16T19:20:04+00:00https://lymphoma-stg.clarovantdigital.com/library/intensive-chemotherapy-with-da-edoch-followed-by-allogeneic-hematopoietic-stem-cell-transplantation-improved-the-outcome-in-htlv-1-associated-adult-t-cell-leukemia-atl/2025-07-16T19:17:54+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-progression-free-survival-is-possible-in-patients-with-diffuse-large-b-cell-lymphoma-receiving-1-salvage-therapies-before-autologous-stem-cell-transplant/2025-07-16T19:10:33+00:00https://lymphoma-stg.clarovantdigital.com/library/results-from-hemato-oncology-latin-america-observational-registry-hola-providing-real-world-outcomes-for-the-treatment-of-patients-with-cll/2025-07-16T19:07:20+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-adjusted-epoch-chemotherapy-for-untreated-peripheral-t-cell-lymphomas-multicenter-phase-ii-trial-of-west-jhog-ptcl0707/2025-07-16T19:03:44+00:00https://lymphoma-stg.clarovantdigital.com/library/pegfilgrastim-use-and-risk-of-bleomycin-induced-pulmonary-toxicity-in-hodgkin-lymphoma/2025-07-16T18:55:56+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-early-mortality-in-fragile-patients-with-non-hodgkin-lymphoma-at-diagnosis-who-need-hospitalization-in-a-developing-country/2026-03-13T13:33:45+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-based-therapy-significantly-improves-os-and-pfs-independent-of-sex-rai-stage-bulky-disease-or-chromosome-11q-deletion-in-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-l/2025-07-16T18:50:38+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-adjusted-etoposide-prednisone-vincristine-cyclophosphamide-doxorubucin-and-rituximab-da-epoch-r-vs-rituxan-cyclophosphamide-doxorubucin-vincristine-and-prednisone-r-chop-as-first-line/2025-07-16T18:43:44+00:00https://lymphoma-stg.clarovantdigital.com/library/real-life-experience-with-brentuximab-vedotin-adcetrisa-the-belgian-national-registry/2025-07-16T18:41:26+00:00https://lymphoma-stg.clarovantdigital.com/library/htlv-1-proviral-load-after-two-months-treatment-with-anti-ccr4-monoclonal-antibody-mogamulizumab-predicts-a-molecular-response-to-disease-and-durable-clinical-remission-in-leukaemic-subtypes-of-adult/2025-07-16T18:38:09+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-in-combination-with-cyclophosphamide-mitoxantrone-vincristine-and-prednisone-r-cnop-as-first-line-regimen-in-elderly-patients-with-diffuse-large-b-cell-lymphoma/2025-07-16T18:33:23+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-ga101-in-combination-with-pixantrone-for-the-treatment-of-patients-with-relapsed-aggressive-b-cell-lymphoma-report-on-an-ongoing-phase-ii-trial-goal/2025-07-16T18:30:15+00:00https://lymphoma-stg.clarovantdigital.com/library/red-cell-distribution-width-rdw-at-diagnosis-of-diffuse-large-b-cell-lymphoma-dlbcl-is-associated-to-higher-mortality-and-worse-overall-survival/2025-07-16T18:25:47+00:00https://lymphoma-stg.clarovantdigital.com/library/high-grade-diffuse-large-b-cell-lymphoma-in-elderly-patients-russian-multicenter-trial-results-in-r-epoch-r-hma-protocol/2025-07-16T18:23:54+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-patients-with-double-expressor-lymphomas-dels-treated-with-r-chop-or-r-epoch/2025-07-14T21:16:11+00:00https://lymphoma-stg.clarovantdigital.com/library/revelance-of-gammaglobulin-levels-at-diagnosis-and-during-disease-course-in-chronic-lymphocytic-leukemia/2025-07-14T21:14:07+00:00https://lymphoma-stg.clarovantdigital.com/library/how-to-improve-the-definition-of-chronic-lymphocytic-leukemia-outcome-using-a-simple-flow-cytometric-score-based-on-cd49d-and-homing-marker-expression/2025-07-14T20:42:20+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-splenectomy-in-the-care-and-treatment-of-the-cll-patient/2025-07-14T20:39:47+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-analysis-of-japanese-and-european-typical-cll-patients/2025-07-14T20:27:15+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-first-line-cll-treatments-in-comparison-to-chlorambucil-a-network-meta-analysis/2025-04-14T20:42:59+00:00https://lymphoma-stg.clarovantdigital.com/library/liver-dysfunction-in-previously-untreated-chronic-lymphocytic-leukemia-prevalence-and-outcomes-in-a-large-cohort/2025-07-14T20:12:46+00:00https://lymphoma-stg.clarovantdigital.com/library/cll-in-india-may-have-a-different-biology-from-that-in-the-west/2025-05-14T18:36:17+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-epigenetic-therapy-with-hydralazine-and-valproate-in-cutaneous-t-cell-lymphoma/2025-07-14T20:07:36+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-demonstrates-promising-activity-in-post-brentuximab-failure-hodgkin-lymphoma-patients-who-had-also-failed-a-prior-autologous-hct-and-facilitates-successful-bridging-to-allogeneic-hct/2025-07-14T20:02:40+00:00https://lymphoma-stg.clarovantdigital.com/library/the-neutrophil-to-lymphocyte-ratio-is-prognostic-in-patients-with-early-stage-peripheral-t-cell-lymphoma/2025-07-14T20:00:30+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-remissions-after-discontinuation-of-ibrutinib-in-relapsed-refractory-cll-a-basis-for-reducing-drug-toxicity-and-treatment-costs/2025-07-14T19:58:24+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-based-therapy-in-the-treatment-of-relapsed-and-refractory-chronic-lymphocytic-leukemia/2025-07-14T19:56:07+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-tolerability-of-obinutuzumab-ga101-with-shorter-duration-of-infusion-in-japanese-patients-with-previously-untreated-cd20-positive-b-cell-non-hodgkins-lymphoma-nhl-comparison-with-gao49/2025-07-14T19:53:26+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-bortezomib-gifox-gemcitabine-ifosfamide-oxaliplatin-in-patients-with-newly-diagnosed-natural-killer-t-cell-lymphoma/2025-07-14T19:51:25+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-in-association-with-r-dhap-ox-for-patients-with-relapsed-refractory-b-cell-lymphoma-preliminary-results-of-the-biblos-phase-ib-lysa-study/2026-01-15T14:08:11+00:00https://lymphoma-stg.clarovantdigital.com/library/post-transplant-brentuximab-maintenance-appears-more-effective-than-post-transplant-salvage-brentuximab-for-relapsed-refractory-hogkins-lymphoma/2025-07-14T19:33:33+00:00https://lymphoma-stg.clarovantdigital.com/library/r-comp-vs-r-chop-as-first-line-treatment-for-de-novo-diffuse-large-b-cell-lymphoma-in-patients-older-than-60-years-preliminary-results-from-a-prospective-randomized-phase-2-study-from-the-spanish-gr/2025-12-10T18:15:17+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-primary-aggressive-gastrointestinal-lymphomas-with-intensive-chemotherapy-a-14-year-experience/2025-07-10T21:33:19+00:00https://lymphoma-stg.clarovantdigital.com/library/expression-of-epstein-barr-virus-in-cell-of-classical-hodgkins-lymphoma-tumor/2026-09-02T16:12:12+00:00https://lymphoma-stg.clarovantdigital.com/library/liver-biopsy-in-patients-with-chronic-lymphocytic-leukemia-indications-and-pathological-findings/2025-07-10T21:27:51+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-safety-experience-with-bendamustine-for-injection-in-a-real-world-setting/2025-07-10T21:21:54+00:00https://lymphoma-stg.clarovantdigital.com/library/does-hypogammaglobulinemia-at-diagosis-effects-survival-and-infection-risk-in-chronic-lymphocytic-leukemia-cll/2025-07-10T21:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/the-combined-evaluation-of-neutrophil-t-lymphocyte-and-monocyte-counts-provides-new-prognostic-information-in-cll-patients/2025-07-10T21:18:27+00:00https://lymphoma-stg.clarovantdigital.com/library/fdg-pet-ct-as-a-diagnostic-and-prognostic-tool-for-the-evaluation-of-patients-with-peripheral-t-cell-lymphoma/2025-07-10T21:09:26+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-the-ribvd-regimen-in-high-risk-mantle-cell-lymphoma-patients-as-defined-by-the-mipic-prognostic-score-identification-of-ki67-ldh-and-performance-status-as-most-important-prognostic-facto/2025-07-10T21:08:00+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-absolute-lymphocyte-count-absolute-monocyte-count-ratio-and-prognostic-score-in-patients-with-nasal-type-extranodal-natural-killer-t-cell-lymphoma/2025-07-10T21:03:16+00:00https://lymphoma-stg.clarovantdigital.com/library/similar-phenotypes-demonstrated-upon-initial-diagnosis-and-at-time-of-recurrence-in-relapsed-dlbcl/2025-07-10T17:34:07+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-expression-profile-in-patients-with-classical-hodgkin-lymphoma-in-brazil-results-from-a-pilot-study/2025-07-10T16:45:23+00:00https://lymphoma-stg.clarovantdigital.com/library/the-investigation-of-hepatitis-virus-infection-in-different-subtypes-of-b-cell-non-hodgkin-lymphoma-in-china-high-infection-of-both-hbv-and-hcv-in-splenic-marginal-lymphoma/2025-07-10T16:34:23+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-maintenance-for-advanced-follicular-lymphoma-fl-patients-comparison-of-outcomes-after-first-and-second-line-treatment-in-a-single-center-series/2025-01-28T21:19:16+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-grade-3a-follicular-lymphoma-best-treated-as-aggressive-or-indolent-lymphoma/2025-07-10T16:25:26+00:00https://lymphoma-stg.clarovantdigital.com/library/risks-and-benefits-of-rituximab-maintenance-in-elderly-patients-with-advanced-follicular-lymphoma/2025-07-10T15:51:56+00:00https://lymphoma-stg.clarovantdigital.com/library/therapy-with-ibritumomab-tiuxetan-zevalina-in-patients-with-previously-untreated-and-relapsed-low-grade-follicular-lymphoma-the-mayo-clinic-florida-experience-2000-2016/2025-07-10T15:49:20+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-plus-r-chop-r2chop-in-patients-with-follicular-lymphoma-data-from-a-phase-1-2-study/2025-12-15T19:33:51+00:00https://lymphoma-stg.clarovantdigital.com/library/myc-and-bcl2-overexpression-and-traslocation-assessed-by-immunohystochemistry-ihc-and-fish-retrospective-analysis-in-a-series-of-de-novo-dlbcl-homogeneously-treated-with-rituximab-chop/2025-12-10T18:16:14+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-the-role-of-radiological-imaging-and-bone-marrow-biopsy-in-staging-of-cutaneous-b-cell-lymphoma/2025-07-10T15:33:10+00:00https://lymphoma-stg.clarovantdigital.com/library/results-from-a-hemato-oncology-latin-america-observational-registry-hola-providing-real-world-outcomes-for-the-treatment-of-patients-with-nhl/2025-07-10T15:38:34+00:00https://lymphoma-stg.clarovantdigital.com/library/characterization-of-real-world-treatment-patterns-and-outcomes-among-older-adults-with-chronic-lymphocytic-leukemia-in-the-pre-novel-agents-era-an-analysis-of-the-2007-2013-seer-medicare-database/2025-07-10T15:11:14+00:00https://lymphoma-stg.clarovantdigital.com/library/use-of-metabolic-tumor-volume-mtv-in-patients-with-mantle-cell-lymphoma/2025-07-10T15:05:05+00:00https://lymphoma-stg.clarovantdigital.com/library/skin-cancers-among-chronic-lymphocytic-leukemia-cll-patients-the-effect-of-uv-radiation-and-cll-clinical-characteristics/2026-01-22T21:57:02+00:00https://lymphoma-stg.clarovantdigital.com/library/measurement-of-quality-of-life-and-depression-of-spouse-caregivers-for-survivors-after-hematopoietic-stem-cell-transplantation/2025-07-09T20:33:50+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-the-impact-of-hematopoietic-stem-cell-transplant-on-the-quality-of-life-of-elderly-patients-treated-for-lymphoma/2025-07-09T20:30:59+00:00https://lymphoma-stg.clarovantdigital.com/library/patterns-of-cutaneous-malignancy-risk-among-survivors-of-non-hodgkin-lymphoma-subtypes/2025-07-09T20:26:43+00:00https://lymphoma-stg.clarovantdigital.com/library/characterization-of-real-world-survival-outcomes-among-older-adults-with-chronic-lymphocytic-leukemia-receiving-second-line-treatment-in-the-pre-novel-agents-era-an-analysis-of-the-2007-2013-seer-med/2025-07-09T20:24:18+00:00https://lymphoma-stg.clarovantdigital.com/library/platelet-function-prior-to-ibrutinib-treatment-is-more-severely-impaired-in-chronic-lymphocytic-leukemia-than-in-mantle-cell-lymphoma/2025-07-09T20:19:16+00:00https://lymphoma-stg.clarovantdigital.com/library/dynamics-of-hemorragic-events-and-primary-hemostasis-deffects-during-treatment-with-ibrutinib-real-life-experience/2025-12-15T19:38:17+00:00https://lymphoma-stg.clarovantdigital.com/library/bone-marrow-derived-mesenchymal-stromal-cells-reduce-the-incidence-of-chronic-graft-versus-host-disease-after-allogenetic-hematopoietic-stem-cell-transplantation/2025-07-09T20:11:06+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-multicenter-clinical-trial-of-everolimus-as-primary-therapy-in-waldenstrom-macroglobulinemia-wmctg-09-214/2025-07-09T19:59:41+00:00https://lymphoma-stg.clarovantdigital.com/library/beam-or-beeam-high-dose-chemotherapy-followed-by-asct-a-single-center-comparative-analysis-of-toxicity/2025-03-04T15:38:53+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcome-of-allogeneic-stem-cell-transplantation-allo-sct-in-patients-with-waldenstrom-macroglobulinemia-wm-a-retrospective-study-of-the-lymphoma-working-party-of-the-european-society-for/2025-12-15T19:30:03+00:00https://lymphoma-stg.clarovantdigital.com/library/thirty-month-complete-response-as-a-surrogate-end-point-in-first-line-follicular-lymphoma-therapy-an-individual-patient-level-analysis-of-multiple-randomized-trials/2025-07-09T19:41:51+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-evolution-leading-to-ibrutinib-resistance-in-chronic-lymphocytic-leukemia/2025-07-09T19:38:46+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-alemtuzumab-campath-1-in-patients-with-htlv-1a%c2%80%c2%93associated-adult-t-cell-leukemia-lymphoma/2025-07-09T19:23:45+00:00https://lymphoma-stg.clarovantdigital.com/library/a-new-insight-in-chimeric-antigen-receptor-engineered-t-cells-for-cancer-immunotherapy/2025-07-09T19:14:58+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-efficacy-and-tolerability-in-patients-with-relapsed-chronic-lymphocytic-leukemia-following-allogeneic-hct/2025-07-09T19:05:05+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-is-an-independent-predictor-for-10-year-survival-in-cll/2025-07-09T18:59:29+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-hematopoiesis-associated-with-adverse-outcomes-after-autologous-stem-cell-transplantation-for-lymphoma/2025-07-09T18:55:32+00:00https://lymphoma-stg.clarovantdigital.com/library/hla-haploidentical-transplantation-for-relapsed-refractory-hodgkin-lymphoma/2025-07-09T18:48:20+00:00https://lymphoma-stg.clarovantdigital.com/library/different-clinical-characteristics-and-treatment-strategies-for-patients-with-localized-sinonasal-diffuse-large-b-cell-lymphoma-and-extranodal-nk-t-cell-lymphoma/2025-07-09T18:43:21+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-stem-cell-transplantation-versus-b-cell-receptor-inhibitors-in-17p-deletion-and-or-refractory-chronic-lymphocytic-leukemia-a-retrospective-comparative-analysis-of-real-life-approaches-to/2025-07-09T18:41:07+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-patients-with-corticosteroid-refractory-graft-versus-host-disease-treated-with-ruxolitinib/2025-07-09T18:38:04+00:00https://lymphoma-stg.clarovantdigital.com/library/cell-of-origin-and-double-protein-expression-as-predictors-of-outcome-after-autologous-stem-cell-transplant-for-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-who-undergo-inte/2025-07-09T18:34:58+00:00https://lymphoma-stg.clarovantdigital.com/library/salvage-use-of-ibrutinib-after-allogeneic-hematopoietic-stem-cell-transplantation-allo-hsct-for-b-cell-malignancies-a-study-of-the-french-cooperative-group-for-cll-the-french-soceity-for-blood-and/2025-07-09T18:18:14+00:00https://lymphoma-stg.clarovantdigital.com/library/italian-real-life-experience-with-brentuximab-vedotin-results-of-a-national-observational-study-on-relapsed-refractory-hodgkins-lymphoma/2025-07-09T18:14:00+00:00https://lymphoma-stg.clarovantdigital.com/library/the-risk-of-central-nervous-system-cns-relapses-in-patients-with-peripheral-t-cell-lymphoma/2025-07-09T18:11:55+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-following-salvage-therapy-in-primary-refractory-peripheral-t-cell-lymphoma-ptcl/2025-07-09T18:01:06+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-randomized-trial-comparing-standard-rchop-versus-brcap-bortezomib-rituximab-cyclophosphamide-adriamycin-and-prednisone-as-first-line-treatment-in-young-patients-with-high-risk-diffuse-lar/2025-12-10T18:16:45+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-phase-i-multi-center-trial-incorporating-lenalidomide-len-into-dose-adjusted-epoch-plus-rituximab-da-epoch-r-in-patients-with-double-hit-dhl-or-double-expressing-del-lymphomas-fin/2025-07-09T17:24:36+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-abbreviated-3-cycles-of-rituximab-plus-chop-cyclophosphamide-adriamycin-vincristine-and-prednisolone-immunochemotherapy-in-patients-with-completely-excised-stage-i-or-ii-cd20-di/2025-07-08T22:33:48+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-myc-and-bcl-2-double-expression-the-in-dlbcl-patients-with-advanced-stage-and-elevated-ldh-who-received-upfront-asct-after-r-chop/2025-12-10T18:17:25+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-in-patients-with-diffuse-large-b-cell-lymphoma-with-partial-responses-to-first-line-r-chop-chemotherapy-prognostic-value-of-secondary-ipi-scores-and-fdg-pet/2025-07-08T22:25:59+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-lenalidomide-to-repair-immune-synapse-response-and-humoral-immunity-in-early-stage-asymptomatic-chronic-llmphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-with-high-risk-gen/2025-07-08T22:23:47+00:00https://lymphoma-stg.clarovantdigital.com/library/major-bleeding-complications-among-patients-treated-with-ibrutinib-and-concomitant-antiplatelet-anticoagulant-or-supplemental-therapy/2025-07-08T22:19:57+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-mutation-signature-and-its-pathogenesis-role-in-chronic-lymphocytic-leukemia-in-china-different-from-the-western-reports/2025-07-08T22:17:49+00:00https://lymphoma-stg.clarovantdigital.com/library/a-single-arm-phase-2a-study-of-nm-il-12-rhu-il12-in-patients-with-mycosis-fungoides-type-ctcl-mf-undergoing-low-dose-total-skin-electron-beam-therapy-ld-tsebt/2025-07-08T22:16:00+00:00https://lymphoma-stg.clarovantdigital.com/library/lack-of-prognostic-significance-of-the-conventional-and-novel-prognostic-markers-in-trisomy-12-chronic-lymphocytic-leukemia-cll/2025-07-08T22:11:33+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-gender-on-outcome-after-chemoimmunotherapy-with-fludarabine-cyclophosphamide-and-rituximab-fcr-or-bendamustine-plus-rituximab-br-in-patients-with-chronic-lymphocytic-leukemia-cll-a-m/2026-01-22T22:04:17+00:00https://lymphoma-stg.clarovantdigital.com/library/fludarabine-cyclophosphamide-rituximab-fcr-and-vorinostat-followed-by-rituximab-and-vorinostat-maintenance-therapy-in-patients-with-previously-untreated-chronic-lymphocytic-leukemia-cll-or-small/2025-07-08T22:07:11+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-the-combination-of-lenalidomide-and-rituximab-in-patients-with-treatment-naa%c2%afve-and-relapsed-chronic-lymphocytic-leukemia/2025-07-08T22:02:46+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-blockade-with-pembrolizumab-in-relapsed-cll-including-richters-transformation-an-updated-report-from-a-phase-2-trial-mc1485/2025-07-08T22:00:31+00:00https://lymphoma-stg.clarovantdigital.com/library/natural-history-of-non-infectious-ibrutinib-attributable-adverse-events-leading-to-alternative-btk-inhibitor-use-in-cll/2025-12-15T22:26:13+00:00https://lymphoma-stg.clarovantdigital.com/library/optimal-sequencing-of-ibrutinib-idelalisib-and-venetoclax-in-cll-results-from-a-large-multi-center-study-of-683-us-patients/2025-07-08T21:55:13+00:00https://lymphoma-stg.clarovantdigital.com/library/favorable-toxicity-profile-and-long-term-outcome-of-elderly-but-physically-fit-cll-patients-pts-receiving-first-line-bendamustine-and-rituximab-br-frontline-chemoimmunotherapy-in-comparison-to-fl/2025-07-08T21:52:19+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-lysa-study-of-obinutuzumab-combined-with-lenalidomide-for-relapsed-or-refractory-aggressive-b-cell-lymphoma/2025-07-08T21:49:22+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-elderly-patients-with-diffuse-large-b-cell-lymphoma-in-a-network-of-community-oncology-practices-in-the-united-states/2025-07-08T21:46:03+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-survival-data-from-a-pivotal-phase-2-study-of-brentuximab-vedotin-in-patients-with-relapsed-or-refractory-systemic-anaplastic-large-cell-lymphoma/2025-07-08T20:30:35+00:00https://lymphoma-stg.clarovantdigital.com/library/biological-and-clinical-relevance-of-associated-genomic-alterations-in-myd88-l265p-and-non-l265p-mutated-diffuse-large-b-cell-lymphoma-analysis-of-361-cases/2025-12-10T18:17:48+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-in-patients-with-previously-treated-chronic-lymphocytic-leukemia/2025-07-08T20:21:55+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-loss-of-lifetime-for-patients-with-diffuse-large-b-cell-lymphoma-in-remission-and-event-free-24-months-after-treatment/2025-07-08T20:19:44+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-course-of-patients-with-primary-ocular-adnexal-malt-lymphoma/2025-07-08T20:02:52+00:00https://lymphoma-stg.clarovantdigital.com/library/bdr-in-newly-diagnosed-patients-with-wm-final-analysis-of-a-phase-2-study-after-a-minimum-follow-up-of-6-years/2025-07-08T19:59:16+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-value-of-interim-18ffluorodeoxyglucosea%c2%80%c2%93positron-emission-tomography-in-advanced-stage-hodgkin-lymphoma-is-not-well-established/2025-07-08T19:45:12+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-abexinostat-a-pan-histone-deacetylase-inhibitor-in-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia/2025-07-08T19:31:26+00:00https://lymphoma-stg.clarovantdigital.com/library/consensus-guidelines-for-the-diagnosis-and-management-of-patients-with-classic-hairy-cell-leukemia/2025-07-09T19:44:48+00:00https://lymphoma-stg.clarovantdigital.com/library/bortezomib-based-regimen-led-to-durable-remissions-in-mantle-cell-lymphoma/2025-07-08T19:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnosis-and-treatment-of-cd20-negative-b-cell-lymphomas/2025-07-08T19:03:27+00:00https://lymphoma-stg.clarovantdigital.com/library/inappropriate-costimulation-and-aberrant-dna-methylation-as-therapeutic-targets-in-angioimmunoblastic-t-cell-lymphoma/2025-07-08T19:00:50+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-blockade-induces-remissions-in-relapsed-classical-hodgkin-lymphoma-following-allogeneic-hematopoietic-stem-cell-transplantation/2025-07-08T18:53:32+00:00https://lymphoma-stg.clarovantdigital.com/library/btkc481s-mediated-resistance-to-ibrutinib-in-chronic-lymphocytic-leukemia/2025-07-08T18:39:19+00:00https://lymphoma-stg.clarovantdigital.com/library/extended-treatment-with-single-agent-ibrutinib-at-the-420-mg-dose-leads-to-durable-responses-in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-07-08T18:36:28+00:00https://lymphoma-stg.clarovantdigital.com/library/familial-associations-of-lymphoma-and-myeloma-with-autoimmune-diseases/2025-07-08T18:29:40+00:00https://lymphoma-stg.clarovantdigital.com/library/late-relapse-of-classical-hodgkin-lymphoma-an-analysis-of-the-german-hodgkin-study-group-hd7-to-hd12-trials/2025-07-08T18:21:40+00:00https://lymphoma-stg.clarovantdigital.com/library/peripheral-t-cell-lymphoma-not-otherwise-specified/2025-07-08T18:12:58+00:00https://lymphoma-stg.clarovantdigital.com/library/angioimmunoblastic-t-cell-lymphoma-the-many-faced-lymphoma-2/2025-07-08T18:09:07+00:00https://lymphoma-stg.clarovantdigital.com/library/acr-appropriateness-criteria-hodgkin-lymphoma-unfavorable-clinical-stage-i-and-ii/2025-07-08T17:59:44+00:00https://lymphoma-stg.clarovantdigital.com/library/an-extensive-molecular-cytogenetic-characterization-in-high-risk-chronic-lymphocytic-leukemia-identifies-karyotype-aberrations-and-tp53-disruption-as-predictors-of-outcome-and-chemorefractoriness/2025-07-08T17:56:44+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-pharmaceutical-psychological-and-exercise-treatments-for-cancer-related-fatigue/2025-07-08T14:23:22+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-allogeneic-hematopoietic-stem-cell-transplant-after-pd-1-blockade-in-relapsed-refractory-lymphoma/2026-01-16T14:49:58+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-manage-ibrutinib-refractory-chronic-lymphocytic-leukemia/2026-01-15T14:06:13+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-second-cancer-in-hodgkin-lymphoma-survivors-and-influence-of-family-history/2025-07-08T14:12:39+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-the-oral-mtorc1-inhibitor-everolimus-in-relapsed-or-refractory-indolent-lymphoma/2025-07-08T14:11:25+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-profiling-of-myc-and-bcl2-in-diffuse-large-b-cell-lymphoma-determines-cell-of-origin-specific-clinical-impact/2025-07-08T13:32:13+00:00https://lymphoma-stg.clarovantdigital.com/library/limited-stage-hodgkin-lymphoma-clarifying-uncertainty/2025-07-08T13:24:02+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-dinaciclib-vs-ofatumumab-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia/2025-07-08T13:14:51+00:00https://lymphoma-stg.clarovantdigital.com/library/the-genetic-basis-of-hepatosplenic-t-cell-lymphoma/2025-07-08T13:11:04+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-genotyping-on-the-liquid-biopsy-2/2025-07-07T22:13:36+00:00https://lymphoma-stg.clarovantdigital.com/library/the-t-cell-receptor-repertoire-influences-the-tumor-microenvironment-and-is-associated-with-survival-in-aggressive-b-cell-lymphoma/2025-07-07T22:08:30+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-maintenance-therapy-for-patients-with-diffuse-large-b-cell-lymphoma/2025-07-07T20:14:39+00:00https://lymphoma-stg.clarovantdigital.com/library/the-diagnosis-and-management-of-nk-t-cell-lymphomas/2025-07-07T20:13:07+00:00https://lymphoma-stg.clarovantdigital.com/library/final-results-of-the-ielsg-19-randomized-trial-of-mucosa-associated-lymphoid-tissue-lymphoma-improved-event-free-and-progression-free-survival-with-rituximab-plus-chlorambucil-versus-either-chlorambu/2025-07-07T20:07:31+00:00https://lymphoma-stg.clarovantdigital.com/library/second-primary-malignant-neoplasms-and-survival-in-adolescent-and-young-adult-cancer-survivors/2025-07-07T20:03:44+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-maintenance-compared-with-placebo-in-responding-elderly-patients-with-diffuse-large-b-cell-lymphoma-treated-with-first-line-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and/2025-07-07T20:02:13+00:00https://lymphoma-stg.clarovantdigital.com/library/accessibility-availability-and-potential-benefits-of-psychoa%c2%80%c2%90oncology-services-the-perspective-of-communitya%c2%80%c2%90based-physicians-providing-cancer-survivorship-care/2025-07-07T19:43:04+00:00https://lymphoma-stg.clarovantdigital.com/library/complete-response-to-chemo-critical-in-cll-patients-who-develop-hodgkin-lymphoma/2025-07-07T19:39:52+00:00https://lymphoma-stg.clarovantdigital.com/library/treatments-and-outcomes-of-patients-with-extranodal-natural-killer-t-cell-lymphoma-diagnosed-between-2000-and-2013-a-cooperative-study-in-japan/2025-07-07T19:34:56+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-or-refractory-double-expressor-and-double-hit-lymphomas-have-inferior-progression-free-survival-after-autologous-stem-cell-transplantation-2/2025-07-07T19:32:31+00:00https://lymphoma-stg.clarovantdigital.com/library/cancer-related-fatigue-in-patients-with-and-survivors-of-hodgkin-lymphoma-the-impact-on-treatment-outcome-and-social-reintegration/2025-07-07T19:27:38+00:00https://lymphoma-stg.clarovantdigital.com/library/can-histologic-transformation-of-follicular-lymphoma-be-predicted-and-prevented/2025-07-07T19:26:02+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-discontinuation-in-cll-examined-to-help-develop-salvage-approaches/2025-07-07T19:20:17+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-contemporary-treatment-in-early-stage-hodgkin-lymphoma-updated-analyses-of-the-german-hodgkin-study-group-hd7-hd8-hd10-and-hd11-trials/2025-07-07T19:15:14+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphoma-remissions-caused-by-anti-cd19-chimeric-antigen-receptor-t-cells-are-associated-with-high-serum-interleukin-15-levels/2025-07-07T19:12:51+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-patients-with-cll-and-richter-transformation-or-with-relapsed-cll/2025-07-07T19:02:29+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-in-relapsed-primary-mediastinal-large-b-cell-lymphoma-results-from-a-phase-2-clinical-trial/2025-07-07T18:59:24+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-heart-failure-in-survivors-of-hodgkin-lymphoma-effects-of-cardiac-exposure-to-radiation-and-anthracyclines-2/2025-07-07T18:51:44+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-bruton-tyrosine-kinase-with-ibrutinib-in-relapsed-refractory-marginal-zone-lymphoma/2025-07-07T18:48:34+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-the-efficacy-and-safety-of-pembrolizumab-for-relapsed-refractory-classic-hodgkin-lymphoma/2025-07-07T18:40:29+00:00https://lymphoma-stg.clarovantdigital.com/library/subgroup-analysis-of-the-phase-ii-delta-study-idelalisib-monotherapy-is-effective-and-has-acceptable-safety-profile-in-heavily-pretreated-patients-with-relapsed-refractory-follicular-lymphoma/2025-07-07T18:35:59+00:00https://lymphoma-stg.clarovantdigital.com/library/pd1-blockade-with-pembrolizumab-is-highly-effective-in-relapsed-or-refractory-nk-t-cell-lymphoma-failing-l-asparaginase/2025-07-07T18:31:21+00:00https://lymphoma-stg.clarovantdigital.com/library/second-line-rituximab-lenalidomide-and-bendamustine-in-mantle-cell-lymphoma-a-phase-ii-clinical-trial-of-the-fondazione-italiana-linfomi/2025-07-07T18:26:53+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-blockade-for-relapsed-lymphoma-posta%c2%80%c2%93allogeneic-hematopoietic-cell-transplant-high-response-rate-but-frequent-gvhd/2025-07-07T18:02:05+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-tolerability-of-nivolumab-after-allogeneic-transplantation-for-relapsed-hodgkin-lymphoma/2025-07-07T17:58:48+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-bortezomib-in-combination-with-cyclophosphamide-and-rituximab-for-relapsed-or-refractory-mantle-cell-lymphoma-2/2025-07-07T17:54:17+00:00https://lymphoma-stg.clarovantdigital.com/library/male-breast-cancer-as-a-second-primary-cancer-increased-risk-following-lymphoma/2025-07-07T17:49:19+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-tolerability-of-pembrolizumab-in-patients-with-relapsed-refractory-primary-mediastinal-large-b-cell-lymphoma/2025-07-07T17:46:01+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-exposure-is-influenced-by-baseline-metabolic-tumor-volume-and-predicts-outcome-of-dlbcl-patients/2025-07-07T17:42:32+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-ibrutinib-dose-adherence-on-therapeutic-efficacy-in-patients-with-previously-treated-cll-sll/2025-07-07T17:30:04+00:00https://lymphoma-stg.clarovantdigital.com/library/lower-levels-of-vitamin-a-are-associated-with-increased-gastrointestinal-graft-versus-host-disease-in-children/2025-07-04T19:51:13+00:00https://lymphoma-stg.clarovantdigital.com/library/idelalisib-is-effective-in-patients-with-high-risk-follicular-lymphoma-and-early-relapse-after-initial-chemoimmunotherapy/2025-07-04T19:49:25+00:00https://lymphoma-stg.clarovantdigital.com/library/return-to-work-for-patients-with-diffuse-large-b-cell-lymphoma-and-transformed-indolent-lymphoma-undergoing-autologous-stem-cell-transplantation/2025-07-04T19:44:13+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-pet-driven-strategy-in-de-novo-diffuse-large-b-cell-lymphoma-do-we-trust-the-driver/2025-07-04T19:41:19+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-maintenance-lacks-a-clear-overall-survival-benefit-for-follicular-lymphoma/2025-07-04T19:39:08+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-features-and-outcomes-of-progression-of-cll-on-the-bcl2-inhibitor-venetoclax/2025-07-04T19:28:48+00:00https://lymphoma-stg.clarovantdigital.com/library/whole-genome-sequencing-of-chronic-lymphocytic-leukaemia-reveals-distinct-differences-in-the-mutational-landscape-between-ighv-mutated-and-ighv-unmutated-subgroups/2025-07-04T19:21:18+00:00https://lymphoma-stg.clarovantdigital.com/library/in-cll-comorbidities-and-the-complex-karyotype-are-associated-with-an-inferior-outcome-independently-of-cll-ipi/2025-07-04T19:10:36+00:00https://lymphoma-stg.clarovantdigital.com/library/copanlisib-in-patients-with-relapsed-or-refractory-indolent-b-cell-lymphoma-primary-results-of-the-pivotal-chronos-1-study/2025-07-04T19:03:33+00:00https://lymphoma-stg.clarovantdigital.com/library/unmutated-ighv-is-not-an-adverse-predictor-of-outcome-to-therapy-with-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll/2025-07-04T19:00:56+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-index-for-chronic-and-smoldering-type-adult-t-cell-leukemia-lymphoma/2025-07-04T18:58:25+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-ibrutinib-and-abt-199-in-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma/2025-07-04T18:55:40+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnosis-and-classification-of-hematologic-malignancies-on-the-basis-of-genetics/2025-12-15T19:52:34+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-3-multicenter-randomized-open-label-study-to-compare-the-efficacy-and-safety-of-lenalidomide-versus-investigators-choice-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymph/2025-07-04T18:33:47+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-double-hit-lymphoma/2025-07-04T18:32:10+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-what-is-there-to-learn-from-clinical-trials/2025-07-04T18:30:18+00:00https://lymphoma-stg.clarovantdigital.com/library/cancer-survivorship-and-opioid-prescribing-rates-a-population-based-matched-cohort-study-among-individuals-with-and-without-a-history-of-cancer/2025-07-04T18:28:44+00:00https://lymphoma-stg.clarovantdigital.com/library/significant-portion-of-pediatric-nhl-cases-occur-in-transplant-recipients/2025-07-04T18:26:33+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-patients-with-aggressive-lymphoma-at-high-risk-of-cns-relapse/2025-07-04T18:22:53+00:00https://lymphoma-stg.clarovantdigital.com/library/pretransplant-vitamin-d-deficiency-is-associated-with-higher-relapse-rates-in-patients-allografted-for-myeloid-malignancies/2025-07-04T14:55:40+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-molecular-remissions-in-chronic-lymphocytic-leukemia-treated-with-cd19-specific-chimeric-antigen-receptora%c2%80%c2%93modified-t-cells-after-failure-of-ibrutinib/2025-07-04T14:22:03+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-ii-results-a%c2%80%c2%93-lenalidomide-is-not-a-viable-option-post-allogeneic-stem-cell-transplant-for-persistent-chronic-lymphocytic-leukemia/2025-07-04T14:09:50+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-alk-with-crizotinib-in-pediatric-anaplastic-large-cell-lymphoma-and-inflammatory-myofibroblastic-tumor-a-childrena%c2%80%c2%99s-oncology-group-study/2025-07-03T19:29:49+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-cd19-car-t-cells-in-cns-diffuse-large-b-cell-lymphoma/2025-07-03T19:26:50+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-unmasks-critical-role-of-bruton-tyrosine-kinase-in-primary-cns-lymphoma/2025-07-03T19:21:29+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-response-adapted-therapy-with-rituximab-and-bendamustine-is-efficient-and-well-tolerated-in-patients-with-malt-lymphoma-a%c2%80%c2%93-long-term-results-of-the-phase-ii-geltamo-malt-2008-01/2025-07-03T19:19:40+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-ii-study-of-r-chop-with-or-without-bortezomib-in-previously-untreated-patients-with-nona%c2%80%c2%93germinal-center-b-cella%c2%80%c2%93like-diffuse-large-b-cell-lymphoma/2025-07-03T19:12:02+00:00https://lymphoma-stg.clarovantdigital.com/library/global-challenges-for-cancer-imaging/2025-07-03T19:07:03+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-or-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-in-previously-untreated-diffuse-large-b-cell-lymphoma/2025-12-15T21:22:38+00:00https://lymphoma-stg.clarovantdigital.com/library/financial-burden-in-survivors-of-childhood-cancer-a-report-from-the-childhood-cancer-survivor-study/2025-07-03T19:03:51+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-impact-of-the-cell-of-origin-classification-and-the-myc-bcl2-dual-expresser-status-in-diffuse-large-b-cell-lymphoma-treated-within-prospective-clinical-trials-of-the-german-high-grade-non-hod/2025-07-03T19:02:40+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-lenalidomide-for-large-cell-lymphoma-who-really-benefits/2025-07-03T19:01:34+00:00https://lymphoma-stg.clarovantdigital.com/library/choices-and-challenges-in-the-treatment-of-adult-t-cell-leukemia-lymphoma/2025-07-03T18:59:35+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-double-hit-lymphoma-who-achieve-first-complete-remission/2025-07-03T18:58:30+00:00https://lymphoma-stg.clarovantdigital.com/library/fdg-peta%c2%80%c2%93driven-consolidation-strategy-in-diffuse-large-b-cell-lymphoma-final-results-of-a-randomized-phase-2-study/2025-07-03T18:55:33+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-follow-up-of-brentuximab-vedotin-combined-with-abvd-or-avd-for-advanced-stage-classical-hodgkin-lymphoma/2025-07-03T18:47:00+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-rituximab-post-asct-associated-with-improved-os-in-mcl/2025-07-03T18:32:36+00:00https://lymphoma-stg.clarovantdigital.com/library/succeeding-in-breaking-the-r-chop-ceiling-in-dlbcl-learning-from-negative-trials/2025-07-03T18:25:48+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-followed-by-consolidative-proton-therapy-achieves-encouraging-relapse-free-survival-rates-in-patients-with-newly-diagnosed-hodgkin-lymphoma/2025-07-03T18:23:24+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-cell-transplantation-for-high-risk-cll-10-year-follow-up-of-the-gcllsg-cll3x-trial/2025-07-03T18:14:14+00:00https://lymphoma-stg.clarovantdigital.com/library/a-malt-lymphoma-prognostic-index/2025-07-03T18:11:50+00:00https://lymphoma-stg.clarovantdigital.com/library/vitamin-d-insufficiency-is-associated-with-an-increased-risk-of-early-clinical-failure-in-follicular-lymphoma/2025-07-03T18:10:27+00:00https://lymphoma-stg.clarovantdigital.com/library/international-working-group-consensus-response-evaluation-criteria-in-lymphoma-recil-2017/2025-07-03T18:09:08+00:00https://lymphoma-stg.clarovantdigital.com/library/emerging-role-of-bcr-signaling-inhibitors-in-immunomodulation-of-chronic-lymphocytic-leukemia/2025-07-03T18:03:20+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-after-autologous-stem-cell-transplantation-in-mantle-cell-lymphoma/2025-07-03T18:00:50+00:00https://lymphoma-stg.clarovantdigital.com/library/preexisting-cardiovascular-risk-and-subsequent-heart-failure-among-non-hodgkin-lymphoma-survivors/2025-07-03T17:57:59+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-the-causal-link-between-malaria-infection-and-endemic-burkitt-lymphoma-in-northern-uganda-a-mendelian-randomization-study/2026-03-13T19:46:24+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-for-the-first-line-treatment-of-follicular-lymphoma/2025-07-03T17:49:32+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-in-b-cell-hematologic-malignancies-a-review-of-20-years-of-clinical-experience/2025-12-10T19:47:54+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-analysis-of-hairy-cell-leukemia-identifies-novel-recurrent-genetic-alterations/2025-07-03T17:21:19+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-safety-and-efficacy-of-cart-20-cells-in-patients-with-refractory-or-relapsed-b-cell-non-hodgkin-lymphoma-5-years-follow-up-results-of-the-phase-i-and-iia-trials/2025-07-03T15:48:37+00:00https://lymphoma-stg.clarovantdigital.com/library/phosphatidylinositol-3-kinase-inhibition-by-copanlisib-in-relapsed-or-refractory-indolent-lymphoma/2025-07-03T15:40:13+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-mutation-and-its-prognostic-significance-in-waldenstroms-macroglobulinemia/2025-07-03T15:35:11+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-results-of-a-phase-2-study-of-rituximab-and-bendamustine-for-mucosa-associated-lymphoid-tissue-lymphoma/2025-07-03T15:33:24+00:00https://lymphoma-stg.clarovantdigital.com/library/surrogate-endpoints-in-oncology-when-are-they-acceptable-for-regulatory-and-clinical-decisions-and-are-they-currently-overused/2025-06-30T20:43:41+00:00https://lymphoma-stg.clarovantdigital.com/library/fear-of-cancer-recurrence-in-an-era-of-personalized-medicine/2025-06-30T20:42:43+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-b-cell-antigen-receptors-in-mantle-cell-lymphoma/2025-06-30T20:40:31+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-outcomes-of-primary-central-nervous-system-lymphoma-in-solid-organ-transplant-recipients/2025-06-30T20:37:19+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-refractory-diffuse-large-b-cell-lymphoma-results-from-the-international-scholar-1-study/2025-06-30T20:35:50+00:00https://lymphoma-stg.clarovantdigital.com/library/refractory-or-relapsed-aggressive-b-cell-lymphoma-failing-r-chop-an-analysis-of-patients-treated-on-the-ricover-60-trial/2025-06-30T20:32:37+00:00https://lymphoma-stg.clarovantdigital.com/library/irradiation-safe-effective-as-chemotherapy-before-cell-transplant-in-mantle-cell-lymphoma/2025-05-27T14:44:14+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-14-with-or-without-radiotherapy-in-non-bulky-limited-stage-diffuse-large-b-cell-lymphoma-dlbcl/2025-05-27T13:51:40+00:00https://lymphoma-stg.clarovantdigital.com/library/an-anergic-immune-signature-in-the-tumor-microenvironment-of-classical-hodgkin-lymphoma-is-associated-with-inferior-outcome/2025-06-30T20:28:16+00:00https://lymphoma-stg.clarovantdigital.com/library/no-benefit-with-prolonged-native-e-coli-asparaginase-in-pediatric-all-nhl/2025-06-30T20:25:48+00:00https://lymphoma-stg.clarovantdigital.com/library/breast-implanta%c2%80%c2%93associated-anaplastic-large-cell-lymphoma/2025-12-15T19:50:27+00:00https://lymphoma-stg.clarovantdigital.com/library/double-hit-lymphoma-a-new-category-of-lymphoma-without-a-standard-of-care-treatment/2025-06-30T20:17:49+00:00https://lymphoma-stg.clarovantdigital.com/library/international-assessment-of-event-free-survival-at-24-months-and-subsequent-survival-in-peripheral-t-cell-lymphoma/2025-06-30T20:16:16+00:00https://lymphoma-stg.clarovantdigital.com/library/the-potential-for-chemotherapy-free-strategies-in-mantle-cell-lymphoma/2025-06-30T20:14:44+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-mutations-identify-younger-mantle-cell-lymphoma-patients-who-do-not-benefit-from-intensive-chemoimmunotherapy-2/2025-06-30T20:12:18+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-patients-with-hiv-related-hematological-malignancies-using-hematopoietic-cell-transplantation/2025-12-15T19:15:37+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-features-of-ocular-adnexal-mantle-cell-lymphoma-in-an-international-multicenter-cohort/2025-06-30T20:02:02+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-results-of-the-foll05-trial-comparing-r-cvp-versus-r-chop-versus-r-fm-for-the-initial-treatment-of-patients-with-advanced-stage-symptomatic-follicular-lymphoma/2025-06-30T19:56:51+00:00https://lymphoma-stg.clarovantdigital.com/library/pi3k-inhibitors-understanding-toxicity-mechanisms-and-management/2026-01-15T17:11:28+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-based-first-line-treatment-of-cgvhd-after-allogeneic-sct-results-of-a-phase-2-study/2025-06-30T19:40:26+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-anthracycline-and-comprehensive-geriatric-assessment-for-elderly-patients-with-diffuse-large-b-cell-lymphoma/2025-06-30T19:37:51+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-baseline-metabolic-tumor-volume-in-relapsed-and-refractory-hodgkin-lymphoma/2025-06-30T19:27:45+00:00https://lymphoma-stg.clarovantdigital.com/library/chemoimmunotherapy-is-not-dead-yet-in-chronic-lymphocytic-leukemia/2025-06-30T19:25:49+00:00https://lymphoma-stg.clarovantdigital.com/library/breast-implants-risk-of-anaplastic-large-cell-lymphoma-bia-alcl/2025-06-30T18:58:55+00:00https://lymphoma-stg.clarovantdigital.com/library/fcr-achieves-long-term-durable-remissions-in-patients-with-ighv-mutated-cll/2025-06-30T18:56:42+00:00https://lymphoma-stg.clarovantdigital.com/library/early-progression-of-disease-as-a-predictor-of-survival-in-chronic-lymphocytic-leukemia/2025-06-30T18:29:27+00:00https://lymphoma-stg.clarovantdigital.com/library/association-between-use-of-thiopurines-or-tumor-necrosis-factor-antagonists-alone-or-in-combination-and-risk-of-lymphoma-in-patients-with-inflammatory-bowel-disease/2025-06-30T18:28:10+00:00https://lymphoma-stg.clarovantdigital.com/library/results-from-the-phase-iiib-mabease-study-strong-case-made-for-rituximab-sc-in-first-line-dlbcl/2025-06-30T18:24:45+00:00https://lymphoma-stg.clarovantdigital.com/library/cancer-incidence-and-mortality-among-young-adults-aged-20a%c2%80%c2%9339-years-worldwide-in-2012-a-population-based-study/2025-06-30T18:07:03+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cells-in-refractory-b-cell-lymphomas/2025-06-30T17:20:13+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-a-review-and-update-on-recent-progress/2025-06-30T16:53:31+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-testing-patterns-and-outcomes-of-chronic-lymphocytic-leukemia-patients-stratified-by-fluorescence-in-situ-hybridization-cytogenetics/2025-06-30T16:50:47+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-effective-as-first-line-therapy-for-waldenstrom-macroglobulinemia/2025-06-26T14:22:39+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-polatuzumab-vedotin-to-bendamustine-and-rituximab-br-improves-outcomes-in-transplant-ineligible-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-versus-br-al/2025-06-26T14:17:47+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-up-front-autologous-stem-cell-transplantation-in-peripheral-t-cell-lymphoma-for-patients-in-response-after-induction-an-analysis-of-patients-from-lysa-centers/2025-06-26T14:12:15+00:00https://lymphoma-stg.clarovantdigital.com/library/myd88-mutations-predict-unfavorable-prognosis-in-chronic-lymphocytic-leukemia-patients-with-mutated-ighv-gene/2025-06-26T14:09:05+00:00https://lymphoma-stg.clarovantdigital.com/library/patienta%c2%80%c2%90reported-comorbidity-and-survival-in-older-adults-with-cancer/2025-06-26T14:07:28+00:00https://lymphoma-stg.clarovantdigital.com/library/breast-implants-and-the-risk-of-anaplastic-large-cell-lymphoma-in-the-breast/2025-06-26T13:55:55+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-for-patients-with-chronic-lymphocytic-leukemia-who-progressed-during-or-after-idelalisib-therapy/2025-06-26T13:52:09+00:00https://lymphoma-stg.clarovantdigital.com/library/infectious-complications-of-cd19-targeted-chimeric-antigen-receptora%c2%80%c2%93modified-t-cell-immunotherapy/2025-06-26T13:48:43+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-expression-and-clinical-pd-1-blockade-in-b-cell-lymphomas/2025-06-26T13:47:05+00:00https://lymphoma-stg.clarovantdigital.com/library/reclassifying-patients-with-early-stage-hodgkin-lymphoma-based-on-functional-radiographic-markers-at-presentation/2025-06-30T19:19:53+00:00https://lymphoma-stg.clarovantdigital.com/library/bleomycin-pulmonary-toxicity-in-hodgkins-lymphoma-treated-with-abvd-regimen-not-followed-by-radiation/2025-06-26T13:43:04+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplantation-after-second-line-brentuximab-vedotin-in-relapsed-or-refractory-hodgkin-lymphoma/2025-06-26T12:51:29+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-results-of-brentuximab-vedotin-in-patients-with-relapsed-or-refractory-systemic-anaplastic-large-cell-lymphoma/2025-06-26T12:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/consolidative-radiotherapy-to-residual-masses-after-chemotherapy-is-associated-with-improved-outcome-in-diffuse-large-b-cell-lymphoma-a-retrospective-population-based-study/2025-05-27T13:50:02+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplantation-in-elderly-lymphoma-patients-in-their-70s-outcomes-and-analysis/2025-06-26T12:12:39+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-brentuximab-vedotin-in-combination-with-dacarbazine-or-bendamustine-in-patients-aged-a%c2%89%c2%a560-years-with-hl/2025-06-26T12:10:48+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-plus-rituximab-versus-ra%c2%80%c2%90chop-as-firsta%c2%80%c2%90line-treatment-for-patients-with-follicular-lymphoma-grade-3a-evidence-from-a-multicenter-retrospective-study/2025-06-26T12:07:04+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-14-with-or-without-radiotherapy-in-nonbulky-limited-stage-diffuse-large-b-cell-lymphoma/2025-06-25T22:49:14+00:00https://lymphoma-stg.clarovantdigital.com/library/single-agent-ibrutinib-in-relapsed-or-refractory-follicular-lymphoma-a-phase-2-consortium-trial/2025-06-25T22:47:22+00:00https://lymphoma-stg.clarovantdigital.com/library/foxp1-expression-is-a-prognostic-biomarker-in-follicular-lymphoma-treated-with-rituximab-and-chemotherapy/2025-06-25T21:00:47+00:00https://lymphoma-stg.clarovantdigital.com/library/pan-phosphatidylinositol-3-kinase-inhibition-with-buparlisib-in-patients-with-relapsed-or-refractory-non-hodgkin-lymphoma/2025-06-25T20:57:01+00:00https://lymphoma-stg.clarovantdigital.com/library/adjuvant-everolimus-in-high-risk-diffuse-large-b-cell-lymphoma-final-results-from-the-pillar-2-randomized-phase-iii-trial/2025-06-25T20:54:29+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-with-chemotherapy-for-stage-iii-or-iv-hodgkina%c2%80%c2%99s-lymphoma/2025-06-25T20:48:40+00:00https://lymphoma-stg.clarovantdigital.com/library/continued-excellent-outcomes-in-previously-untreated-patients-with-follicular-lymphoma-after-treatment-with-chop-plus-rituximab-or-chop-plus-131i-tositumomab-long-term-follow-up-of-phase-iii-randomiz/2025-06-25T20:44:58+00:00https://lymphoma-stg.clarovantdigital.com/library/early-chemotherapy-intensification-with-escalated-beacopp-in-patients-with-advanced-stage-hodgkin-lymphoma-with-a-positive-interim-positron-emission-tomography-computed-tomography-scan-after-two-abvd/2025-06-24T19:53:40+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-cll-patients-with-ibrutinib/2025-06-24T19:45:13+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-1-study-of-romidepsin-and-pralatrexate-reveals-marked-activity-in-relapsed-and-refractory-t-cell-lymphoma/2025-06-24T19:43:47+00:00https://lymphoma-stg.clarovantdigital.com/library/immunotherapy-in-relapsed-refractory-hodgkin-lymphoma/2025-06-24T19:06:31+00:00https://lymphoma-stg.clarovantdigital.com/library/frailty-and-the-management-of-hematologic-malignancies/2025-06-24T18:59:06+00:00https://lymphoma-stg.clarovantdigital.com/library/activity-of-pembrolizumab-in-relapsed-refractory-nk-t-cell-lymphoma/2025-06-24T13:46:41+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-mirna-classifier-in-early-stage-mycosis-fungoides-development-and-validation-in-a-danish-nationwide-study/2025-06-24T13:38:59+00:00https://lymphoma-stg.clarovantdigital.com/library/lack-of-usefulness-of-computed-tomography-for-surveillance-in-patients-with-aggressive-non-hodgkin-lymphoma/2025-06-24T13:37:02+00:00https://lymphoma-stg.clarovantdigital.com/library/cancer-specific-stress-and-trajectories-of-psychological-and-physical-functioning-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia/2025-06-24T13:32:24+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphoma-treatment-outcomes-just-as-good-for-people-with-hiv/2025-06-24T13:26:51+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-iia-study-of-the-cd19-antibody-mor208-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkina%c2%80%c2%99s-lymphoma/2025-06-24T13:15:02+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-factors-for-complete-response-to-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia/2025-06-23T19:07:49+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-immune-related-adverse-events-in-patients-treated-with-immune-checkpoint-inhibitor-therapy-american-society-of-clinical-oncology-clinical-practice-guideline/2025-06-23T19:05:36+00:00https://lymphoma-stg.clarovantdigital.com/library/duvelisib-a-novel-oral-dual-inhibitor-of-pi3k-oy-is-clinically-active-in-advanced-hematologic-malignancies/2025-06-23T19:03:43+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-10-years-real-world-clinical-experience-with-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisolone/2025-06-23T18:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-checkpoint-inhibition-in-hodgkin-lymphoma/2025-06-23T18:42:51+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-remission-with-mogamulizumab-in-peripheral-t-cell-lymphoma-with-aberrant-cd20-expression-case-report-and-literature-review/2025-06-23T18:38:43+00:00https://lymphoma-stg.clarovantdigital.com/library/survivorship-burden-for-individuals-households-and-society-estimates-and-methodology/2024-07-30T20:33:10+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-results-for-the-use-of-rituximab-and-chemotherapy-combo-for-pcnsl/2025-06-23T18:34:28+00:00https://lymphoma-stg.clarovantdigital.com/library/prevalence-of-cognitive-impairment-and-association-with-survival-among-older-patients-with-hematologic-cancers/2025-06-23T18:29:17+00:00https://lymphoma-stg.clarovantdigital.com/library/frequency-and-level-of-evidence-used-in-recommendations-by-the-national-comprehensive-cancer-network-guidelines-beyond-approvals-of-the-us-food-and-drug-administration-retrospective-observational-stu/2025-06-23T18:21:25+00:00https://lymphoma-stg.clarovantdigital.com/library/posttransplant-chimeric-antigen-receptor-therapy/2025-06-23T18:20:12+00:00https://lymphoma-stg.clarovantdigital.com/library/stem-cell-transplants-bring-long-term-benefits-to-relapsed-follicular-lymphoma-patients/2025-06-23T18:15:07+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-results-of-brentuximab-vedotin-in-combination-with-nivolumab-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma-2/2025-06-23T18:06:04+00:00https://lymphoma-stg.clarovantdigital.com/library/critical-revision-of-the-role-of-surgery-for-treatment-of-primary-brain-b-cell-lymphoma-in-an-immunocompetent-patient-a-case-report-and-literature-review/2025-06-23T17:27:27+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclaxa%c2%80%c2%93rituximab-in-relapsed-or-refractory-chronic-lymphocytic-leukemia/2025-06-23T17:25:19+00:00https://lymphoma-stg.clarovantdigital.com/library/pk-and-pd-comparison-between-rituximab-biosimilar-rtxm83-and-rituximab-in-diffuse-large-b-cell-lymphoma-patients/2025-06-23T17:18:54+00:00https://lymphoma-stg.clarovantdigital.com/library/overall-survival-benefit-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-who-received-obinutuzumab-plus-bendamustine-induction-and-obinutuzumab-maintenance-in-the-gadolin-study/2026-01-15T13:42:22+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-venetoclax-for-the-treatment-of-mantle-cell-lymphoma/2025-05-23T19:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-baseline-metabolic-tumor-volume-in-early-stage-hodgkin-lymphoma-in-the-standard-arm-of-the-h10-trial/2025-06-19T20:52:30+00:00https://lymphoma-stg.clarovantdigital.com/library/balancing-risk-and-benefit-in-early-stage-classical-hodgkin-lymphoma/2025-05-27T13:43:52+00:00https://lymphoma-stg.clarovantdigital.com/library/optimizing-therapy-in-advanced-stage-hodgkin-lymphoma/2025-05-27T13:38:46+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-relapsed-refractory-classical-hodgkin-lymphoma-in-transplant-ineligible-patients/2025-05-27T13:25:19+00:00https://lymphoma-stg.clarovantdigital.com/library/genetics-and-pathogenesis-of-diffuse-large-b-cell-lymphoma/2025-06-19T20:43:05+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-transplantation-versus-allogeneic-transplantation-in-patients-with-follicular-lymphoma-experiencing-early-treatment-failure/2025-06-19T20:41:27+00:00https://lymphoma-stg.clarovantdigital.com/library/late-mortality-after-autologous-blood-or-marrow-transplantation-in-childhood-a-bmtss-2-report/2025-06-19T20:38:28+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-ptcl-patients-failing-first-line-therapy-international-t-cell-project-analysis/2025-06-19T20:32:46+00:00https://lymphoma-stg.clarovantdigital.com/library/review-of-targeted-therapy-in-chronic-lymphocytic-leukemia-what-a-radiologist-needs-to-know-about-ct-interpretation/2025-05-13T14:00:29+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnosis-to-treatment-interval-is-an-important-clinical-factor-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-and-has-implication-for-bias-in-clinical-trials/2025-06-19T20:12:13+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-in-pretreated-mantle-cell-lymphoma-patients-an-italian-observational-multicenter-retrospective-study-in-daily-clinical-practice-the-lenamant-study/2025-06-11T17:00:00+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-for-relapsed-refractory-classic-hodgkin-lymphoma-after-failure-of-autologous-hematopoietic-cell-transplantation-extended-follow-up-of-the-multicohort-single-arm-phase-ii-checkmate-205-trial/2025-06-19T20:10:12+00:00https://lymphoma-stg.clarovantdigital.com/library/non-drug-costs-of-car-t-cell-therapy-may-exceed-50000/2025-12-19T18:51:22+00:00https://lymphoma-stg.clarovantdigital.com/library/at-what-cost-to-clinical-trial-enrollment-a-retrospective-study-of-patient-travel-burden-in-cancer-clinical-trials/2025-06-19T17:32:16+00:00https://lymphoma-stg.clarovantdigital.com/library/early-onset-invasive-aspergillosis-and-other-fungal-infections-in-patients-treated-with-ibrutinib/2025-06-19T14:30:23+00:00https://lymphoma-stg.clarovantdigital.com/library/single-agent-ibrutinib-in-treatment-naa%c2%afve-and-relapsed-refractory-chronic-lymphocytic-leukemia-a-5-year-experience/2025-06-19T14:28:35+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-cd30-and-pd-1-targeted-therapies-for-classical-hodgkin-lymphoma/2025-06-19T14:25:10+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-for-patients-with-chronic-lymphocytic-leukemia-with-17p-deletion-results-from-the-full-population-of-a-phase-ii-pivotal-trial/2025-06-19T14:20:17+00:00https://lymphoma-stg.clarovantdigital.com/library/metformin-is-not-associated-with-incidence-risk-of-non-hodgkin-lymphomas-among-diabetic-patients/2025-06-19T14:15:00+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-rituximab-is-an-effective-salvage-therapy-in-cll/2025-06-19T14:01:08+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-versus-rituximab-in-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-a-randomized-opena%c2%80%c2%90label-phase-3-study/2026-01-15T14:05:47+00:00https://lymphoma-stg.clarovantdigital.com/library/serious-infections-in-patients-receiving-ibrutinib-for-treatment-of-lymphoid-cancer/2025-06-19T13:53:13+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-outcomes-for-frontline-brentuximab-vedotin-with-chp-for-cd30-expressing-peripheral-t-cell-lymphomas-2/2025-06-19T13:50:03+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-survival-improving-over-time-in-advanced-hodgkin-lymphoma/2025-12-19T18:50:33+00:00https://lymphoma-stg.clarovantdigital.com/library/positron-emission-tomographya%c2%80%c2%93guided-therapy-of-aggressive-non-hodgkin-lymphomas-petal-a-multicenter-randomized-phase-iii-trial/2025-06-19T13:39:00+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-results-from-the-phase-iii-ray-trial-ibrutinib-vs-temsirolimus-for-mcl/2025-06-18T20:58:35+00:00https://lymphoma-stg.clarovantdigital.com/library/cells-cytokines-chemokines-and-cancer-stress-a-biobehavioral-study-of-patients-with-chronic-lymphocytic-leukemia/2025-06-18T20:55:05+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-results-of-rituximab-pre-and-post-beam-with-or-without-90yttrium-ibritumomab-tiuxetan-during-autologous-transplant-for-diffuse-large-b-cell-lymphoma/2025-06-18T20:51:47+00:00https://lymphoma-stg.clarovantdigital.com/library/frequency-of-bowel-perforation-and-impact-of-bowel-rest-in-aggressive-nona%c2%80%c2%90hodgkin-lymphoma-with-gastrointestinal-involvement/2025-06-18T20:49:41+00:00https://lymphoma-stg.clarovantdigital.com/library/a-new-prognostic-model-for-ptcl-nos-developed-on-prospectively-collected-data/2025-06-18T20:34:44+00:00https://lymphoma-stg.clarovantdigital.com/library/rapid-progression-of-adult-t-cell-leukemiaa%c2%80%c2%93lymphoma-after-pd-1-inhibitor-therapy/2025-06-18T20:29:35+00:00https://lymphoma-stg.clarovantdigital.com/library/chop-versus-gem-p-in-previously-untreated-patients-with-peripheral-t-cell-lymphoma-chemo-t-a-phase-2-multicentre-randomised-open-label-trial/2025-06-18T20:27:48+00:00https://lymphoma-stg.clarovantdigital.com/library/reducing-dose-intensity-may-be-associated-with-shortened-pfs-in-waldenstrom-macroglobulinemia/2025-06-18T20:20:26+00:00https://lymphoma-stg.clarovantdigital.com/library/depth-and-durability-of-response-to-ibrutinib-in-cll-5-year-follow-up-of-a-phase-2-study/2025-06-18T20:03:39+00:00https://lymphoma-stg.clarovantdigital.com/library/longa%c2%80%c2%90term-survival-rates-of-patients-with-stage-iiia%c2%80%c2%93iv-hodgkin-lymphoma-according-to-age-sex-race-and-socioeconomic-status-1984a%c2%80%c2%932013/2025-06-18T19:52:28+00:00https://lymphoma-stg.clarovantdigital.com/library/biallelic-birc3-inactivation-in-chronic-lymphocytic-leukaemia-patients-with-11q-deletion-identifies-a-subgroup-with-very-aggressive-disease/2025-06-18T19:42:31+00:00https://lymphoma-stg.clarovantdigital.com/library/six-gene-signature-predicts-poor-pfs-in-mcl/2025-06-18T19:40:07+00:00https://lymphoma-stg.clarovantdigital.com/library/myc-bcl2-bcl6-triple-hit-lymphoma-a-study-of-40-patients-with-a-comparison-to-myc-bcl2-and-myc-bcl6-double-hit-lymphomas/2025-06-18T19:14:08+00:00https://lymphoma-stg.clarovantdigital.com/library/an-evidence-based-review-of-anti-cd20-antibody-containing-regimens-for-the-treatment-of-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-diffuse-large-b-cell-lymphoma-or-follicular/2025-06-18T19:11:59+00:00https://lymphoma-stg.clarovantdigital.com/library/update-on-hairy-cell-leukemia/2025-06-18T19:08:57+00:00https://lymphoma-stg.clarovantdigital.com/library/spontaneous-regression-of-mantle-cell-lymphoma-a-report-of-four-cases/2020-05-20T10:33:05+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-reveals-genetics-clonal-evolution-and-residual-disease-in-classical-hodgkin-lymphoma/2025-06-18T19:00:07+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-assesses-the-use-of-rituximab-and-bendamustine-in-frail-elderly-dlbcl-patients/2025-06-18T18:58:11+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-3-trial-of-ibrutinib-plus-rituximab-in-waldenstroma%c2%80%c2%99s-macroglobulinemia/2025-06-18T18:53:37+00:00https://lymphoma-stg.clarovantdigital.com/library/global-regional-and-national-cancer-incidence-mortality-years-of-life-lost-years-lived-with-disability-and-disability-adjusted-life-years-for-29-cancer-groups-1990-to-2016/2025-06-18T18:50:43+00:00https://lymphoma-stg.clarovantdigital.com/library/an-open-label-phase-2-trial-of-entospletinib-gs-9973-a-selective-spleen-tyrosine-kinase-inhibitor-in-diffuse-large-b-cell-lymphoma/2025-06-18T18:23:02+00:00https://lymphoma-stg.clarovantdigital.com/library/immunochemotherapy-with-obinutuzumab-or-rituximab-for-previously-untreated-follicular-lymphoma-in-the-gallium-study-influence-of-chemotherapy-on-efficacy-and-safety/2025-06-17T21:01:14+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-monotherapy-may-improve-survival-in-deletion-p17-chronic-lymphocytic-leukemia/2025-06-17T20:54:28+00:00https://lymphoma-stg.clarovantdigital.com/library/salvage-radiotherapy-improves-survival-in-patients-with-locoregionally-relapsed-stage-iea%c2%80%c2%93iie-extranodal-natural-killer-t-cell-lymphoma-nasal-type/2025-06-17T20:45:35+00:00https://lymphoma-stg.clarovantdigital.com/library/predictors-of-atrial-fibrillation-in-ibrutinib-treated-cll-patients-a-prospective-study/2025-06-17T20:44:32+00:00https://lymphoma-stg.clarovantdigital.com/library/the-association-between-dietary-quality-and-overall-and-cancer-specific-mortality-among-cancer-survivors-nhanes-iii/2025-06-17T20:40:18+00:00https://lymphoma-stg.clarovantdigital.com/library/aggressive-b-cell-lymphomas-in-patients-with-myelofibrosis-receiving-jak1-2-inhibitor-therapy/2025-06-17T20:38:34+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-effective-against-cll-in-a%c2%80%c2%98real-worlda%c2%80%c2%99-setting/2025-06-17T20:04:48+00:00https://lymphoma-stg.clarovantdigital.com/library/how-to-decide-which-dlbcl-patients-should-receive-cns-prophylaxis/2025-06-17T20:00:16+00:00https://lymphoma-stg.clarovantdigital.com/library/increased-risk-of-infectious-complications-in-older-patients-with-indolent-non-hodgkin-lymphoma-exposed-to-bendamustine/2025-06-17T19:56:05+00:00https://lymphoma-stg.clarovantdigital.com/library/whole-body-mri-versus-18f-fdg-pet-ct-for-pretherapeutic-assessment-and-staging-of-lymphoma-a-meta-analysis/2025-06-17T19:49:40+00:00https://lymphoma-stg.clarovantdigital.com/library/iwcll-guidelines-for-diagnosis-indications-for-treatment-response-assessment-and-supportive-management-of-cll/2025-06-17T19:34:05+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-as-treatment-for-patients-with-relapsed-refractory-follicular-lymphoma-results-from-the-open-label-multicenter-phase-ii-dawn-study/2025-06-17T18:20:18+00:00https://lymphoma-stg.clarovantdigital.com/library/venous-thromboembolism-in-patients-with-b-cell-non-hodgkin-lymphoma-treated-with-lenalidomide-a-systematic-review-and-meta-analysis/2025-06-17T18:16:46+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-analysis-of-4-randomized-controlled-studies-of-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-or-mantle-cell-lymphoma/2025-06-17T18:13:37+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-characteristics-of-chinese-diffuse-large-b-cell-lymphoma-patients-implications-for-cancer-immunotherapies/2025-06-17T18:10:37+00:00https://lymphoma-stg.clarovantdigital.com/library/cns-relapse-in-patients-with-dlbcl-treated-with-lenalidomide-plus-r-chop-r2chop-analysis-from-two-phase-2-studies/2025-06-17T18:06:35+00:00https://lymphoma-stg.clarovantdigital.com/library/progression-free-survival-as-a-surrogate-end-point-for-overall-survival-in-first-line-diffuse-large-b-cell-lymphoma-an-individual-patienta%c2%80%c2%93level-analysis-of-multiple-randomized-trials-sea/2025-06-17T17:36:59+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-expression-profiling-reveals-a-close-relationship-between-follicular-lymphoma-grade-3a-and-3b-but-distinct-profiles-of-follicular-lymphoma-grade-1-and-2/2025-06-17T17:32:21+00:00https://lymphoma-stg.clarovantdigital.com/library/still-a-role-for-second-line-chemoimmunotherapy-in-chronic-lymphocytic-leukemia/2025-12-28T13:45:53+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-plus-bendamustine-a-highly-active-first-salvage-regimen-for-relapsed-or-refractory-hodgkin-lymphoma/2025-06-17T15:55:59+00:00https://lymphoma-stg.clarovantdigital.com/library/recommendations-for-managing-pd-1-blockade-in-the-context-of-allogeneic-hct-in-hodgkin-lymphoma-taming-a-necessary-evil/2025-06-17T15:54:09+00:00https://lymphoma-stg.clarovantdigital.com/library/how-and-when-i-do-allogeneic-transplant-in-cll/2025-06-17T15:52:17+00:00https://lymphoma-stg.clarovantdigital.com/library/bortezomib-based-therapy-for-transplant-ineligible-east-asian-patients-with-newly-diagnosed-mantle-cell-lymphoma/2025-06-17T15:49:56+00:00https://lymphoma-stg.clarovantdigital.com/library/western-diet-linked-with-cll/2025-06-17T15:46:18+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-trial-of-systemic-therapy-after-involved-field-radiotherapy-in-patients-with-early-stage-follicular-lymphoma-trog-99-03/2025-06-17T15:41:51+00:00https://lymphoma-stg.clarovantdigital.com/library/up-front-rituximab-maintenance-improves-outcome-in-patients-with-follicular-lymphoma-a-collaborative-nordic-study/2025-06-17T14:38:01+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-appears-safe-effective-in-relapsed-refractory-cll/2025-06-17T14:35:24+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-patients-with-early-stage-infradiaphragmatic-hodgkin-lymphoma-a-comprehensive-analysis-from-the-german-hodgkin-study-group/2025-06-17T14:28:47+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-clinical-trial-of-ixazomib-dexamethasone-and-rituximab-as-primary-therapy-in-waldenstrom-macroglobulinemia/2025-06-17T14:14:20+00:00https://lymphoma-stg.clarovantdigital.com/library/monoclonal-antibody-biosimilars-in-oncology-critical-appraisal-of-available-data-on-switching/2025-06-17T14:07:44+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-advanced-hodgkin-lymphoma-after-umbilical-cord-blood-transplantation-a-eurocord-and-ebmt-lymphoma-and-cellular-therapy-immunobiology-working-party-study/2025-06-16T21:08:51+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-burkitt-lymphoma-in-children-adolescents-and-young-adults-in-sub-saharan-africa/2026-03-13T19:45:52+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-and-refractory-nodular-lymphocyte-predominant-hodgkin-lymphoma-an-analysis-from-the-german-hodgkin-study-group/2025-06-16T21:05:14+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-rituximab-bortezomib-demonstrates-90-2-dfs-at-2-years-in-mcl/2025-06-16T21:02:44+00:00https://lymphoma-stg.clarovantdigital.com/library/dual-immunotherapy-adds-value-in-relapsed-refractory-hodgkin-lymphoma/2025-06-16T20:57:30+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-treatment-for-patients-with-mantle-cell-lymphoma-a-systematic-review-and-meta-analysis-of-randomized-trials/2025-06-16T20:55:29+00:00https://lymphoma-stg.clarovantdigital.com/library/contemporarily-treated-patients-with-hodgkin-lymphoma-have-childbearing-potential-in-line-with-matched-comparators/2025-06-16T20:42:20+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-consolidation-benefits-patients-with-cll-receiving-chemoimmunotherapy-results-for-calgb-10404-alliance/2025-06-16T20:35:22+00:00https://lymphoma-stg.clarovantdigital.com/library/improvement-of-fatigue-physical-functioning-and-well-being-among-patients-with-severe-impairment-at-baseline-receiving-ibrutinib-in-combination-with-bendamustine-and-rituximab-for-relapsed-chronic-l/2025-06-16T20:28:09+00:00https://lymphoma-stg.clarovantdigital.com/library/cancer-related-fatigue-and-muscle-quality-in-hodgkina%c2%80%c2%99s-lymphoma-survivors/2025-06-16T20:24:42+00:00https://lymphoma-stg.clarovantdigital.com/library/peripheral-t-cell-lymphomas-incorporating-new-developments-in-diagnostics-prognostication-and-treatment-into-clinical-practicea%c2%80%c2%94part-2-enktl-eatl-indolent-t-cell-ldp-of-the-gi-tract/2025-06-16T20:22:55+00:00https://lymphoma-stg.clarovantdigital.com/library/staging-of-mycosis-fungoides-and-sezary-syndrome-time-for-an-update/2025-06-11T20:14:07+00:00https://lymphoma-stg.clarovantdigital.com/library/improvement-in-parameters-of-hematologic-and-immunologic-function-and-patient-well-being-in-the-phase-iii-resonate-study-of-ibrutinib-vs-ofatumumab-in-patients-with-previously-treated-chronic-lymphocy/2025-06-11T20:06:12+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-measurements-as-early-outcome-predictors-in-diffuse-large-b-cell-lymphoma/2025-06-11T20:02:12+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-ibrutinib-as-first-line-therapy-for-chronic-lymphocytic-leukemia-in-older-adults-without-deletion-17p/2025-06-11T19:46:54+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-primary-mediastinal-b-cell-lymphoma/2025-06-11T19:37:42+00:00https://lymphoma-stg.clarovantdigital.com/library/what-is-the-best-approach-to-managing-chemobrain/2025-06-11T19:30:52+00:00https://lymphoma-stg.clarovantdigital.com/library/early-stage-follicular-lymphoma-what-is-the-preferred-treatment-strategy/2025-06-11T19:26:50+00:00https://lymphoma-stg.clarovantdigital.com/library/high-risk-chronic-lymphocytic-leukemia-in-the-era-of-pathway-inhibitors-integrating-molecular-and-cellular-therapies/2025-06-11T19:23:30+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-ba%c2%80%c2%91cell-lymphoma-with-pulmonary-and-cerebral-involvement-a-case-report/2025-06-11T19:21:28+00:00https://lymphoma-stg.clarovantdigital.com/library/changing-geographical-patterns-and-trends-in-cancer-incidence-in-children-and-adolescents-in-europe-1991a%c2%80%c2%932010-automated-childhood-cancer-information-system-a-population-based-study/2025-06-11T19:15:19+00:00https://lymphoma-stg.clarovantdigital.com/library/current-status-and-progress-of-lymphoma-management-in-china/2025-06-11T19:14:06+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-phase-ii-study-of-sequential-brentuximab-vedotin-and-doxorubicin-vinblastine-and-dacarbazine-chemotherapy-for-older-patients-with-untreated-classical-hodgkin-lymphoma/2025-06-11T17:56:36+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-follow-up-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma/2025-06-11T17:53:22+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-and-efficacy-of-addition-of-individualized-dose-lenalidomide-to-chlorambucil-and-rituximab-as-first-line-treatment-in-elderly-and-fcr-unfit-patients-with-advanced-chronic-lymphocytic-leuke/2025-06-11T17:48:44+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-rituximab-and-half-dose-chop-as-primary-therapy-for-untreated-symptomatic-waldenstrom-macroglobulinemia-review-of-a-combined-regimen-of-rituximab-with-an-alkylating-agent/2025-06-11T17:36:08+00:00https://lymphoma-stg.clarovantdigital.com/library/a-step-forward-in-addressing-cancer-survivorship-in-the-asia-pacific-region/2025-06-11T17:32:13+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-plus-lenalidomide-in-advanced-untreated-follicular-lymphoma/2025-06-11T17:49:32+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-gastrointestinal-diffuse-large-b-cell-lymphoma/2025-06-11T17:20:16+00:00https://lymphoma-stg.clarovantdigital.com/library/global-cancer-statistics-2018-globocan-estimates-of-incidence-and-mortality-worldwide-for-36-cancers-in-185-countries/2025-06-11T16:46:15+00:00https://lymphoma-stg.clarovantdigital.com/library/comprehensive-safety-analysis-of-venetoclax-monotherapy-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia/2025-06-11T16:44:52+00:00https://lymphoma-stg.clarovantdigital.com/library/another-step-towards-improving-oncofertility-counselling-of-young-women-with-hodgkins-lymphoma/2025-06-11T16:43:15+00:00https://lymphoma-stg.clarovantdigital.com/library/determinants-of-ovarian-function-after-response-adapted-therapy-in-patients-with-advanced-hodgkins-lymphoma-rathl-a-secondary-analysis-of-a-randomised-phase-3-trial/2025-06-11T16:41:18+00:00https://lymphoma-stg.clarovantdigital.com/library/peg-l-chop-treatment-is-safe-and-effective-in-adult-extranodal-nk-t-cell-lymphoma-with-a-low-rate-of-clinical-hypersensitivity/2025-06-11T16:37:47+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-release-syndrome-grading-modeling-and-new-therapy/2025-06-10T20:13:15+00:00https://lymphoma-stg.clarovantdigital.com/library/the-burden-of-cancers-and-their-variations-across-the-states-of-india-the-global-burden-of-disease-study-1990a%c2%80%c2%932016/2025-06-10T20:11:37+00:00https://lymphoma-stg.clarovantdigital.com/library/body-composition-measurements-and-risk-of-hematological-malignancies-a-population-based-cohort-study-during-20-years-of-follow-up/2025-06-10T20:06:01+00:00https://lymphoma-stg.clarovantdigital.com/library/the-rationale-for-combination-therapy-in-patients-with-aggressive-b-cell-non-hodgkin-lymphoma-ten-questions/2025-06-10T20:02:22+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-free-initial-treatment-of-advanced-indolent-lymphoma-has-durable-effect-with-low-toxicity-results-from-two-nordic-lymphoma-group-trials-with-more-than-10-years-of-follow-up/2025-06-09T21:06:31+00:00https://lymphoma-stg.clarovantdigital.com/library/routine-blood-tests-found-of-limited-use-for-lymphoma-patients-in-remission/2025-06-09T20:49:39+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-transformation-to-higher-grade-lymphoma-and-its-impact-on-survival-in-a-large-cohort-of-patients-with-marginal-zone-lymphoma-from-a-single-institution/2025-06-09T20:44:09+00:00https://lymphoma-stg.clarovantdigital.com/library/the-light-chain-iglv3-21-defines-a-new-poor-prognostic-subgroup-in-chronic-lymphocytic-leukemia-results-of-a-multicenter-study/2025-06-09T20:40:34+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-frequency-of-organic-food-consumption-with-cancer-risk-findings-from-the-nutrinet-sante-prospective-cohort-study/2025-06-09T20:37:36+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-for-recurrent-hodgkin-lymphoma-after-allogeneic-hematopoietic-stem-cell-transplantation-a-report-from-the-ebmt-lymphoma-working-party/2025-06-09T20:31:27+00:00https://lymphoma-stg.clarovantdigital.com/library/proton-therapy-for-adults-with-mediastinal-lymphomas-the-international-lymphoma-radiation-oncology-group-guidelines/2025-06-09T20:28:58+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-advanced-patient-age-on-mortality-after-allogeneic-hematopoietic-cell-transplantation-for-non-hodgkin-lymphoma-a-retrospective-study-by-the-european-society-for-blood-and-marrow-transpl/2025-06-09T20:26:08+00:00https://lymphoma-stg.clarovantdigital.com/library/comorbidities-predict-inferior-outcomes-in-chronic-lymphocytic-leukemia-treated-with-ibrutinib/2025-06-09T20:22:35+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-double-expression-of-c-myc-bcl2-protein-and-cell-of-origin-subtypes-on-the-outcome-among-patients-with-diffuse-large-b-cell-lymphoma-a-single-asian-center-experience/2025-06-09T19:21:06+00:00https://lymphoma-stg.clarovantdigital.com/library/pegaspargase-gemcitabine-dexamethasone-and-cisplatin-p-gdp-combined-chemotherapy-is-effective-for-newly-diagnosed-extranodal-nk-t-cell-lymphoma-a-retrospective-study/2025-06-09T19:19:34+00:00https://lymphoma-stg.clarovantdigital.com/library/behavior-change-techniques-for-increasing-physical-activity-in-cancer-survivors-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/2020-05-20T10:33:48+00:00https://lymphoma-stg.clarovantdigital.com/library/reala%c2%80%c2%90world-testing-and-treatment-patterns-in-chronic-lymphocytic-leukemia-a-seer-patterns-of-care-analysis/2025-06-09T18:55:44+00:00https://lymphoma-stg.clarovantdigital.com/library/an-opena%c2%80%c2%90label-phase-2-trial-of-entospletinib-in-indolent-nona%c2%80%c2%90hodgkin-lymphoma-and-mantle-cell-lymphoma/2025-03-04T18:35:14+00:00https://lymphoma-stg.clarovantdigital.com/library/cd47-blockade-by-hu5f9-g4-and-rituximab-in-non-hodgkina%c2%80%c2%99s-lymphoma/2025-06-09T18:49:38+00:00https://lymphoma-stg.clarovantdigital.com/library/tackling-ebv-associated-lymphoma-early-research-finds-overall-survival-benefit-after-donor-transplants/2025-06-09T18:45:10+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-breast-implanta%c2%80%c2%93associated-anaplastic-large-cell-lymphoma/2025-06-09T18:40:19+00:00https://lymphoma-stg.clarovantdigital.com/library/systematic-review-of-therapy-used-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma/2025-06-09T18:03:39+00:00https://lymphoma-stg.clarovantdigital.com/library/how-does-a-supervised-exercise-program-improve-quality-of-life-in-patients-with-cancer-a-concept-mapping-study-examining-patients-perspectives/2025-06-09T18:00:26+00:00https://lymphoma-stg.clarovantdigital.com/library/new-algorithm-improves-outcome-prediction-for-diffuse-large-b-cell-lymphoma/2025-06-09T17:56:02+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-distress-in-hodgkin-lymphoma-across-the-survivorship-continuum/2025-06-09T17:50:40+00:00https://lymphoma-stg.clarovantdigital.com/library/using-gene-expression-profiling-to-move-beyond-myc-bcl2-rearrangements-in-high-grade-lymphoma/2025-06-09T17:39:10+00:00https://lymphoma-stg.clarovantdigital.com/library/tisagenlecleucel-in-adult-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2025-06-09T17:36:36+00:00https://lymphoma-stg.clarovantdigital.com/library/radiation-therapy-as-a-bridging-strategy-for-refractory-diffuse-large-b-cell-lymphoma-patients-awaiting-car-t-manufacturing-of-axicabtagene-ciloleucel/2025-06-09T17:26:12+00:00https://lymphoma-stg.clarovantdigital.com/library/2-year-follow-up-and-high-risk-subset-analysis-of-zuma-1-the-pivotal-study-of-axicabtagene-ciloleucel-axi-cel-in-patients-with-refractory-large-b-cell-lymphoma/2025-06-05T22:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-and-neurocognitive-outcomes-in-patients-treated-with-axicabtagene-ciloleucel/2025-06-05T22:01:34+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-of-axicabtagene-ciloleucel-cd19-car-t-cell-therapy-in-elderly-patients-with-relapsed-or-refractory-large-b-cell-lymphoma/2025-12-10T19:43:25+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-in-the-real-world-outcomes-and-predictors-of-response-resistance-and-toxicity/2025-06-05T21:58:02+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-rituximab-cyclophosphamide-doxorubicin-vincristine-and-prednisolone-r-chop-improves-outcomes-in-bcl2-positive-first-line-diffuse-large-b-cell-lymphoma-dlbcl-first-safety-effic/2025-06-05T21:54:15+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-mogamulizumab-by-prior-systemic-therapy-in-patients-with-previously-treated-cutaneous-t-cell-lymphoma-post-hoc-analysis-from-the-phase-3-mavoric-study/2025-06-05T21:51:40+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-clinical-benefit-to-anti-ccr4-mogamulizumab-results-from-the-phase-3-mavoric-study-in-previously-treated-cutaneous-t-cell-lymphoma-ctcl/2025-06-05T21:41:02+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-fludarabine-cyclophosphamide-and-obinutuzumab-ifcg-for-firstline-treatment-of-patients-with-cll-with-mutated-ighv-and-without-tp53-aberrations/2025-06-05T21:31:24+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-obinutuzumab-versus-chlorambucil-obinutuzumab-as-first-line-treatment-in-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cll-sll-results-from-phase-3-illumina/2025-06-05T21:28:32+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-combination-obinutuzumab-ibrutinib-and-venetoclax-in-treatment-naive-and-relapsed-refractory-chronic-lymphocytic-leukemia/2025-05-13T13:55:02+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-free-combination-of-obinutuzumab-and-ibrutinib-in-first-line-treatment-of-follicular-lymphoma-the-alternative-study-by-the-german-low-grade-lymphoma-study-group-glsg/2025-06-05T21:25:12+00:00https://lymphoma-stg.clarovantdigital.com/library/the-phase-3-duo-trial-duvelisib-vs-ofatumumab-in-relapsed-and-refractory-cll-sll/2025-06-05T21:21:06+00:00https://lymphoma-stg.clarovantdigital.com/library/a-randomized-double-blind-efficacy-and-safety-study-of-pf-05280586-a-potential-rituximab-biosimilar-compared-with-rituximab-reference-product-mabthera-in-subjects-with-previously-untreated-cd20-p/2025-06-05T21:18:05+00:00https://lymphoma-stg.clarovantdigital.com/library/augment-a-phase-iii-randomized-study-of-lenalidomide-plus-rituximab-r2-vs-rituximab-placebo-in-patients-with-relapsed-refractory-indolent-non-hodgkin-lymphoma/2025-06-05T21:08:43+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-venetoclax-in-relapsed-refractory-cll-results-of-the-bloodwise-tap-clarity-study/2025-05-13T13:52:54+00:00https://lymphoma-stg.clarovantdigital.com/library/the-magnitude-of-improvement-in-progression-free-survival-with-targeted-therapy-in-relapsed-refractory-chronic-lymphocytic-leukemia-based-on-genetic-risk-a-systematic-review-and-meta-analysis/2025-06-05T21:04:12+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-patients-receiving-venetoclax-for-chronic-lymphocytic-leukemia-cll-in-real-life-clinical-practice-results-of-the-french-atu-program-on-behalf-of-the-filo-group/2025-06-05T21:02:40+00:00https://lymphoma-stg.clarovantdigital.com/library/exercise-is-medicine-restoring-function-in-older-adults-with-hematologic-malignancy/2025-06-05T21:00:51+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-improves-quality-of-life-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia/2025-06-05T17:48:50+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-venetoclax-therapy-for-complex-karyotype-relapsed-refractory-chronic-lymphocytic-leukemia/2025-06-05T17:47:17+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-as-monotherapy-or-in-combination-patterns-of-use-and-predictors-of-outcomes-in-an-international-multicenter-study-of-cll-patients/2025-06-05T17:45:15+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-prospective-phase-ii-study-of-venetoclax-in-patients-with-previously-treated-waldenstrom-macroglobulinemia/2025-06-05T17:43:37+00:00https://lymphoma-stg.clarovantdigital.com/library/rapid-mrd-negative-responses-in-patients-with-relapsed-refractory-cll-treated-with-liso-cel-a-cd19-directed-car-t-cell-product-preliminary-results-from-transcend-cll-004-a-phase-1-2-study-including/2025-12-10T19:44:13+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-trial-of-nivolumab-combined-with-ibrutinib-for-patients-with-richter-transformation/2025-06-05T17:37:30+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-high-grade-b-cell-lymphoma-defining-a-poor-risk-group-that-requires-different-approaches-to-therapy/2025-06-05T17:34:01+00:00https://lymphoma-stg.clarovantdigital.com/library/the-risks-of-cancer-development-in-systemic-lupus-erythematosus-sle-patients-a-systematic-review-and-meta-analysis/2025-06-05T17:31:47+00:00https://lymphoma-stg.clarovantdigital.com/library/double-hit-gene-expression-signature-defines-a-distinct-subgroup-of-germinal-center-b-cell-like-diffuse-large-b-cell-lymphoma/2025-06-05T17:29:41+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-patients-with-relapsed-refractory-r-r-and-high-risk-treatment-naive-tn-chronic-lymphocytic-leukemia-cll/2025-06-05T17:21:28+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-acalabrutinib-monotherapy-in-patients-with-relapsed-refractory-mantle-cell-lymphoma/2025-06-05T17:22:14+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-effective-as-surrogate-endpoint-in-cll/2025-06-05T14:57:11+00:00https://lymphoma-stg.clarovantdigital.com/library/late-effects-of-cd19-targeted-car-t-cell-therapy/2025-06-05T14:51:06+00:00https://lymphoma-stg.clarovantdigital.com/library/the-echelon-2-trial-results-of-a-randomized-double-blind-active-controlled-phase-3-study-of-brentuximab-vedotin-and-chp-achp-versus-chop-in-the-frontline-treatment-of-patients-with-cd30-periphe/2025-06-05T14:43:54+00:00https://lymphoma-stg.clarovantdigital.com/library/resolution-of-peripheral-neuropathy-pn-in-patients-who-received-aavd-or-abvd-in-the-phase-3-echelon-1-trial/2025-06-05T14:42:19+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-plus-chemotherapy-in-patients-with-advanced-stage-classical-hodgkin-lymphoma-chl-evaluation-of-modified-progression-free-survival-mpfs-and-traditional-pfs-in-the-phase-3-echel/2025-06-05T14:41:11+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-with-chemotherapy-in-adolescents-and-young-adults-aya-with-stage-iii-or-iv-hodgkin-lymphoma-a-subgroup-analysis-from-the-phase-3-echelon-1-study/2025-06-05T14:39:43+00:00https://lymphoma-stg.clarovantdigital.com/library/older-patients-pts-with-previously-untreated-classical-hodgkin-lymphoma-chl-a-detailed-analysis-from-the-phase-3-echelon-1-study/2025-06-05T14:37:47+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-pretreatment-neutrophil-lymphocyte-ratio-and-platelet-lymphocyte-ratio-in-patients-with-diffuse-large-b-cell-lymphoma/2025-06-05T14:32:21+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-efficacy-and-safety-of-biosimilar-ct-p10-to-rituximab-in-patients-with-previously-untreated-low-tumor-burden-follicular-lymphoma-ltbfl-a-randomized-phase-iii-study/2025-06-05T14:29:19+00:00https://lymphoma-stg.clarovantdigital.com/library/similar-efficacy-and-safety-of-ct-p10-and-reference-rituximab-in-patients-with-advanced-stage-follicular-lymphoma-updated-phase-iii-study-results/2025-06-05T14:27:26+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-regimens-versus-chemoimmunotherapy-in-older-patients-with-untreated-cll/2025-06-05T14:19:54+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-plus-bendamustine-with-rituximab-or-obinutuzumab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-updated-results-of-a-phase-ib-ii-study/2025-06-05T14:15:02+00:00https://lymphoma-stg.clarovantdigital.com/library/cd47-expression-defines-the-efficacy-of-rituximab-in-non-germinal-center-b-cell-non-gcb-diffuse-large-b-cell-lymphoma-dlbcl/2025-06-05T14:11:20+00:00https://lymphoma-stg.clarovantdigital.com/library/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl-the-french-lymphoma-study-association-lysa-registry-data/2025-06-05T14:08:26+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-activity-of-the-investigational-bruton-tyrosine-kinase-inhibitor-zanubrutinib-bgb-3111-in-patients-with-mantle-cell-lymphoma-from-a-phase-2-trial/2025-06-05T14:06:18+00:00https://lymphoma-stg.clarovantdigital.com/library/a-randomized-phase-iii-study-of-ibrutinib-pci-32765-based-therapy-vs-standard-fludarabine-cyclophosphamide-and-rituximab-fcr-chemoimmunotherapy-in-untreated-younger-patients-with-chronic-lympho/2025-06-05T14:04:11+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-bleeding-with-ibrutinib-in-patients-with-b-cell-malignancies-an-updated-meta-analysis-of-phase-iii-randomized-controlled-trials/2025-06-05T13:58:43+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-the-risk-of-atrial-fibrillation-flutter-among-patients-initiating-ibrutinib/2025-06-05T13:57:09+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-bendamustine-rituximab-combination-for-relapsed-and-refractory-aggressive-b-cell-lymphoma-a%c2%80%c2%94-interim-analysis-of-phase-ii-clinical-trial/2025-06-05T13:51:26+00:00https://lymphoma-stg.clarovantdigital.com/library/up-to-7-years-of-follow-up-of-single-agent-ibrutinib-in-the-phase-1b-2-pcyc-1102-trial-of-first-line-and-relapsed-refractory-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-12-15T19:41:44+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-infection-with-ibrutinib-in-patients-with-b-cell-malignancies-a-meta-analysis-of-phase-iii-randomized-controlled-trials/2025-06-05T13:45:26+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-is-effective-in-relapsed-or-refractory-transformed-indolent-b-cell-non-hodgkin-lymphoma-results-from-a-prospective-phase-ii-study/2025-06-05T13:42:37+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-of-single-agent-ibrutinib-in-recurrent-refractory-primary-pcnsl-and-secondary-cns-lymphoma-scnsl/2025-06-05T12:14:01+00:00https://lymphoma-stg.clarovantdigital.com/library/real-word-clinical-management-of-patients-treated-with-idelalisib-in-france-a-study-of-529-cases-of-chronic-lymphocytic-leukemia-cll-and-follicular-lymphoma-fl/2025-06-05T12:12:07+00:00https://lymphoma-stg.clarovantdigital.com/library/the-combination-of-complex-karyotypes-subtypes-and-ighv-mutational-status-provides-prognostic-and-predictive-information-in-chronic-lymphocytic-leukemia/2025-06-05T12:10:27+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-atrial-fibrillation-with-ibrutinib-in-patients-with-b-cell-malignancies-an-updated-meta-analysis-of-phase-iii-randomized-controlled-trials/2025-06-05T12:08:49+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-dose-reduction-does-not-affect-progression-free-survival-in-patients-with-waldenstrom-macroglobulinemia/2025-06-05T12:07:00+00:00https://lymphoma-stg.clarovantdigital.com/library/influence-of-minimal-residual-disease-on-survival-of-patients-with-mantle-cell-lymphoma/2025-06-04T21:16:59+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-therapy-in-patients-with-waldenstrom-macroglobulinemia-outcomes-outside-of-clinical-trial-setting/2025-06-04T21:15:38+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-cll-transformed-into-hodgkin-lymphoma-hl-clinical-characteristics-and-outcomes-from-a-large-multi-center-collaboration/2025-06-04T21:13:33+00:00https://lymphoma-stg.clarovantdigital.com/library/a-global-randomized-placebo-controlled-phase-3-study-of-ibrutinib-plus-rituximab-cyclophosphamide-doxorubicin-vincristine-and-prednisone-rchop-in-patients-with-previously-untreated-non-germin/2025-06-04T21:11:19+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-ibrutinib-in-combination-with-rituximab-and-lenalidomide-in-previously-untreated-subjects-with-follicular-and-marginal-zone-lymphoma-an-open-label-phase-ii-study/2025-05-30T14:24:07+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-treatment-in-waldenstroms-macroglobulinemia-follow-up-efficacy-and-safety-from-the-innovate-study/2025-05-30T14:22:12+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-alone-or-in-combination-with-rituximab-produces-superior-progression-free-survival-pfs-compared-with-bendamustine-plus-rituximab-in-untreated-older-patients-with-chronic-lymphocytic-leukem/2025-01-28T21:13:12+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-pet-directed-therapy-in-limited-stage-hodgkin-lymphoma-initially-treated-with-abvd/2025-05-30T14:19:40+00:00https://lymphoma-stg.clarovantdigital.com/library/optimal-management-of-adverse-events-from-copanlisib-in-the-treatment-of-patients-with-non-hodgkin-lymphomas/2025-05-30T14:18:21+00:00https://lymphoma-stg.clarovantdigital.com/library/cause-of-death-in-follicular-lymphoma-in-the-first-decade-of-the-rituximab-era-a-pooled-analysis-of-french-and-us-cohorts/2025-05-30T14:16:04+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-implications-of-specific-comorbidities-in-mantle-cell-lymphoma-patients-a-swedish-lymphoma-registry-study/2025-05-30T14:14:23+00:00https://lymphoma-stg.clarovantdigital.com/library/low-relapse-rate-after-2-years-in-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-treated-with-r-chop-and-achieved-complete-response/2025-05-30T14:11:48+00:00https://lymphoma-stg.clarovantdigital.com/library/comprehensive-genomic-profiling-of-angioimmunoblastic-t-cell-lymphoma-aitl-in-chinese-patients/2025-05-30T14:09:52+00:00https://lymphoma-stg.clarovantdigital.com/library/new-guidance-released-for-cutaneous-b-cell-lymphomas/2026-06-25T16:53:49+00:00https://lymphoma-stg.clarovantdigital.com/library/new-treatment-options-in-advanced-stage-follicular-lymphoma/2025-05-30T14:03:30+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-combined-modality-therapy-vs-chemotherapy-alone-with-overall-survival-in-early-stage-pediatric-hodgkin-lymphoma/2025-05-30T13:57:56+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-rituximab-bendamustine-bortezomib-and-dexamethasone-for-first-line-treatment-of-older-patients-with-mantle-cell-lymphoma/2025-05-29T20:52:21+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-the-primary-analysis-of-complement-ab-a-phase-iii-study-of-ofatumumab-in-combination-with-bendamustine-versus-bendamustine-alone-in-patients-with-indolent-non-hodgkins-lymphoma-that-is-u/2025-05-29T20:50:29+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-survival-outcomes-in-follicular-lymphoma-patients-a-2007-2015-humedica-database-study/2025-05-29T20:24:07+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-solid-subsequent-malignant-neoplasms-after-childhood-hodgkin-lymphomaa%c2%80%c2%93identification-of-higha%c2%80%c2%90risk-populations-to-guide-surveillance-a-report-from-the-late-effects-stud/2025-05-29T20:22:47+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-patients-ineligible-for-or-having-failed-autologous-transplantation-a-single-arm-phase-ii-study/2025-05-29T20:07:42+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-outcomes-of-younger-patients-with-mantle-cell-lymphoma-treated-in-the-rituximab-era/2025-05-29T20:05:03+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-adjusted-epoch-plus-rituximab-improves-the-clinical-outcome-of-young-patients-affected-by-double-expressor-diffuse-large-b-cell-lymphoma/2025-05-29T19:58:30+00:00https://lymphoma-stg.clarovantdigital.com/library/bcl-2-mechanisms-and-prevalence/2025-05-29T19:31:57+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-hbv-reactivation-in-patients-with-b-cell-lymphomas-receiving-obinutuzumab-or-rituximab-immunochemotherapy/2025-05-29T19:29:56+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-localized-extranodal-nk-t-cell-lymphoma-nasal-type-a-systematic-review/2025-05-29T19:13:12+00:00https://lymphoma-stg.clarovantdigital.com/library/high-prevalence-of-advanced-colorectal-neoplasia-and-serrated-polyposis-syndrome-in-hodgkin-lymphoma-survivors/2025-05-29T19:08:58+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-toxicities-of-programmed-deatha%c2%80%c2%901-pda%c2%80%c2%901-inhibitors-in-hodgkin-lymphoma-patients-in-the-united-states-a-reala%c2%80%c2%90world-multicenter-retrospective-analysis/2025-05-29T19:04:05+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-herpes-zoster-prior-to-and-following-cancer-diagnosis-and-treatment-a-population-based-prospective-cohort-study/2025-05-29T18:57:23+00:00https://lymphoma-stg.clarovantdigital.com/library/the-outcome-of-refractory-or-relapsed-but-not-refractory-diffuse-large-b-cell-lymphoma-in-china-results-from-the-real-trend-study/2025-05-29T18:54:15+00:00https://lymphoma-stg.clarovantdigital.com/library/non-interventional-retrospective-multicenter-study-evaluating-real-word-idelalisib-use-in-chronic-lymphocytic-leukemia-and-indolent-non-hodgkin-lymphoma-patients-enrolled-in-the-french-early-access-pr/2025-05-29T18:51:23+00:00https://lymphoma-stg.clarovantdigital.com/library/stem-cell-transplantation-for-pediatric-patients-with-non-anaplastic-peripheral-t-cell-lymphoma-on-behalf-of-the-ebmt-pediatric-diseases-working-party/2025-05-29T15:12:19+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-allogeneic-transplant-in-diffuse-large-b-cell-lymphoma/2025-05-29T15:10:23+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-prevalence-mortality-and-causes-of-death-in-waldenstrom-macroglobulinemia-in-south-korea-a-nationwide-population-based-study/2026-04-24T19:55:22+00:00https://lymphoma-stg.clarovantdigital.com/library/pre-treatment-derived-neutrophil-to-lymphocyte-ratio-as-a-prognostic-factor-in-extranodal-natural-killer-t-cell-lymphoma/2025-05-29T15:04:34+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-implications-of-myd88-and-cxcr4-in-patients-with-waldenstrom-macroglobulinemia/2025-05-29T14:55:55+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-yttrium-90-iburitumomab-tiuxetan-for-early-relapsed-refractory-indolent-b-cell-lymphoma-a-single-institute-retrospective-analysis-in-the-rituximab-era/2026-01-06T21:01:35+00:00https://lymphoma-stg.clarovantdigital.com/library/central-nervous-system-relapse-in-patients-with-peripheral-t-cell-lymphoma/2025-05-29T14:50:54+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-analysis-of-outcomes-of-diffuse-large-b-cell-lymphoma-dlbcl-in-the-elder-patients-in-china/2025-05-29T14:48:27+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-on-survival-of-ebv-positive-diffuse-large-b-cell-lymphoma-not-otherwise-specified-in-young-adults/2026-09-02T16:11:28+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-gastrointestinal-involvement-in-newly-diagnosed-diffuse-large-b-cell-lymphoma/2025-05-29T14:44:59+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-co-morbidity-profile-should-drive-pi3k-inhibitor-selection-for-relapsed-follicular-lymphoma/2025-05-29T14:42:56+00:00https://lymphoma-stg.clarovantdigital.com/library/a-case-control-study-to-compare-the-survival-benefits-of-patients-who-suffer-from-peripheral-t-cell-lymphoma-ptcl-treated-with-chidamide-a-histone-deacetylase-inhibitor-in-china-with-a-historical/2025-05-29T14:40:26+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-rituximab-in-the-clinical-outcomes-of-hairy-cell-leukemia-a-single-institution-analysis/2025-05-29T14:32:29+00:00https://lymphoma-stg.clarovantdigital.com/library/rdw-is-a-prognostic-marker-for-patients-with-aggressive-peripheral-t-cell-lymphoma/2025-05-29T14:28:46+00:00https://lymphoma-stg.clarovantdigital.com/library/repeat-infusion-of-cd19-specific-chimeric-antigen-receptor-t-cell-could-improve-the-efficacy-with-consistent-safety-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2025-05-29T14:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/bone-marrow-biopsy-is-still-indispensable-for-evaluating-bone-marrow-involvement-in-dlbcl-patients-even-in-the-pet-ct-era/2026-01-20T19:46:10+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-in-the-risk-of-second-primary-malignancies-spms-among-survivors-of-chronic-lymphocytic-leukemia-cll/2025-05-29T14:12:16+00:00https://lymphoma-stg.clarovantdigital.com/library/adverse-events-among-patients-with-hairy-cell-leukemia-treated-with-purine-nucleoside-analogs-in-the-united-states/2025-05-29T14:11:24+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-health-behaviors-and-quality-of-life-in-lymphoma-survivors/2025-05-29T14:07:42+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-allogeneic-stem-cell-transplant-in-peripheral-t-cell-lymphoma/2025-05-29T13:55:46+00:00https://lymphoma-stg.clarovantdigital.com/library/increased-risk-of-diabetes-mellitus-among-adult-survivors-of-b-cell-non-hodgkin-lymphoma/2025-05-29T13:45:04+00:00https://lymphoma-stg.clarovantdigital.com/library/obesity-negatively-impacts-outcome-in-female-patients-with-chronic-lymphocytic-leukemia-cll-treated-with-fludarabine-cyclophosphamide-and-rituximab-fcr-an-analysis-of-three-phase-iii-studies-of/2025-05-29T13:43:28+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-characteristics-and-treatment-patterns-in-the-first-line-and-second-line-treatment-of-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma-in-the-united-kingdom-france-and-germany/2025-05-29T13:41:53+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-rituximab-to-high-dose-methotrexate-regimens-improves-complete-response-rates-and-median-overall-survival-in-non-germinal-center-primary-cns-lymphoma/2025-05-28T20:55:53+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-prophylactic-antiviral-therapy-on-clinical-outcomes-of-hepatitis-b-virus-surface-antigen-positive-patients-with-diffuse-large-b-cell-lymphoma-treated-with-rituximab-containing-chemotherapy/2025-05-28T20:54:17+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-follicular-lymphoma-fl-with-early-progression-ep-does-choice-of-second-line-therapy-impact-the-course-of-disease/2025-05-28T20:51:03+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-histological-transformation-in-patients-with-primary-refractory-follicular-lymphoma/2025-05-28T20:49:26+00:00https://lymphoma-stg.clarovantdigital.com/library/a-longitudinal-toxicity-over-time-toxt-analysis-of-bortezomib-when-added-to-bendamustine-rituximab-br-in-previously-untreated-high-risk-hr-follicular-lymphoma-fl-from-in-e2408/2025-05-28T20:46:38+00:00https://lymphoma-stg.clarovantdigital.com/library/ofatumumab-is-active-and-safe-in-patients-with-relapsed-refractory-splenic-marginal-zone-lymphoma-smzl-results-from-the-interim-analysis-of-an-italian-multicenter-phase-2-study-more-trial/2025-05-28T20:44:49+00:00https://lymphoma-stg.clarovantdigital.com/library/grading-of-neurotoxicity-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-receiving-tisagenlecleucel-treatment-in-the-juliet-study/2025-05-28T20:38:21+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-a-phase-3-randomised-multicenter-study-comparing-pixantrone-rituximab-with-gemcitabine-rituximab-in-patients-with-relapsed-aggressive-b-cell-non-hodgkin-lymphoma-not-eligible-for-stem-c/2025-05-28T20:14:03+00:00https://lymphoma-stg.clarovantdigital.com/library/a-u-s-food-and-drug-administration-age-based-pooled-analysis-of-cytokine-release-syndrome-and-neurotoxicity-in-subjects-with-relapsed-refractory-lymphoma-treated-with-chimeric-antigen-receptor-car/2025-05-28T20:08:45+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-and-determinants-of-failure-to-complete-6-8-cycles-of-primary-r-chop-treatment-for-reasons-unrelated-to-progression-among-patients-with-diffuse-large-b-cell-lymphoma-dlbcl/2025-05-28T19:32:35+00:00https://lymphoma-stg.clarovantdigital.com/library/consensus-grading-of-cytokine-release-syndrome-crs-in-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-treated-with-tisagenlecleucel-on-the-juliet-study/2025-05-28T19:30:41+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-results-from-an-ongoing-phase-2-multicenter-study-of-tazemetostat-an-ezh2-inhibitor-in-patients-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl/2025-05-28T19:11:31+00:00https://lymphoma-stg.clarovantdigital.com/library/depth-of-response-in-waldenstrom-macroglobulinemia/2025-05-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-follicular-lymphoma-patients-treated-with-frontline-bendamustine-and-rituximab-impact-of-histologic-grade-and-early-progression-on-overall-survival/2025-05-28T18:50:16+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-circulating-bcl-2-igh-levels-before-and-after-treatment-in-415-patients-with-advanced-follicular-lymphoma-receiving-first-line-immuno-chemotherapy-in-2-prospective-stil-trials-th/2025-05-28T18:48:39+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-car-t-cells-treatment-for-minimal-residual-disease-in-b-cell-lymphoma-with-a-higher-response-rate-and-fewer-adverse-reactions/2025-05-28T18:44:50+00:00https://lymphoma-stg.clarovantdigital.com/library/high-prevalence-and-clinical-impact-of-malnutrition-in-older-patients-with-a-hematological-malignancya%c2%80%c2%94basis-for-patient-orientated-guidelines-and-healthcare-interventions/2025-05-28T18:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/under-reporting-of-patient-reported-outcome-pro-in-clinical-trials/2025-05-28T18:29:40+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-evaluation-of-efficacy-and-safety-of-ofatumumab-added-to-fludarabine-cyclophosphamide-in-subjects-with-relapsed-chronic-lymphocytic-leukemia-final-analysis-of-complement-2-trial/2025-05-28T18:28:33+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-trial-in-unfit-elderly-chronic-lymphocytic-leukemia-cll-patients-with-comorbidities-of-dose-reduced-oral-fludarabine-and-cyclophosphamide-plus-obinutuzumab-fcg-versus-chlorambucil-plu/2025-05-26T20:19:28+00:00https://lymphoma-stg.clarovantdigital.com/library/characterization-of-the-long-term-efficacy-and-safety-of-duvelisib-monotherapy-in-patients-with-relapsed-refractory-cll-sll-on-treatment-for-more-than-2-years-across-4-clinical-studies/2025-05-28T18:25:43+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-front-line-therapy-with-ofatumumab-high-dose-methylprednisolone-and-lenalidomide-hilo-trial-for-treatment-naive-chronic-lymphocytic-leukemia/2025-05-28T18:23:32+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-outcomes-following-idelalisib-interruption-in-the-treatment-of-relapsed-or-refractory-indolent-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia/2025-05-28T18:21:54+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-analysis-results-from-an-international-multi-centre-non-interventional-retrospective-study-to-describe-treatment-pathways-outcomes-and-resource-use-in-patients-with-classical-hodgkin-lymph/2025-05-28T18:20:05+00:00https://lymphoma-stg.clarovantdigital.com/library/increased-risk-of-second-primary-hematologic-and-solid-malignancies-in-patients-with-mycosis-fungoides/2025-05-28T15:39:21+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-therapy-with-bendamustine-and-rituximab-br-in-follicular-lymphoma-prognosis-among-patients-with-progression-of-disease-by-24-months-pod24-is-poor-with-majority-having-transformed-lympho/2025-05-28T15:37:35+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-brentuximab-vedotin-in-the-treatment-of-elderly-hodgkin-lymphoma-patients-at-first-relapse-or-with-primary-refractory-disease/2025-05-28T15:35:57+00:00https://lymphoma-stg.clarovantdigital.com/library/induction-therapy-with-everolimus-in-combination-with-dhap-dexamethasone-high-dose-arac-cisplatinum-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-a-randomized-placebo-contro/2025-05-28T15:33:50+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-in-post-relapse-survival-in-classical-hodgkin-lymphoma-patients-after-experiencing-therapy-failure-following-autologous-hematopoietic-cell-transplantation/2025-05-28T15:30:31+00:00https://lymphoma-stg.clarovantdigital.com/library/idelalisib-for-treatment-of-follicular-lymphoma-and-chronic-lymphocytic-leukemia-in-clinical-trials-versus-the-real-world-treatment-duration-and-survival-are-associated-with-pretreatment-modified-cha/2025-05-28T15:29:16+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-results-of-a-phase-ii-study-of-sequential-chemotherapy-and-lenalidomide-followed-by-rituximab-and-lenalidomide-maintenance-for-untreated-mantle-cell-lymphoma/2025-05-28T15:27:00+00:00https://lymphoma-stg.clarovantdigital.com/library/deepening-of-response-after-completing-rituximab-containing-primary-therapy-in-patients-with-waldenstrom-macroglobulinemia/2025-05-28T15:25:24+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-interim-and-end-of-treatment-pet-ct-in-patients-with-mature-t-cell-and-nk-cell-lymphomas-a-10-year-single-institution-study/2025-05-28T15:22:07+00:00https://lymphoma-stg.clarovantdigital.com/library/pegaspargase-with-concurrent-radiotherapy-in-a-once-every-three-weeks-schedule-in-patients-with-newly-diagnosed-stage-ie-to-iie-nasal-extranodal-nk-t-cell-lymphoma-a-phase-ii-study/2025-05-27T13:22:51+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-risk-factors-of-central-nervous-system-relapse-in-localized-extranodal-nk-t-cell-lymphoma-nasal-type-an-analysis-of-nkea-study/2025-05-28T15:13:42+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-in-combination-with-intravenous-rituximab-revri-in-relapsed-refractory-primary-cns-lymphoma-or-primary-intraocular-lymphoma-a-multicenter-prospective-a%c2%80%c2%9cproof-of-concepta/2025-05-28T15:09:25+00:00https://lymphoma-stg.clarovantdigital.com/library/newer-staging-method-helps-confirm-potential-of-radiotherapy-alone-for-stage-i-ii-follicular-lymphoma/2025-05-27T21:50:56+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-rituximab-shows-improved-duration-of-response-in-follicular-lymphoma-in-retrospective-analysis/2025-05-27T21:46:44+00:00https://lymphoma-stg.clarovantdigital.com/library/peripheral-t-cell-lymphomas-in-spain-profiling-clinical-phenotypic-and-genetic-characteristics-in-spanish-population/2025-05-27T21:40:57+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-for-heavily-pretreated-relapsed-refractory-hodgkin-lymphoma-real-life-experience-in-spain-spanish-group-of-lymphoma-and-bone-marrow-transplantation-geltamo/2025-05-27T21:38:53+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-i-ii-study-of-choep-plus-lenalidomide-as-initial-therapy-for-patients-with-stage-ii-iv-peripheral-t-cell-lymphoma-phase-ii-results/2025-05-27T21:37:28+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-for-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-after-autologous-hematopoietic-cell-transplantation-auto-hct-extended-follow-up-of-the-phase-2-single-arm-checkmate-205-study/2025-05-27T21:35:27+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-responses-with-pembrolizumab-in-relapsed-refractory-mycosis-fungoides-and-sezary-syndrome-final-results-from-a-phase-2-multicenter-study/2025-05-27T21:33:28+00:00https://lymphoma-stg.clarovantdigital.com/library/two-year-follow-up-of-keynote-087-study-pembrolizumab-monotherapy-in-relapsed-refractory-classic-hodgkin-lymphoma/2025-05-27T21:23:16+00:00https://lymphoma-stg.clarovantdigital.com/library/combining-brentuximab-vedotin-with-dhap-as-salvage-treatment-in-relapsed-refractory-hodgkin-lymphoma-the-phase-ii-hovon-llpc-transplant-brave-study/2025-05-27T21:21:58+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-responses-observed-with-jak-inhibition-in-t-cell-lymphomas/2025-05-27T21:20:28+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiology-and-survivorship-of-anaplastic-large-cell-lymphoma/2025-05-27T21:18:09+00:00https://lymphoma-stg.clarovantdigital.com/library/chidamide-plus-r-chop21-in-elderly-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-results-of-a-phase-ii-study/2025-05-27T21:16:57+00:00https://lymphoma-stg.clarovantdigital.com/library/high-efficacy-of-lenalidomide-plus-r-chop-r2chop-combination-in-first-line-treatment-of-activated-b-cell-abc-dlbcl-defined-using-gene-expression-prophyling-a-combined-analysis-from-two-phase-2-tr/2025-05-27T21:14:51+00:00https://lymphoma-stg.clarovantdigital.com/library/the-neutrophil-to-lymphocyte-ratio-is-prognostic-in-patients-with-diffuse-large-b-cell-lymphoma-a-study-from-the-latin-american-group-of-lymphomas-gell/2025-05-27T21:11:46+00:00https://lymphoma-stg.clarovantdigital.com/library/an-increasing-trend-of-incidence-prevalence-and-mortality-and-occurrence-of-second-primary-malignancies-among-patients-with-b-cell-non-hodgkin-lymphoma-a-10-year-longitudinal-population-based-retro/2026-04-24T19:54:49+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-atezolizumab-in-combination-with-rituximab-plus-chop-in-previously-untreated-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-primary-analysis-of-a-phase-i-ii-study/2025-05-27T21:07:15+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-outcome-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-in-a-population-based-cohort-of-3165-patients-in-sweden/2025-05-27T21:05:10+00:00https://lymphoma-stg.clarovantdigital.com/library/understanding-the-differences-between-clinical-trial-participants-and-real-world-patients-with-non-hodgkin-lymphoma/2025-05-27T20:19:47+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-priming-chimeric-antigen-receptor-t-cell-therapy-is-a-safe-and-promising-approach-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-patients-with-high-tumor-burden/2025-05-27T12:43:42+00:00https://lymphoma-stg.clarovantdigital.com/library/frequency-of-tumor-lysis-syndrome-among-patients-diagnosed-with-hematologic-malignancies/2025-05-27T12:02:30+00:00https://lymphoma-stg.clarovantdigital.com/library/sequential-infusion-of-anti-cd22-and-anti-cd19-chimeric-antigen-receptor-t-cells-following-autologous-hsct-in-patients-with-b-nhl/2025-05-27T12:00:02+00:00https://lymphoma-stg.clarovantdigital.com/library/second-primary-malignancies-and-disease-transformation-in-newly-diagnosed-symptomatic-patients-with-waldenstroms-macroglobulinemia-an-analysis-from-the-greek-myeloma-study-group/2025-05-26T23:52:05+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-autologous-stem-cell-transplantation-in-waldenstroms-macroglobulinemia/2025-05-26T23:50:08+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-associated-with-richters-transformation-in-patients-with-chronic-lymphocytic-leukemia/2025-05-26T23:48:38+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-ga101-in-combination-with-pixantrone-for-the-treatment-of-patients-with-relapsed-aggressive-b-cell-lymphoma-a-phase-ii-trial-goal/2025-05-26T23:46:53+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-and-interim-functional-imaging-with-pet-effectively-risk-stratifies-patients-with-peripheral-t-cell-lymphoma/2025-05-26T23:45:05+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-phase-ii-trial-addressing-lenalidomide-maintenance-in-patients-with-relapsed-diffuse-large-b-cell-lymphoma-rdlbcl-who-are-not-eligible-for-autologous-stem-cell-transplantation-asct-ef/2025-05-26T23:42:21+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-with-or-without-lenalidomide-bortezomib-as-a-first-line-treatment-for-patients-with-non-germinal-center-diffuse-large-b-cell-lymphoma-dlbcl-subtype-son-espases-university-hospital-experience/2025-05-26T23:41:03+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-death-relapse-or-progression-and-loss-of-life-expectancy-at-different-progression-free-survival-milestones-in-primary-central-nervous-system-lymphoma/2025-05-22T21:01:24+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-impacting-progression-free-survival-after-cd19-specific-car-t-cell-therapy-for-relapsed-refractory-aggressive-b-cell-non-hodgkin-lymphoma/2025-05-22T20:59:47+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-disease-control-for-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-an-updated-analysis-of-juliet-a-global-pivotal-phase-2-trial-of-tisagenlecleucel/2025-05-22T20:57:49+00:00https://lymphoma-stg.clarovantdigital.com/library/superior-clinical-benefit-of-brentuximab-vedotin-in-mycosis-fungoides-versus-physicians-choice-irrespective-of-cd30-level-or-large-cell-transformation-status-in-the-phase-3-alcanza-study/2025-05-22T20:55:53+00:00https://lymphoma-stg.clarovantdigital.com/library/hematopoietic-stem-cell-transplant-in-novel-agent-era-is-associated-with-improved-survival-in-relapsed-and-refractory-peripheral-t-cell-lymphoma/2025-05-22T20:53:59+00:00https://lymphoma-stg.clarovantdigital.com/library/central-nervous-system-relapse-in-patients-with-extranodal-nk-t-cell-lymphoma-nasal-type/2025-05-22T20:51:59+00:00https://lymphoma-stg.clarovantdigital.com/library/analysis-of-immune-related-adverse-reactions-in-patients-with-classical-hodgkin-lymphoma-chl-on-programmed-death-1-pd-1-inhibitor-therapy/2025-05-22T20:50:18+00:00https://lymphoma-stg.clarovantdigital.com/library/alemtuzumab-added-to-chop-for-treatment-of-peripheral-t-cell-lymphoma-ptcl-in-previously-untreated-young-and-elderly-patients-pooled-analysis-of-the-international-act-1-2-phase-iii-trials/2025-05-22T20:48:39+00:00https://lymphoma-stg.clarovantdigital.com/library/daratumumab-monotherapy-for-patients-with-relapsed-or-refractory-r-r-natural-killer-t-cell-lymphoma-nktcl-nasal-type-an-open-label-single-arm-multicenter-phase-2-study/2026-01-15T17:10:34+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-factors-outcomes-and-clinical-characteristics-in-patients-with-transformed-follicular-lymphoma-t-fl-cohort-study-of-172-patients/2025-05-22T20:31:29+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-based-immunochemotherapy-prolongs-progression-free-survival-and-time-to-next-anti-lymphoma-treatment-in-patients-with-previously-untreated-follicular-lymphoma-four-year-results-from-the/2025-05-22T20:30:14+00:00https://lymphoma-stg.clarovantdigital.com/library/extranodal-natural-killer-t-cell-lymphoma-nasal-type-in-87-cases-from-spain-clinical-presentation-treatment-and-prognostic-factors-study-from-the-geltamo-group/2025-05-22T20:27:43+00:00https://lymphoma-stg.clarovantdigital.com/library/superiority-of-allogenic-stem-cell-transplantation-after-anti-pd1-therapy-over-anti-pd1-monotherapy-alone-in-relapse-refractory-hodgkin-lymphoma-real-world-evidence-from-the-french-early-access-progr/2025-05-22T20:10:25+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-and-safety-from-the-copanlisib-chronos-1-study-in-patients-with-relapsed-or-refractory-indolent-b-cell-lymphoma/2025-05-22T20:09:04+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-of-venetoclax-rituximab-in-relapsed-refractory-chronic-lymphocytic-leukemia-eradicates-minimal-residual-disease-and-prolongs-survival-post-treatment-follow-up-of-the-murano-phase-iii-s/2025-05-22T19:49:50+00:00https://lymphoma-stg.clarovantdigital.com/library/bone-marrow-biopsy-impacts-response-assessment-in-a-minority-of-patients-with-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-treated-with-immunochemotherapy-results-from-the-randomized-phase-i/2025-05-22T19:45:44+00:00https://lymphoma-stg.clarovantdigital.com/library/p-gemox-regimenpegaspargase-gemcitabine-oxaliplatin-for-extranodal-natural-killer-cell-lymphoma-10-years-real-world-clinical-experience-from-china/2025-05-22T19:43:46+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-brentuximab-vedotin-plus-adriamycin-and-dacarbazine-without-radiation-in-non-bulky-limited-stage-classical-hodgkin-lymphoma/2025-05-22T19:40:57+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-of-the-front-line-phase-iii-randomized-act-1-trial-in-younger-patients-with-systemic-peripheral-t-cell-lymphoma-treated-with-chop-chemotherapy-with-or-without-alemtuzumab-and-consolidat/2025-05-22T19:39:19+00:00https://lymphoma-stg.clarovantdigital.com/library/the-novel-syk-jak-inhibitor-cerdulatinib-demonstrates-good-tolerability-and-clinical-response-in-a-phase-2a-study-in-relapsed-refractory-peripheral-t-cell-lymphoma-and-cutaneous-t-cell-lymphoma/2026-01-15T17:10:05+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-subtypes-of-splenic-marginal-zone-lymphoma-smzl-are-associated-with-distinct-pathogenic-mechanisms-and-outcomes-interim-analysis-of-the-ielsg46-study/2025-05-22T19:26:04+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-impact-of-clonal-and-subclonal-tp53-mutations-in-chronic-lymphocytic-leukemia/2025-05-22T19:23:27+00:00https://lymphoma-stg.clarovantdigital.com/library/b-cap-brentuximab-vedotin-cyclophosphamide-doxorubicin-and-prednisolone-in-older-patients-with-advanced-stage-hodgkin-lymphoma-results-of-a-phase-ii-intergroup-trial-by-the-german-hodgkin-study-g/2025-05-22T19:21:37+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-guided-treatment-of-early-stage-favorable-hodgkin-lymphoma-final-results-of-the-international-randomized-phase-3-trial-hd16-by-the-german-hodgkin-study-group/2025-05-27T12:11:02+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-swog-s0816-response-adapted-therapy-for-stage-iii-iv-hodgkin-lymphoma-demonstrates-limitations-of-pet-adapted-approach/2025-05-27T12:11:45+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-iii-study-of-alisertib-or-investigatora%c2%80%c2%99s-choice-selected-single-agent-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma/2025-05-22T19:15:40+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-breast-diffuse-large-ba%c2%80%c2%90cell-lymphoma-in-the-rituximab-era-therapeutic-strategies-and-patterns-of-failure/2025-05-22T19:13:23+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-therapy-with-nivolumab-and-brentuximab-vedotin-bv-followed-by-bv-and-bendamustine-for-suboptimal-response-in-children-adolescents-and-young-adults-with-standard-risk-relapsed-re/2025-05-22T18:50:21+00:00https://lymphoma-stg.clarovantdigital.com/library/relapse-risk-and-loss-in-expectation-of-lifetime-in-young-classical-hodgkin-lymphoma-patients-a-nordic-lymphoma-group-study-of-2582-patients/2025-05-22T18:46:56+00:00https://lymphoma-stg.clarovantdigital.com/library/tislelizumab-bgb-a317-for-relapsed-refractory-classical-hodgkin-lymphoma-preliminary-efficacy-and-safety-results-from-a-phase-2-study/2025-05-22T18:44:58+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-for-patients-with-high-risk-relapsed-or-refractory-indolent-b-cell-lymphoma-treated-with-copanlisib-in-the-chronos-1-study/2025-05-22T18:42:14+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-response-at-end-of-induction-and-during-maintenance-correlates-with-updated-outcome-in-the-phase-iii-gallium-study-of-obinutuzumab-or-rituximab-based-immunochemotherapy-in-pr/2025-05-22T18:39:42+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-maintenance-after-autologous-transplantation-prolongs-pfs-in-young-mcl-patients-results-of-the-randomized-phase-iii-mcl-0208-trial-from-fondazione-italiana-linfomi-fil/2025-05-22T18:37:33+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-with-combination-of-dabrafenib-and-trametinib-in-patients-with-recurrent-refractory-braf-v600e-mutated-hairy-cell-leukemia-hcl/2025-05-22T18:35:44+00:00https://lymphoma-stg.clarovantdigital.com/library/acquired-resistance-to-braf-inhibition-in-hcl-is-rare-and-retreatment-with-vemurafenib-at-relapse-can-induce-high-response-rates-final-results-of-a-phase-ii-trial-of-vemurafenib-in-relapsed-hcl/2025-07-03T17:25:39+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-outcomes-among-very-elderly-patients-with-major-lymphoma-subtypes-a-nordic-lymphoma-group-study/2025-05-22T18:31:24+00:00https://lymphoma-stg.clarovantdigital.com/library/normalization-of-survival-and-no-relapses-after-one-year-in-adult-burkitt-lymphoma-patients-treated-with-intensive-immunochemotherapy-an-international-study-of-159-real-world-patients/2025-05-22T18:28:45+00:00https://lymphoma-stg.clarovantdigital.com/library/relapses-after-achieving-efs24-in-patients-with-diffuse-large-b-cell-lymphoma-in-the-rituximab-era/2025-05-22T18:26:19+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-lysa-study-of-obinutuzumab-combined-with-lenalidomide-for-advanced-untretated-follicular-b-cell-lymphoma-in-need-of-systemic-therapy/2025-05-22T18:24:18+00:00https://lymphoma-stg.clarovantdigital.com/library/myd88-l265p-mutation-and-cdkn2a-loss-are-early-mutational-events-in-primary-central-nervous-system-diffuse-large-b-cell-lymphomas/2025-05-13T21:30:06+00:00https://lymphoma-stg.clarovantdigital.com/library/lowa%c2%80%c2%90dose-lenalidomide-maintenance-after-induction-therapy-in-older-patients-with-primary-central-nervous-system-lymphoma/2025-05-13T21:25:57+00:00https://lymphoma-stg.clarovantdigital.com/library/asbmt-consensus-grading-for-cytokine-release-syndrome-and-neurologic-toxicity-associated-with-immune-effector-cells/2025-05-13T21:21:35+00:00https://lymphoma-stg.clarovantdigital.com/library/dynamo-a-phase-ii-study-of-duvelisib-ipi-145-in-patients-with-refractory-indolent-non-hodgkin-lymphoma/2025-05-13T21:20:00+00:00https://lymphoma-stg.clarovantdigital.com/library/ofatumumab-monotherapy-in-naa%c2%afve-fl-patients-results-from-a-phase-ii-trial/2025-05-13T21:18:10+00:00https://lymphoma-stg.clarovantdigital.com/library/a-pet-radiomics-model-to-predict-refractory-mediastinal-hodgkin-lymphoma/2025-05-13T21:16:22+00:00https://lymphoma-stg.clarovantdigital.com/library/the-average-relative-dose-intensity-of-ra%c2%80%c2%90chop-is-an-independent-factor-determining-favorable-overall-survival-in-diffuse-large-ba%c2%80%c2%90cell-lymphoma-patients/2025-05-13T21:14:35+00:00https://lymphoma-stg.clarovantdigital.com/library/myelodysplastic-syndrome-and-acute-myeloid-leukemia-after-receipt-of-granulocyte-colonya%c2%80%c2%90stimulating-factors-in-older-patients-with-nona%c2%80%c2%90hodgkin-lymphoma/2025-05-13T21:09:38+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-effectiveness-of-mogamulizumab-in-relapsed-or-refractory-adult-ta%c2%80%c2%90cell-leukemiaa%c2%80%c2%90lymphoma/2026-01-15T17:06:39+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-interferona%c2%80%c2%90alfaa%c2%80%c2%902b-and-dose-dense-cvp-is-highly-efficient-in-patients-with-flipi-greater-than-2-follicular-lymphoma-final-results-of-the-lnha%c2%80%c2%90proa%c2%80/2025-04-25T18:25:15+00:00https://lymphoma-stg.clarovantdigital.com/library/distinctive-incidence-patterns-of-follicular-lymphoma-in-taiwan-implications-of-ethnic-differences/2020-05-20T10:34:37+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-surgery-on-long-term-survival-of-patients-with-primary-gastric-diffuse-large-b-cell-lymphoma-a-seer-population-based-study/2020-05-20T10:34:38+00:00https://lymphoma-stg.clarovantdigital.com/library/body-mass-index-and-hodgkins-lymphoma-uk-population-based-cohort-study-of-5-8-million-individuals/2025-04-24T19:04:01+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-of-patients-with-indolent-non-hodgkin-lymphoma-or-mantle-cell-lymphoma-with-bendamustine-plus-rituximab-versus-r-chop-or-r-cvp-results-of-the-bright-5-year-follow-up-study/2025-04-24T19:02:04+00:00https://lymphoma-stg.clarovantdigital.com/library/integration-of-cell-of-origin-into-the-clinical-cns-international-prognostic-index-improves-cns-relapse-prediction-in-dlbcl/2025-04-24T18:58:50+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-survival-outcomes-in-patients-with-follicular-lymphoma-a-2007-to-2015-humedica-database-study/2025-04-24T18:52:19+00:00https://lymphoma-stg.clarovantdigital.com/library/mortality-of-lymphoma-and-myeloma-in-china-2004a%c2%80%c2%932017-an-observational-study/2025-04-24T18:47:48+00:00https://lymphoma-stg.clarovantdigital.com/library/direct-costs-associated-with-relapsed-diffuse-large-ba%c2%80%c2%90cell-lymphoma-therapies/2025-12-15T20:14:59+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-trial-of-ibrutinib-vs-ibrutinib-plus-rituximab-in-patients-with-chronic-lymphocytic-leukemia/2025-04-24T18:36:37+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-susceptibility-to-radiation-induced-breast-cancer-after-hodgkin-lymphoma/2025-04-24T18:34:14+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-or-autologous-stem-cell-transplantation-for-primary-cns-lymphoma-in-patients-60-years-of-age-and-younger-results-of-the-intergroup-anocef-goelams-randomized-phase-ii-precis-study/2025-04-24T18:31:51+00:00https://lymphoma-stg.clarovantdigital.com/library/pentostatin-cyclophosphamide-and-rituximab-combination-for-advanced-stage-inhl/2025-04-24T18:25:31+00:00https://lymphoma-stg.clarovantdigital.com/library/entospletinib-monotherapy-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-previously-treated-with-b-cell-receptor-inhibitors-results-of-a-phase-2-study/2025-12-28T13:46:55+00:00https://lymphoma-stg.clarovantdigital.com/library/higha%c2%80%c2%90dose-methotrexate-plus-temozolomide-with-or-without-rituximab-in-patients-with-untreated-primary-central-nervous-system-lymphoma-a-retrospective-study-from-china/2020-05-20T10:34:43+00:00https://lymphoma-stg.clarovantdigital.com/library/pretreatment-hemoglobin-as-an-independent-prognostic-factor-in-primary-central-nervous-system-lymphomas/2025-04-23T19:43:41+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-presentation-management-and-biomarkers-of-neurotoxicity-after-adoptive-immunotherapy-with-car-t-cells/2025-04-23T19:39:47+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-plus-chemotherapy-in-north-american-subjects-with-newly-diagnosed-stage-iii-or-iv-hodgkin-lymphoma/2025-04-15T21:14:19+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-characterization-of-pediatric-follicular-lymphoma/2025-04-15T21:11:46+00:00https://lymphoma-stg.clarovantdigital.com/library/pesticide-use-and-risk-of-non-hodgkin-lymphoid-malignancies-in-agricultural-cohorts-from-france-norway-and-the-usa-a-pooled-analysis-from-the-agricoh-consortium/2020-05-20T10:35:57+00:00https://lymphoma-stg.clarovantdigital.com/library/pathogenesis-and-biomarkers-of-natural-killer-t-cell-lymphoma-nktl/2026-09-02T16:10:46+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-l1-and-tumor-associated-macrophages-in-de-novo-dlbcl/2025-04-03T20:08:07+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-iii-trial-of-ibrutinib-and-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-in-nona%c2%80%c2%93germinal-center-b-cell-diffuse-large-b-cell-lymphoma/2025-04-03T19:38:00+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-low-dose-low-frequency-oral-psoralena%c2%80%c2%93uv-a-treatment-with-or-without-maintenance-on-early-stage-mycosis-fungoides/2025-04-03T19:35:33+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-manage-ibrutinib-intolerance-and-complications-in-patients-with-chronic-lymphocytic-leukemia/2025-04-03T19:31:42+00:00https://lymphoma-stg.clarovantdigital.com/library/augment-a-phase-iii-study-of-lenalidomide-plus-rituximab-versus-placebo-plus-rituximab-in-relapsed-or-refractory-indolent-lymphoma/2025-04-03T19:30:03+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-chop-vs-chope-for-treatment-of-peripheral-t-cell-lymphoma-a-meta-analysis/2025-04-03T19:28:32+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-transplantation-for-high-risk-chronic-lymphocytic-leukemiaa%c2%80%c2%94a-summary-of-a-16-year-experience/2025-12-19T15:21:22+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prognostic-and-clinicopathological-significance-of-pd-l1-expression-in-patients-with-diffuse-large-b-cell-lymphoma-a-meta-analysis/2025-03-06T00:45:13+00:00https://lymphoma-stg.clarovantdigital.com/library/ebmt-2019-preliminary-in-human-evaluation-of-a-cd19-cd22-dual-car-t-construct-for-b-nhl/2025-03-06T00:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-expression-profiling-of-bortezomib-added-to-standard-chemoimmunotherapy-for-diffuse-large-b-cell-lymphoma-remodl-b-an-open-label-randomised-phase-3-trial/2025-03-06T00:37:13+00:00https://lymphoma-stg.clarovantdigital.com/library/ebmt-2019-a-consensus-grading-system-for-toxicities-in-car-t-trials/2025-03-06T00:34:24+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-age-on-clinical-risk-scores-in-follicular-lymphoma/2025-03-06T00:32:42+00:00https://lymphoma-stg.clarovantdigital.com/library/allergies-and-the-subsequent-risk-of-cancer-among-elderly-adults-in-the-united-states/2020-05-20T10:36:00+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-adjusted-epoch-r-compared-with-r-chop-as-frontline-therapy-for-diffuse-large-b-cell-lymphoma-clinical-outcomes-of-the-phase-iii-intergroup-trial-alliance-calgb-50303/2025-03-06T00:30:09+00:00https://lymphoma-stg.clarovantdigital.com/library/low-absolute-nk-cell-counts-in-peripheral-blood-are-associated-with-inferior-survival-in-patients-with-mantle-cell-lymphoma/2025-03-06T00:27:22+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-in-pretreated-patients-with-diffuse-large-ba%c2%80%c2%90cell-lymphoma-an-italian-observational-multicenter-retrospective-study-in-daily-clinical-practice/2025-03-06T00:25:36+00:00https://lymphoma-stg.clarovantdigital.com/library/genomea%c2%80%c2%90wide-analysis-of-epsteina%c2%80%c2%90barr-virus-isolated-from-extranodal-nk-ta%c2%80%c2%90cell-lymphoma-nasal-type/2025-03-06T00:23:41+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-pathogenic-pathways-in-extranodal-nk-t-cell-lymphoma/2025-03-06T00:18:34+00:00https://lymphoma-stg.clarovantdigital.com/library/the-management-of-primary-mediastinal-ba%c2%80%c2%90cell-lymphoma-a-british-society-for-haematology-good-practice-paper/2026-01-06T21:16:21+00:00https://lymphoma-stg.clarovantdigital.com/library/diabetes-mellitus-predicts-inferior-survival-in-diffuse-large-b-cell-lymphoma-a-propensity-score-matched-analysis/2025-03-05T19:47:54+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-results-of-a-phase-2-trial-of-first-line-idelalisib-plus-ofatumumab-in-chronic-lymphocytic-leukemia/2025-03-05T19:26:00+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-lymphocyte-monocyte-ratio-at-diagnosis-in-hodgkin-lymphoma-a-meta-analysis/2025-03-05T19:21:52+00:00https://lymphoma-stg.clarovantdigital.com/library/major-hemorrhage-in-chronic-lymphocytic-leukemia-patients-in-the-us-veterans-health-administration-system-in-the-prea%c2%80%c2%90ibrutinib-era-incidence-and-risk-factors/2025-03-05T19:17:56+00:00https://lymphoma-stg.clarovantdigital.com/library/intraocular-involvement-of-mantle-cell-lymphoma-a-case-report-and-literature-review/2020-05-20T10:36:05+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-prognostic-significance-of-eber-positivity-in-diffuse-large-b-cell-lymphoma-a-meta-analysis/2025-03-05T19:15:25+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-red-blood-cell-distribution-width-and-outcomes-in-patients-with-mantle-cell-lymphoma/2025-03-05T19:14:05+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-rheumatological-disorders-on-lymphomas-and-myeloma-a-report-on-risk-and-survival-from-the-uka%c2%80%c2%99s-population-based-haematological-malignancy-research-network/2025-03-05T19:12:24+00:00https://lymphoma-stg.clarovantdigital.com/library/types-of-second-primary-cancers-influence-survival-in-chronic-lymphocytic-and-hairy-cell-leukemia-patients/2025-03-05T19:05:50+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-occupational-pesticide-exposure-with-immunochemotherapy-response-and-survival-among-patients-with-diffuse-large-b-cell-lymphoma/2025-03-05T19:03:39+00:00https://lymphoma-stg.clarovantdigital.com/library/the-2018-update-of-the-who-eortc-classification-for-primary-cutaneous-lymphomas/2026-09-02T16:10:06+00:00https://lymphoma-stg.clarovantdigital.com/library/final-results-of-a-randomized-phase-iii-study-of-rituximab-with-or-without-idelalisib-followed-by-open-label-idelalisib-in-patients-with-relapsed-chronic-lymphocytic-leukemia/2025-03-05T18:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-90y-ibritumomab-tiuxetan-consolidation-in-mcl-patients/2026-01-06T20:59:16+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-efficacy-of-cisplatin-dexamethasone-gemcitabine-and-pegaspargase-ddgp-in-the-initial-treatment-of-advanced-stage-stage-iiia%c2%80%c2%93iv-extranodal-nk-t-cell-lymphoma-and-its-correlat/2025-03-05T18:35:22+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-low-dose-decitabine-to-antia%c2%80%c2%93pd-1-antibody-camrelizumab-in-relapsed-refractory-classical-hodgkin-lymphoma/2025-03-05T18:04:11+00:00https://lymphoma-stg.clarovantdigital.com/library/ofatumumab-is-safe-and-effective-as-front-line-treatment-in-older-patients-with-chronic-lymphocytic-leukemia-and-severe-co-morbidities-including-other-malignancies/2025-03-05T17:58:58+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-ba%c2%80%c2%90cell-lymphoma-2019-update-on-diagnosis-risk-stratification-and-treatment/2025-03-04T16:03:18+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-peripheral-blood-absolute-lymphocyte-count-and-derived-neutrophil-to-lymphocyte-ratio-in-patients-with-newly-diagnosed-extranodal-natural-killer-t-cell-lymphoma/2025-03-03T22:10:26+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-r-or-g-chop-in-non-hodgkin-lymphoma-results-from-the-cavalli-phase-1b-trial/2025-03-03T22:03:48+00:00https://lymphoma-stg.clarovantdigital.com/library/cranial-aspergillosis-in-a-patient-receiving-ibrutinib-for-chronic-lymphocytic-leukemia/2025-03-03T21:59:19+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnosis-of-central-nervous-system-lymphoma-via-cerebrospinal-fluid-cytology-a-case-report/2025-03-03T21:56:45+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-bendamustine-and-ofatumumab-in-elderly-patients-with-newly-diagnosed-diffuse-large-ba%c2%80%c2%90cell-lymphoma-who-are-poor-candidates-for-ra%c2%80%c2%90chop-chemotherapy/2024-12-05T22:30:53+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-the-resonate-phase-3-trial-of-ibrutinib-vs-ofatumumab/2024-12-05T21:43:40+00:00https://lymphoma-stg.clarovantdigital.com/library/micrornas-as-biomarkers-of-b-cell-lymphoma/2024-12-05T21:41:54+00:00https://lymphoma-stg.clarovantdigital.com/library/active-surveillance-for-nodular-lymphocyte-predominant-hodgkin-lymphoma/2024-12-05T21:08:26+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-nk-cell-count-on-dlbcl-outcomes-following-immunochemotherapy/2024-12-05T21:06:55+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-plus-rituximab-r2-in-previously-untreated-marginal-zone-lymphoma-subgroup-analysis-and-longa%c2%80%c2%90term-followa%c2%80%c2%90up-of-an-opena%c2%80%c2%90label-phase-2-trial/2024-12-05T21:04:56+00:00https://lymphoma-stg.clarovantdigital.com/library/rare-cases-of-primary-central-nervous-system-anaplastic-variant-of-diffuse-large-b-cell-lymphoma/2024-12-05T21:03:18+00:00https://lymphoma-stg.clarovantdigital.com/library/histological-transformation-in-duodenal-type-follicular-lymphoma-a-case-report-and-review-of-the-literature/2024-12-05T20:26:53+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-for-newly-diagnosed-advanced-stage-classic-hodgkin-lymphoma-safety-and-efficacy-in-the-phase-ii-checkmate-205-study/2024-12-05T20:23:56+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-value-of-interim-positron-emission-tomography-in-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/2024-12-05T20:22:08+00:00https://lymphoma-stg.clarovantdigital.com/library/characterisation-of-a-new-clinical-presentation-of-chronic-lymphocytic-leukaemia-symptomatic-bronchial-involvement-a-study-from-the-filo-group/2024-12-05T19:42:43+00:00https://lymphoma-stg.clarovantdigital.com/library/effectiveness-of-lenalidomide-in-relapsed-primary-cutaneous-diffuse-large-ba%c2%80%c2%90cell-lymphoma-leg-type/2024-12-05T19:39:15+00:00https://lymphoma-stg.clarovantdigital.com/library/cause-specific-mortality-in-survivors-of-lymphoplasmacytic-lymphoma-lpl-and-waldenstrom-macroglobulinemia-wm/2024-12-05T19:31:50+00:00https://lymphoma-stg.clarovantdigital.com/library/the-efficacy-of-ibrutinib-based-combination-therapy-for-mantle-cell-lymphoma-a-systematic-review/2024-12-05T19:30:48+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-an-indian-experience/2024-12-05T19:29:10+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-chronic-lymphocytic-leukemia-cll-patients-with-notch1-signaling-pathway-mutations/2024-12-05T19:28:18+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-lenalidomide-in-diffuse-large-b-cell-dlbcl-and-high-grade-nhl-hgbcl-a-single-center-retrospective-analysis/2024-12-05T19:26:18+00:00https://lymphoma-stg.clarovantdigital.com/library/a-rare-case-of-follicular-lymphoma-transformed-to-a-higha%c2%80%c2%90grade-ba%c2%80%c2%90cell-lymphoma-in-orbit/2024-12-05T19:24:32+00:00https://lymphoma-stg.clarovantdigital.com/library/high-risk-patients-with-diffuse-large-b-cell-lymphoma-are-not-enrolled-on-clinical-trials/2024-12-05T19:21:47+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-maintenance-following-induction-for-untreated-mantle-cell-lymphoma-mcl-initial-safety-report/2024-12-05T19:20:34+00:00https://lymphoma-stg.clarovantdigital.com/library/detection-of-extranodal-and-spleen-involvement-by-fdga%c2%80%c2%90pet-imaging-predicts-adverse-survival-in-untreated-follicular-lymphoma/2024-12-05T19:19:00+00:00https://lymphoma-stg.clarovantdigital.com/library/decreased-mitochondrial-fitness-correlates-with-impaired-car-t-cell-persistence-and-poorer-responses-in-cll/2024-12-03T20:07:00+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-ibrutinib-combination-effective-for-certain-patients-with-chronic-lymphocytic-leukemia/2024-12-03T20:02:03+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-head-and-neck-cancer-in-patients-with-prior-hematologic-malignant-tumors/2024-12-03T19:54:35+00:00https://lymphoma-stg.clarovantdigital.com/library/patterns-of-survival-in-patients-with-recurrent-mantle-cell-lymphoma-in-the-modern-era-progressive-shortening-in-response-duration-and-survival-after-each-relapse/2024-12-03T18:27:12+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-of-bexarotene-for-cutaneous-t-cell-lymphoma-results-from-a-phase-ii-trial/2024-12-03T18:25:36+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-score-predicts-atrial-fibrillation-with-ibrutinib-therapy-for-chronic-lymphocytic-leukemia/2024-12-03T18:21:40+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-chimeric-antigen-receptor-t-cell-therapy-in-multiply-relapsed-or-refractory-adult-large-b-cell-lymphoma/2025-12-19T18:50:12+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-combo-induces-high-responses-in-cll/2024-12-02T20:05:20+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-monotherapy-in-patients-with-chronic-lymphocytic-leukemia-who-are-intolerant-to-ibrutinib/2024-12-02T20:00:40+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-2019-update-on-the-diagnosis-pathogenesis-prognostication-and-management/2024-12-02T19:58:42+00:00https://lymphoma-stg.clarovantdigital.com/library/asco-2019-allo-sct-versus-auto-sct-as-first-line-consolidation-in-ptcl-aatt-study/2024-12-02T19:55:05+00:00https://lymphoma-stg.clarovantdigital.com/library/asco-2019-obinutuzumab-plus-venetoclax-is-superior-than-combination-with-chlorambucil-in-naa%c2%afve-cll-with-comorbidities/2024-12-02T19:50:18+00:00https://lymphoma-stg.clarovantdigital.com/library/postrelapse-survival-in-diffuse-large-b-cell-lymphoma-after-therapy-failure-following-autologous-transplantation/2024-12-02T19:30:44+00:00https://lymphoma-stg.clarovantdigital.com/library/no-benefit-with-rituximab-maintenance-following-complete-remission-for-diffuse-large-b-cell-lymphoma/2024-12-02T19:29:09+00:00https://lymphoma-stg.clarovantdigital.com/library/adcetris-combo-continues-to-show-better-results-than-chemotherapy-alone-phase-3-update-reveals/2024-12-02T19:26:03+00:00https://lymphoma-stg.clarovantdigital.com/library/meta-analysis-of-progression-free-survival-in-phase-3-trials-of-follicular-lymphoma-treatments/2024-12-02T19:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-adverse-events-and-economic-burden-in-a-privately-insured-population-of-patients-with-chronic-lymphocytic-leukemia-in-the-united-states/2025-12-19T18:49:42+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-doxorubicin-vinblastine-and-dacarbazine-for-non-bulky-limited-stage-classical-hodgkin-lymphoma/2024-12-02T18:50:10+00:00https://lymphoma-stg.clarovantdigital.com/library/skin-directed-therapy-in-cutaneous-t-cell-lymphoma/2025-05-27T12:12:22+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-safety-of-single-agent-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-in-3-pivotal-studies/2024-11-27T22:56:42+00:00https://lymphoma-stg.clarovantdigital.com/library/nonrelapse-mortality-after-car-t-therapy-remains-high/2024-11-27T23:04:10+00:00https://lymphoma-stg.clarovantdigital.com/library/asco-2019-smart-start-phase-2-trial-rituximab-lenalidomide-ibrutinib-combination-for-naive-dlbcl/2024-11-27T22:53:46+00:00https://lymphoma-stg.clarovantdigital.com/library/evolution-of-clonal-hematopoiesis-in-mantle-cell-lymphoma-patients-before-during-and-after-induction-chemotherapy-and-autologous-stem-cell-transplantation/2024-11-27T22:26:36+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1-2-of-acalabrutinib-plus-pembrolizumab-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2026-01-15T17:06:10+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-compared-to-standard-chemotherapy-for-central-nervous-system-recurrence-of-mantle-cell-lymphoma/2024-11-27T22:19:21+00:00https://lymphoma-stg.clarovantdigital.com/library/high-efficacy-of-venetoclax-plus-obinutuzumab-in-patients-with-complex-karyotype-ckt-and-chronic-lymphocytic-leukemia-cll-a-prospective-analysis-from-the-cll14-trial/2025-05-23T19:10:16+00:00https://lymphoma-stg.clarovantdigital.com/library/liso-cel-demonstrates-safety-efficacy-in-mcl-cohort/2024-11-27T21:59:19+00:00https://lymphoma-stg.clarovantdigital.com/library/value-of-ct-guided-percutaneous-needle-biopsy-of-bone-in-the-diagnosis-of-lymphomas-based-on-pet-ct-results/2024-11-27T21:45:02+00:00https://lymphoma-stg.clarovantdigital.com/library/distribution-of-hospital-care-among-pediatric-and-young-adult-hodgkin-lymphoma-survivorsa%c2%80%c2%94a-populationa%c2%80%c2%90based-cohort-study-from-sweden-and-denmark/2024-11-27T21:42:20+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-associated-with-long-term-fatigue-in-non-hodgkin-lymphoma-survivors/2026-08-18T15:16:14+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-diffuse-large-b-cell-lymphoma-with-extra-copies-of-myc-bcl2-and-or-bcl6-comparison-with-double-triple-hit-lymphoma-and-double-expressor-lymphoma/2024-11-27T20:09:27+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-experience-of-ra%c2%80%c2%90chop-with-or-without-consolidative-radiotherapy-vs-daa%c2%80%c2%90epocha%c2%80%c2%90r-in-the-firsta%c2%80%c2%90line-treatment-of-primary-mediastinal-ba%c2%80/2025-05-27T12:13:08+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-preceded-by-blood-brain-barrier-permeabilization-with-engineered-tumor-necrosis-factor-i%c2%b1-in-primary-cns-lymphoma/2024-11-27T19:51:03+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-early-relapsing-follicular-lymphoma-2/2024-11-27T19:42:58+00:00https://lymphoma-stg.clarovantdigital.com/library/eha-2019-two-year-follow-up-of-checkmate-205-nivolumab-plus-doxorubicin-vinblastine-and-dacarbazine-in-newly-diagnosed-advanced-stage-chl/2024-11-27T19:37:38+00:00https://lymphoma-stg.clarovantdigital.com/library/mogamulizumab-treatment-elicits-autoantibodies-attacking-the-skin-in-patients-with-adult-t-cell-leukemia-lymphoma/2024-11-27T19:32:07+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-studies-assessing-outcomes-of-ibrutinib-therapy-in-patients-with-del-11q-chronic-lymphocytic-leukemia/2025-12-15T22:23:48+00:00https://lymphoma-stg.clarovantdigital.com/library/early-progression-after-br-is-associated-with-high-risk-of-transformation-in-advanced-stage-follicular-lymphoma/2024-11-27T19:22:36+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-score-could-allow-patients-to-avoid-unnecessary-treatment-for-hodgkin-lymphoma/2024-11-27T19:19:58+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-progression-free-survival-benefit-of-rituximab-maintenance-in-patients-with-follicular-lymphoma-long-term-results-of-the-prima-study/2024-11-27T19:13:43+00:00https://lymphoma-stg.clarovantdigital.com/library/tisagenlecleucel-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-patients-without-measurable-disease-at-infusion/2024-11-27T19:11:12+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-venetoclax-in-relapsed-chronic-lymphocytic-leukemia-is-influenced-by-disease-and-response-variables/2026-01-15T17:05:01+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-blockade-with-pembrolizumab-for-classical-hodgkin-lymphoma-after-autologous-stem-cell-transplantation-2/2024-11-22T21:35:23+00:00https://lymphoma-stg.clarovantdigital.com/library/eha-2019-anti-cd47-antibody-hu5f9-g4-with-rituximab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-and-indolent-non-hodgkin-lymphoma/2026-01-06T21:02:41+00:00https://lymphoma-stg.clarovantdigital.com/library/eha-2019-ibrutinib-in-early-and-late-cll-news-from-eha/2026-01-15T17:04:23+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-evidence-links-textured-breast-implants-to-rare-lymphoma/2024-11-22T20:00:33+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-trial-of-ofatumumab-and-bendamustine-versus-ofatumumab-bendamustine-and-bortezomib-in-previously-untreated-patients-with-higha%c2%80%c2%90risk-follicular-lymphoma-calgb-50904-alliance/2024-11-22T19:55:34+00:00https://lymphoma-stg.clarovantdigital.com/library/activation-of-hedgehog-signaling-associates-with-early-disease-progression-in-chronic-lymphocytic-leukemia/2024-11-22T19:47:27+00:00https://lymphoma-stg.clarovantdigital.com/library/concurrent-ibrutinib-with-car-t-cell-therapy-improves-orr-reduces-severe-crs-in-high-risk-cll/2026-01-15T17:03:35+00:00https://lymphoma-stg.clarovantdigital.com/library/eha-2019-results-of-the-phase-ii-lyma-101-trial/2024-11-22T18:49:35+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-ra%c2%80%c2%90gcvp-in-patients-with-late-relapse-of-diffuse-large-ba%c2%80%c2%90cell-lymphoma/2024-11-22T18:38:31+00:00https://lymphoma-stg.clarovantdigital.com/library/the-association-between-hla-and-non-hodgkin-lymphoma-subtypes-among-a-transplant-indicated-population/2024-11-22T18:35:29+00:00https://lymphoma-stg.clarovantdigital.com/library/gait-speed-grip-strength-and-clinical-outcomes-in-older-patients-with-hematologic-malignancies/2024-11-21T22:02:12+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-and-emerging-therapies-for-b-cell-lymphoma/2024-11-21T21:58:48+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-concurrent-indolent-lymphoma-on-the-clinical-outcome-of-newly-diagnosed-diffuse-large-b-cell-lymphoma/2024-11-21T21:56:05+00:00https://lymphoma-stg.clarovantdigital.com/library/short-regimen-of-rituximab-plus-lenalidomide-in-follicular-lymphoma-patients-in-need-of-first-line-therapy/2024-11-21T21:49:59+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-venetoclax-in-relapsed-refractory-chronic-lymphocytic-leukemia-the-clarity-study/2024-11-21T21:34:51+00:00https://lymphoma-stg.clarovantdigital.com/library/the-burden-of-burkitt-lymphoma-in-africa/2026-09-02T16:09:25+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutiniba%c2%80%c2%93rituximab-or-chemoimmunotherapy-for-chronic-lymphocytic-leukemia/2024-11-21T20:11:01+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-natural-killer-cell-count-in-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-patients-treated-with-immunochemotherapy/2024-11-21T19:53:12+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-role-of-cd4-t-cell-depletion-after-frontline-fludarabine-cyclophosphamide-and-rituximab-in-chronic-lymphocytic-leukaemia/2024-11-21T19:50:28+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcome-of-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma-treated-with-blinatumomab/2026-01-15T14:05:03+00:00https://lymphoma-stg.clarovantdigital.com/library/few-oncologists-advise-cancer-survivors-on-lifestyle-changes/2024-11-21T19:11:30+00:00https://lymphoma-stg.clarovantdigital.com/library/medium-and-long-term-risks-of-specific-cardiovascular-diseases-in-survivors-of-20-adult-cancers-a-population-based-cohort-study-using-multiple-linked-uk-electronic-health-records-databases/2020-05-20T10:36:34+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-approaches-for-older-and-oldest-patients-with-diffuse-large-b-cell-lymphoma-a%c2%80%c2%93-use-of-non-r-chop-alternative-therapies-and-impact-of-comorbidities-on-treatment-choices-and-outcome/2024-11-21T19:05:22+00:00https://lymphoma-stg.clarovantdigital.com/library/a-tool-to-select-candidates-for-allogeneic-hematopoietic-cell-transplant-in-cll/2024-11-21T19:00:39+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-combined-with-brentuximab-vedotin-for-relapsed-refractory-primary-mediastinal-large-b-cell-lymphoma-efficacy-and-safety-from-the-phase-ii-checkmate-436-study/2024-11-21T18:54:57+00:00https://lymphoma-stg.clarovantdigital.com/library/breast-implanta%c2%80%c2%93associated-anaplastic-large-cell-lymphoma-why-must-we-learn-about-it/2024-11-21T18:51:24+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-helicobacter-pylori-infection-in-gastric-diffuse-large-b-cell-lymphoma/2024-11-21T18:48:49+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-germline-brca2-mutations-with-the-risk-of-pediatric-or-adolescent-nona%c2%80%c2%93hodgkin-lymphoma/2024-11-21T18:45:43+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-socs1-mutations-in-diffuse-large-ba%c2%80%c2%90cell-lymphoma/2024-11-21T16:26:23+00:00https://lymphoma-stg.clarovantdigital.com/library/analysis-of-153115-patients-with-hematological-malignancies-refines-the-spectrum-of-familial-risk/2024-11-20T22:10:16+00:00https://lymphoma-stg.clarovantdigital.com/library/low-dose-radiation-4-gy-with-without-concurrent-chemotherapy-is-highly-effective-for-relapsed-refractory-mantle-cell-lymphoma/2024-11-20T22:08:40+00:00https://lymphoma-stg.clarovantdigital.com/library/progression-of-disease-within-24-months-in-follicular-lymphoma-is-associated-with-reduced-intratumoral-immune-infiltration/2024-11-20T22:06:56+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-relapsed-or-refractory-hodgkin-lymphoma-two-year-follow-up-of-keynote-087/2026-01-16T15:01:57+00:00https://lymphoma-stg.clarovantdigital.com/library/high-rate-of-durable-complete-remission-in-follicular-lymphoma-after-cd19-car-t-cell-immunotherapy-2/2024-11-20T21:26:39+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-mortality-trends-and-geographic-patterns-of-follicular-lymphoma-in-canada/2024-11-20T21:19:54+00:00https://lymphoma-stg.clarovantdigital.com/library/measuring-patient-reported-outcomes-in-waldenstrom-macroglobulinemia-patients-receiving-rituximab-vs-ibrutinib-rituximab/2024-11-20T21:14:20+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-hsct-consolidation-shows-no-benefit-for-certain-patients-with-b-cell-lymphomas/2024-11-20T21:06:10+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-plus-fludarabine-and-cyclophosphamide-in-previously-untreated-fit-patients-with-chronic-lymphocytic-leukemia-a-subgroup-analysis-of-the-green-study/2024-11-20T20:59:52+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-complex-karyotype-on-the-overall-survival-of-patients-with-relapsed-chronic-lymphocytic-leukemia-treated-with-idelalisib-plus-rituximab/2026-01-06T21:18:39+00:00https://lymphoma-stg.clarovantdigital.com/library/relevant-biomarkers-for-the-treatment-of-hematological-malignancies/2024-11-20T20:52:10+00:00https://lymphoma-stg.clarovantdigital.com/library/early-progression-as-a-predictor-of-survival-in-marginal-zone-lymphomas-an-analysis-from-the-fil-nf10-study/2020-05-20T10:36:39+00:00https://lymphoma-stg.clarovantdigital.com/library/gemcitabine-cisplatin-prednisone-and-thalidomide-for-relapse-and-refractory-peripheral-t-cell-lymphoma-a-retrospective-study-from-china/2024-11-20T20:26:43+00:00https://lymphoma-stg.clarovantdigital.com/library/yttrium-90-ibritumomab-tiuxetan-consolidation-versus-rituximab-maintenance-therapy-after-induction-chemotherapy-in-patients-with-indolent-non-hodgkin-lymphoma-a-single-institution-experience/2026-01-06T20:58:46+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-myc-rearrangement-and-translocation-partner-in-diffuse-large-b-cell-lymphoma-a-study-by-the-lunenburg-lymphoma-biomarker-consortium/2024-11-20T20:18:04+00:00https://lymphoma-stg.clarovantdigital.com/library/positron-emission-tomographya%c2%80%c2%93guided-treatment-in-early-stage-favorable-hodgkin-lymphoma-final-results-of-the-international-randomized-phase-iii-hd16-trial-by-the-german-hodgkin-study-gro/2024-11-20T19:59:39+00:00https://lymphoma-stg.clarovantdigital.com/library/distinct-immune-composition-in-lymph-node-and-peripheral-blood-of-cll-patients-is-reshaped-during-venetoclax-treatment/2024-11-20T19:57:21+00:00https://lymphoma-stg.clarovantdigital.com/library/can-combination-targeted-therapy-bring-about-another-paradigm-shift-in-chronic-lymphocytic-leukemia/2024-11-20T19:54:15+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-peta%c2%80%c2%90results-for-prognosis-in-adults-with-hodgkin-lymphoma-a-systematic-review-and-metaa%c2%80%c2%90analysis-of-prognostic-factor-studies/2024-11-20T19:49:30+00:00https://lymphoma-stg.clarovantdigital.com/library/cytarabine-based-induction-immunochemotherapy-in-the-front-line-treatment-of-older-patients-with-mantle-cell-lymphoma/2024-11-20T19:38:26+00:00https://lymphoma-stg.clarovantdigital.com/library/induction-radiation-therapy-before-car-t-reduces-treatment-related-toxicities/2024-11-15T20:12:30+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-comparability-between-rituximab-biosimilar-rtxm83-and-rituximab-in-diffuse-large-b-cell-lymphoma-patients/2024-11-15T20:05:35+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplantation-may-be-curative-for-patients-with-follicular-lymphoma-with-early-therapy-failure-without-the-need-for-immunotherapy/2025-12-15T21:25:51+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1-study-of-the-selective-btk-inhibitor-zanubrutinib-in-b-cell-malignancies-and-safety-and-efficacy-evaluation-in-cll/2024-11-15T19:14:53+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-response-with-single-agent-acalabrutinib-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma/2024-11-15T18:49:21+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-lenalidomide-and-rituximab-has-promising-activity-in-relapsed-refractory-nona%c2%80%c2%93germinal-center-b-cella%c2%80%c2%93like-dlbcl/2024-11-15T18:35:48+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-toxicities-associated-with-ibrutinib/2024-11-15T18:31:46+00:00https://lymphoma-stg.clarovantdigital.com/library/invasive-fungal-diseases-in-patients-with-hodgkina%c2%80%c2%99s-lymphoma-before-and-after-allogeneic-hematopoietic-stem-cell-transplantation/2024-11-15T18:23:16+00:00https://lymphoma-stg.clarovantdigital.com/library/migration-properties-distinguish-tumor-cells-of-classical-hodgkin-lymphoma-from-anaplastic-large-cell-lymphoma-cells/2024-11-15T18:12:31+00:00https://lymphoma-stg.clarovantdigital.com/library/responsea%c2%80%c2%90adapted-treatment-with-rituximab-bendamustine-mitoxantrone-and-dexamethasone-followed-by-rituximab-maintenance-in-patients-with-relapsed-or-refractory-follicular-lymphoma-after/2024-11-06T19:02:58+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-patients-with-aggressive-ba%c2%80%c2%90cell-nona%c2%80%c2%90hodgkin-lymphoma-after-intensive-frontline-treatment-failure/2024-11-15T16:18:24+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-of-switching-from-intravenous-to-subcutaneous-rituximab-during-firsta%c2%80%c2%90line-treatment-of-patients-with-nona%c2%80%c2%90hodgkin-lymphoma-the-spanish-population-of-the-mabrella-study/2024-11-15T16:14:32+00:00https://lymphoma-stg.clarovantdigital.com/library/hypertension-and-incident-cardiovascular-events-following-ibrutinib-initiation/2024-11-15T16:08:46+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-tisagenlecleucel-treatment-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-and-no-evidence-of-active-disease-following-bridging-chemotherapy-in-th/2024-11-15T16:05:23+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-stage-i-ii-follicular-lymphoma-in-the-pet-era-an-international-study-from-the-australian-lymphoma-alliance/2024-11-15T16:00:50+00:00https://lymphoma-stg.clarovantdigital.com/library/venous-and-arterial-thrombosis-in-patients-with-haematological-malignancy-during-treatment-with-ibrutinib/2024-11-15T15:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/second-primaries-different-in-early-vs-late-stage-dlbcl/2024-11-14T22:11:28+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-open-label-phase-ii-study-of-bendamustine-and-rituximab-followed-by-90-yttrium-y-ibritumomab-tiuxetan-for-untreated-follicular-lymphoma-fol-brite/2026-01-06T21:00:38+00:00https://lymphoma-stg.clarovantdigital.com/library/cxcr4-clonality-is-an-important-determinant-of-ibrutinib-outcomes-in-patients-with-waldenstrom-macroglobulinemia/2024-11-14T21:03:39+00:00https://lymphoma-stg.clarovantdigital.com/library/differences-in-postrelapse-mortality-may-be-driving-racial-ethnic-disparities-observed-in-children-with-hodgkin-lymphoma/2024-11-14T20:02:55+00:00https://lymphoma-stg.clarovantdigital.com/library/refining-diffuse-large-b-cell-lymphoma-subgroups-using-integrated-analysis-of-molecular-profiles/2024-11-14T19:57:48+00:00https://lymphoma-stg.clarovantdigital.com/library/ash-2018-pembrolizumab-for-r-r-pmbcl-patients-results-from-the-phase-ii-keynote-170-trial-and-updated-data-from-the-phase-ib-keynote-013/2024-11-14T19:38:07+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-predictors-of-response-of-lenalidomide-and-rituximab-in-patients-with-treatment-naive-and-relapsed-cll/2024-11-14T19:35:24+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-of-cd5-positive-diffuse-large-b-cell-lymphoma-among-koreans-high-incidence-of-bcl2-and-myc-double-expressors/2024-11-14T19:33:01+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-from-resonate-up-to-six-years-of-followa%c2%80%c2%90up-on-ibrutinib-in-patients-with-previously-treated-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/2025-03-03T21:39:44+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-expression-profiling-more-sensitive-than-fish-for-identifying-double-hit-dlbcl/2024-11-14T14:49:50+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-testing-and-treatment-patterns-in-chronic-lymphocytic-leukemia-in-the-era-of-novel-targeted-therapies-results-from-the-informcll-registry/2024-11-14T14:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-nomogram-for-overall-survival-in-early-stage-extranodal-natural-killer-t-cell-lymphoma-treated-with-high-dose-radiotherapy/2025-05-27T12:13:50+00:00https://lymphoma-stg.clarovantdigital.com/library/cutaneous-t-cell-lymphoma-do-antibiotics-make-a-difference/2024-11-13T20:24:17+00:00https://lymphoma-stg.clarovantdigital.com/library/are-we-ready-to-treat-diffuse-large-b-cell-and-high-grade-lymphoma-according-to-major-genetic-subtypes/2024-11-13T20:18:58+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2024-11-13T20:14:02+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-outcomes-of-the-s1106-study-of-r-hyper-cvad-vs-r-bendamustine-in-transplant-eligible-patients-with-mantle-cell-lymphoma/2025-01-28T21:10:11+00:00https://lymphoma-stg.clarovantdigital.com/library/expert-qa-addressing-the-survivorship-gap-in-pediatric-hodgkin-lymphoma/2024-11-13T20:05:06+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-survival-in-the-absence-of-disease-recurrence-in-advanced-stage-follicular-lymphoma-following-chemo-immunotherapy-13-year-update-of-the-prospective-multicenter-randomized-gitmo-iil-trial/2024-11-13T20:01:53+00:00https://lymphoma-stg.clarovantdigital.com/library/educational-theme-prognostic-factors-in-lymphoma/2024-11-13T19:59:41+00:00https://lymphoma-stg.clarovantdigital.com/library/matching-adjusted-indirect-comparisons-of-the-efficacy-and-safety-of-acalabrutinib-versus-other-targeted-therapies-in-relapsed-refractory-mantle-cell-lymphoma/2024-11-12T19:35:05+00:00https://lymphoma-stg.clarovantdigital.com/library/ruxolitinib-shows-activity-against-hodgkin-lymphoma-but-not-primary-mediastinal-large-b-cell-lymphoma/2026-01-15T14:04:39+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-mortality-trends-and-risk-prediction-nomogram-for-extranodal-diffuse-large-b-cell-lymphoma-an-analysis-of-the-surveillance-epidemiology-and-end-results-database/2020-05-20T10:36:50+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-therapy-and-survival-among-patients-with-nodular-lymphocytea%c2%80%c2%90predominant-hodgkin-lymphoma-a-populationa%c2%80%c2%90based-analysis-in-the-netherlands-1993a%c2%80%c2%932016/2024-11-12T19:12:04+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-markers-in-pediatric-type-follicular-lymphoma/2024-11-12T19:03:17+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-diabetes-mellitus-with-non-hodgkin-lymphoma-risk/2020-05-20T10:36:50+00:00https://lymphoma-stg.clarovantdigital.com/library/acceptability-of-routine-evaluations-using-patienta%c2%80%c2%90reported-outcomes-of-common-terminology-criteria-for-adverse-events-and-other-patienta%c2%80%c2%90reported-symptom-outcome-tools-in-cance/2024-11-12T18:58:55+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-cd22-targeted-car-t-therapy-for-relapsed-refractory-b-cell-malignancies/2024-11-12T18:53:46+00:00https://lymphoma-stg.clarovantdigital.com/library/significant-weight-gain-in-cll-patients-treated-with-ibrutinib-a-potentially-deleterious-consequence-of-therapy/2024-11-12T18:44:14+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-interim-positron-emission-tomography-in-mantle-cell-lymphoma-patients-treated-with-frontline-ra%c2%80%c2%90chop/2024-11-12T18:42:08+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-therapy-of-stage-iii-iv-hodgkin-lymphoma-using-pet-imaging-a-five-year-follow-up-of-the-swog-s0816-trial/2024-11-12T18:36:30+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-activity-of-ibrutinib-in-combination-with-durvalumab-in-patients-with-relapsed-or-refractory-follicular-lymphoma-or-diffuse-large-ba%c2%80%c2%90cell-lymphoma/2024-11-12T18:29:59+00:00https://lymphoma-stg.clarovantdigital.com/library/multi-antigen-targeted-chimeric-antigen-receptor-t-cells-for-cancer-therapy/2024-11-07T19:06:31+00:00https://lymphoma-stg.clarovantdigital.com/library/dna-methylation-profiles-in-chronic-lymphocytic-leukemia-patients-treated-with-chemoimmunotherapy/2024-11-07T19:02:16+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-hypertension-in-cll-what-are-the-risks/2026-01-20T19:22:51+00:00https://lymphoma-stg.clarovantdigital.com/library/a-cross-sectional-study-examining-the-effects-of-patient-information-level-on-healthcare-experience-in-2-patient-populations-extranodal-natural-killer-t-cell-lymphoma-enktl-and-waldenstrom-macroglo/2020-05-20T10:36:53+00:00https://lymphoma-stg.clarovantdigital.com/library/a-cross-sectional-study-of-unmet-needs-of-lymphoma-patients-in-patient-doctor-communication-follicular-lymphoma-fl-and-diffuse-large-b-cell-lymphoma-dlbcl/2020-05-20T10:36:53+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-abdominal-lymph-node-involvement-in-diffuse-large-ba%c2%80%c2%90cell-lymphoma/2026-01-06T20:52:11+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-strategies-for-lymphoma-in-patients-with-hiv/2024-11-07T18:49:30+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-loss-with-preservation-of-other-b-cell-lineage-features-in-patients-with-large-b-cell-lymphoma-who-relapsed-post-axi-cel/2024-11-07T18:47:10+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-plus-obinutuzumab-and-lenalidomide-in-patients-with-relapsed-refractory-follicular-lymphoma-primary-analysis-of-the-full-efficacy-population-in-a-phase-ib-ii-trial/2024-11-07T18:44:43+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-outcomes-of-relapsed-follicular-lymphoma-patients-treated-with-novel-agents-a-multi-center-analysis/2024-11-07T18:43:16+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-results-from-a-multicenter-single-arm-phase-2-study-of-cs1001-an-anti-programmed-death-ligand-1-pd-l1-human-monoclonal-antibody-mab-in-patients-pts-with-relapsed-or-refractory-ex/2024-11-07T18:40:51+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-ibr-plus-venetoclax-ven-for-first-line-treatment-of-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-results-from-the-mrd-cohort-of-the-phase-2-captivate-study/2024-11-07T18:39:07+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-safety-and-efficacy-results-from-a-phase-2-study-of-acalabrutinib-venetoclax-and-obinutuzumab-in-patients-with-previously-untreated-chronic-lymphocytic-leukemia-cll/2024-11-07T18:35:59+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-1-2-study-of-umbralisib-ublituximab-and-venetoclax-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll/2024-11-07T18:34:16+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hsct-after-pd-1-therapy-safe-effective-in-hodgkin-lymphoma/2024-11-07T18:30:27+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-and-nivolumab-for-relapsed-or-refractory-classic-hodgkin-lymphoma-long-term-follow-up-results-from-the-single-arm-phase-1-2-study/2024-11-07T18:28:32+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-monotherapy-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-42-month-follow-up-of-a-phase-2-study/2024-11-07T18:27:09+00:00https://lymphoma-stg.clarovantdigital.com/library/proof-of-concept-for-tipifarnib-in-relapsed-or-refractory-angioimmunoblastic-t-cell-lymphoma-aitl-and-cxcl12-peripheral-t-cell-lymphoma-ptcl-preliminary-results-from-an-open-label-phase-2-study/2026-01-15T17:09:41+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-follicular-lymphoma-fl-patients-pts-demonstrating-undetectable-minimal-residual-disease-mrd-using-a-next-generation-based-dna-assay-support-for-fl-as-a-curable-disease/2024-11-07T18:23:32+00:00https://lymphoma-stg.clarovantdigital.com/library/utilization-and-early-discontinuation-of-first-line-ibrutinib-for-patients-with-chronic-lymphocytic-leukemia-treated-in-the-community-oncology-setting-in-the-united-states/2025-12-19T18:48:58+00:00https://lymphoma-stg.clarovantdigital.com/library/rapid-and-durable-responses-with-the-syk-jak-inhibitor-cerdulatinib-in-a-phase-2-study-in-relapsed-refractory-follicular-lymphoma-alone-or-in-combination-with-rituximab/2024-11-07T18:20:18+00:00https://lymphoma-stg.clarovantdigital.com/library/kte-x19-an-anti-cd19-chimeric-antigen-receptor-car-t-cell-therapy-in-patients-pts-with-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-results-of-the-phase-2-zuma-2-study/2024-11-07T18:18:59+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-serious-adverse-events-pneumonitis-infection-and-sepsis-in-patients-with-relapsed-and-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-treated-with-phosphatidylinosit/2025-03-03T21:38:19+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-induces-complete-remissions-in-poor-prognosis-non-hodgkin-lymphoma-patients-including-those-who-are-resistant-to-or-relapsing-after-chimeric-antigen-receptor-t-cell-car-t-therapies-a/2024-11-07T18:12:45+00:00https://lymphoma-stg.clarovantdigital.com/library/tisagenlecleucel-chimeric-antigen-receptor-car-t-cell-therapy-for-adults-with-diffuse-large-b-cell-lymphoma-dlbcl-real-world-experience-from-the-center-for-international-blood-marrow-transplant/2024-11-07T17:24:42+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-optimization-of-duvelisib-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-from-the-phase-2-primo-trial-selection-of-regimen-for-the-dose-expansion-phase/2026-01-15T17:03:05+00:00https://lymphoma-stg.clarovantdigital.com/library/using-ibrutinib-in-earlier-lines-of-treatment-results-in-better-outcomes-for-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-03-03T21:37:14+00:00https://lymphoma-stg.clarovantdigital.com/library/ongoing-results-of-a-phase-1b-2-dose-escalation-and-cohort-expansion-study-of-the-selective-noncovalent-reversible-brutons-tyrosine-kinase-inhibitor-vecabrutinib-in-b-cell-malignancies/2024-11-07T15:45:17+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-futility-analysis-of-a-phase-2-study-of-loncastuximab-tesirine-a-novel-pyrrolobenzodiazepine-based-antibody-drug-conjugate-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lympho/2026-01-15T17:02:32+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-nivolumab-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma/2024-11-07T15:42:13+00:00https://lymphoma-stg.clarovantdigital.com/library/pivotal-safety-and-efficacy-results-from-transcend-nhl-001-a-multicenter-phase-1-study-of-lisocabtagene-maraleucel-liso-cel-in-relapsed-refractory-r-r-large-b-cell-lymphomas/2024-11-07T15:40:26+00:00https://lymphoma-stg.clarovantdigital.com/library/rapid-undetectable-mrd-umrd-responses-in-patients-with-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-treated-with-lisocabtagene-maraleucel-liso-cel-a/2025-03-03T21:36:37+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-lisocabtagene-maraleucel-liso-cel-treatment-on-health-related-quality-of-life-and-health-utility-in-patients-pts-with-relapsed-refractory-r-r-aggressive-b-cell-non-hodgkin-lymphoma-nh/2024-11-07T15:32:26+00:00https://lymphoma-stg.clarovantdigital.com/library/outpatient-treatment-with-lisocabtagene-maraleucel-liso-cel-in-three-ongoing-clinical-studies-in-relapsed-refractory-r-r-b-cell-non-hodgkin-lymphoma-nhl-including-second-line-transplant-ineligi/2024-11-07T15:33:19+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-directed-therapy-for-patients-with-limited-stage-diffuse-large-b-cell-lymphoma-results-of-intergroup-nctn-study-s1001/2025-05-27T12:14:27+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-rituximab-provides-superior-clinical-outcome-compared-to-fcr-in-younger-patients-with-chronic-lymphocytic-leukemia-cll-extended-follow-up-from-the-e1912-trial/2024-11-07T15:27:09+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-adapted-nivolumab-or-nivolumab-plus-ice-as-first-salvage-therapy-in-relapsed-or-refractory-hodgkin-lymphoma/2024-11-07T15:25:27+00:00https://lymphoma-stg.clarovantdigital.com/library/minorities-do-not-have-worse-outcomes-for-diffuse-large-b-cell-lymphoma-dlbcl-if-optimally-managed/2025-12-19T18:48:24+00:00https://lymphoma-stg.clarovantdigital.com/library/loxo-305-shows-high-efficacy-in-patient-with-heavily-pretreated-b-cell-malignancies/2026-01-15T17:01:53+00:00https://lymphoma-stg.clarovantdigital.com/library/nonmyeloablative-allogeneic-transplantation-nmat-confers-an-overall-survival-benefit-with-similar-non-relapse-mortality-when-compared-to-autologous-stem-transplantation-asct-for-patients-pts-wit/2024-11-07T15:20:30+00:00https://lymphoma-stg.clarovantdigital.com/library/earlier-steroid-use-with-axicabtagene-ciloleucel-axi-cel-in-patients-with-relapsed-refractory-large-b-cell-lymphoma/2026-01-16T15:01:07+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-zanubrutinib-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll-with-del17p-initial-results-from-arm-c-of-the-sequoia-bg/2025-03-03T21:35:25+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-with-the-bruton-tyrosine-kinase-inhibitor-zanubrutinib-bgb-3111-demonstrates-high-overall-response-rate-and-durable-responses-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocyti/2025-03-03T21:34:53+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-zanubrutinib-bgb-3111-in-patients-with-relapsed-refractory-marginal-zone-lymphoma/2024-11-07T15:14:16+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-with-ibrutinib-versus-the-prior-regimen-a-pooled-analysis-in-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-with-up-to-7-5-years-of-extended-follow-up/2024-11-07T15:13:01+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-i-ii-study-of-lenalidomide-plus-obinutuzumab-in-relapsed-indolent-lymphoma/2026-01-15T17:00:38+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-mrd-assessment-in-the-ecog1411-randomized-phase-2-trial-of-front-line-bendamustine-rituximab-br-based-induction-followed-by-rituximab-r-a%c2%b1-lenalidomide-l-consolid/2024-11-07T14:50:59+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-dpx-survivac-low-dose-cyclophosphamide-and-pembrolizumab-in-recurrent-refractory-dlbcl-the-spirel-study/2024-11-06T20:56:29+00:00https://lymphoma-stg.clarovantdigital.com/library/prevention-and-management-of-tumor-lysis-syndrome-in-patients-with-cll-and-coexisting-conditions-treated-with-venetoclax-obinutuzumab-or-chlorambucil-obinutuzumab-results-from-the-randomized-cll14-tr/2024-11-06T20:55:12+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-the-safety-run-in-phase-of-cll14-bo25323-a-prospective-open-label-multicenter-randomized-phase-iii-trial-to-compare-the-efficacy-and-safety-of-obinutuzumab-and-venetoclax-gdc-0199-abt/2024-11-06T20:46:38+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-undetectable-by-next-generation-sequencing-predicts-improved-outcome-in-cll-after-chemoimmunotherapy/2020-05-20T10:36:59+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-venetoclax-plus-obinutuzumab-in-newly-diagnosed-mantle-cell-lymphoma-patients/2025-12-15T19:37:25+00:00https://lymphoma-stg.clarovantdigital.com/library/rapid-improvement-of-patient-reported-outcomes-with-venetoclax-plus-obinutuzumab-in-patients-with-previously-untreated-cll-and-coexisting-conditions-a-prospective-analysis-from-the-cll14-trial/2024-11-06T20:10:10+00:00https://lymphoma-stg.clarovantdigital.com/library/front-line-treatment-with-obinutuzumab-a%c2%b1-chlorambucil-for-chronic-lymphocytic-leukemia-in-real-world-clinical-practice/2024-11-06T20:07:48+00:00https://lymphoma-stg.clarovantdigital.com/library/quantitative-analysis-of-minimal-residual-disease-mrd-shows-high-rates-of-undetectable-mrd-after-fixed-duration-chemotherapy-free-treatment-and-serves-as-surrogate-marker-for-progression-free-surviv/2025-05-13T13:50:54+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-and-ibrutinib-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-r-r-cll-15-month-safety-response-and-mrd-evaluation-third-interim-analysis-from-the-phase-ii-vision-ho/2024-11-06T20:03:40+00:00https://lymphoma-stg.clarovantdigital.com/library/time-to-second-treatment-as-a-proxy-for-overall-survival-in-cll-sll-identifying-risk-factors-to-help-guide-treatment-selection/2025-03-03T21:33:43+00:00https://lymphoma-stg.clarovantdigital.com/library/four-year-analysis-of-murano-study-confirms-sustained-benefit-of-time-limited-venetoclax-rituximab-venr-in-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-cll/2024-11-06T20:01:01+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-waldenstrom-macroglobulinemia-2/2024-11-04T16:47:39+00:00https://lymphoma-stg.clarovantdigital.com/library/r-bac-maintains-high-response-rate-in-mantle-cell-lymphoma-following-relapse-on-btk-inhibitor-therapy/2024-11-04T16:45:44+00:00https://lymphoma-stg.clarovantdigital.com/library/elevate-tn-phase-3-study-of-acalabrutinib-combined-with-obinutuzumab-o-or-alone-vs-o-plus-chlorambucil-clb-in-patients-pts-with-treatment-naive-chronic-lymphocytic-leukemia-cll/2024-11-04T16:44:17+00:00https://lymphoma-stg.clarovantdigital.com/library/toxicities-and-outcomes-of-acalabrutinib-treated-patients-with-chronic-lymphocytic-leukemia-a-retrospective-analysis-of-real-world-patients/2024-11-04T16:42:21+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-discontinuation-patterns-for-patients-with-cll-in-the-real-world-settings-results-from-a-multi-center-study/2024-11-04T16:39:52+00:00https://lymphoma-stg.clarovantdigital.com/library/economic-burden-of-neurologic-toxicities-associated-with-treating-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-the-united-states/2025-12-19T18:47:57+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-in-first-refractory-relapsed-classical-hodgkin-lymphoma-patients-treated-by-chemotherapy-ice-before-autologous-transplantation/2024-11-04T16:30:04+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-frontline-brentuximab-vedotin-plus-nivolumab-in-patients-with-hodgkin-lymphoma-aged-over-60-years/2024-11-04T16:28:17+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-multicenter-study-of-tazemetostat-an-ezh2-inhibitor-in-patients-with-relapsed-or-refractory-follicular-lymphoma/2024-11-04T16:17:52+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-ibrutinib-in-combination-with-rituximab-as-frontline-treatment-for-indolent-clinical-forms-of-mantle-cell-lymphoma-mcl-preliminary-results-of-geltamo-imcl-2015-phase-ii-trial/2024-11-04T16:14:26+00:00https://lymphoma-stg.clarovantdigital.com/library/oral-fludarabine-and-intravenous-rituximab-fr-for-chronic-lymphocytic-leukemia-cll-long-term-outcomes-and-secondary-malignancies-in-673-patients-treated-in-british-columbia-bc/2025-12-15T16:21:05+00:00https://lymphoma-stg.clarovantdigital.com/library/a-single-arm-multicenter-phase-ii-study-of-camrelizumab-in-relapsed-or-refractory-classical-hodgkin-lymphoma/2024-11-04T16:00:40+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-experience-of-chimeric-antigen-receptor-car-t-cell-therapy-vs-stem-cell-transplant-longitudinal-patient-reported-adverse-events-cognition-and-quality-of-life/2024-11-07T19:04:07+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-associated-with-response-car-t-cell-in-vivo-expansion-and-progression-free-survival-after-repeat-infusions-of-cd19-car-t-cells/2024-11-04T15:58:12+00:00https://lymphoma-stg.clarovantdigital.com/library/an-exploratory-analysis-of-brentuximab-vedotin-plus-chp-achp-in-the-frontline-treatment-of-patients-with-cd30-peripheral-t-cell-lymphomas-echelon-2-impact-of-consolidative-stem-cell-transplant/2024-11-04T15:54:20+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-the-dual-syk-jak-inhibitor-cerdulatinib-demonstrates-good-tolerability-and-clinical-response-in-relapsed-refractory-peripheral-t-cell-lymphoma-and-cutaneous-t-cell-lymphoma-2/2026-01-15T16:59:58+00:00https://lymphoma-stg.clarovantdigital.com/library/overall-survival-adverse-events-and-economic-burden-in-medicare-patients-with-chronic-lymphocytic-leukemia-receiving-cancer-directed-therapy/2025-12-19T18:47:01+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-chemo-free-therapy-with-the-braf-inhibitor-vemurafenib-combined-with-obinutuzumab-is-effective-in-patients-with-hcl/2024-11-04T15:25:33+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-and-outcomes-of-patients-receiving-bridging-therapy-while-awaiting-manufacture-of-standard-of-care-axicabtagene-ciloleucel-cd19-chimeric-antigen-receptor-car-t-cell-therapy-for-relap/2024-11-04T15:20:27+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1-2-study-of-auto3-the-first-bicistronic-chimeric-antigen-receptor-car-targeting-cd19-and-cd22-followed-by-an-anti-pd1-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma/2024-11-04T15:06:25+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-lenalidomide-in-higha%c2%80%c2%90risk-diffuse-large-ba%c2%80%c2%90cell-lymphoma/2026-01-15T14:04:14+00:00https://lymphoma-stg.clarovantdigital.com/library/whole-exome-and-transcriptome-sequencing-in-1042-cases-reveals-distinct-clinically-relevant-genetic-subgroups-of-follicular-lymphoma/2024-10-31T16:15:59+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-intensification-in-early-unfavorable-hodgkin-lymphoma-long-term-follow-up-of-the-german-hodgkin-study-group-ghsg-hd14-trial/2024-10-31T16:10:13+00:00https://lymphoma-stg.clarovantdigital.com/library/an-analysis-from-the-wm-uk-rory-morrison-registry-waldenstra%c2%b6ms-macroglobulinaemia-patient-demographics-disease-characteristics-and-evolving-treatment-choices/2024-10-31T16:08:55+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-tirabrutinib-ono-gs-4059-a-second-generation-brutons-tyrosine-kinase-inhibitor-monotherapy-in-patients-with-treatment-naa%c2%afve-or-relapsed-refractory-waldenstra%c2%b6m-macrogl/2024-10-31T16:07:24+00:00https://lymphoma-stg.clarovantdigital.com/library/two-years-rituximab-maintenance-vs-observation-after-first-line-treatment-with-bendamustine-plus-rituximab-b-r-in-patients-with-waldenstra%c2%b6ms-macroglobulinemia-mw-results-of-a-prospective/2024-10-31T16:05:16+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-benefit-associated-with-treating-follicular-lymphoma-in-patients-80-years-or-older/2020-05-20T10:37:05+00:00https://lymphoma-stg.clarovantdigital.com/library/ofatumumab-maintenance-prolongs-progression-free-survival-in-relapsed-chronic-lymphocytic-leukemia-final-analysis-of-the-prolong-study/2024-10-31T16:02:15+00:00https://lymphoma-stg.clarovantdigital.com/library/frequency-and-prognosis-of-associated-malignancies-in-504-patients-with-lymphomatoid-papulosis/2024-10-31T15:59:19+00:00https://lymphoma-stg.clarovantdigital.com/library/effective-delivery-of-complex-innovative-design-cid-cancer-trials/2020-05-20T10:37:05+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-cd19-car-t-cell-therapy-results-in-high-rates-of-systemic-and-neurologic-remissions-in-ten-patients-with-refractory-large-b-cell-lymphoma-including-two-with-hiv-and-viral-hepat/2024-10-31T15:54:35+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-t-cell-malignancies-using-car-based-immunotherapy-challenges-and-potential-solutions/2024-10-31T15:49:42+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-related-adverse-events-associated-with-checkpoint-inhibition-in-the-setting-of-car-t-cell-therapy-a-case-series/2025-12-15T19:39:14+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-maintenance-for-diffuse-large-ba%c2%80%c2%90cell-lymphoma-patients-responding-to-ra%c2%80%c2%90chop-quality-of-life-dosing-and-safety-results-from-the-randomised-controlled-remarc-stud/2024-10-31T15:41:26+00:00https://lymphoma-stg.clarovantdigital.com/library/idelalisib-for-treatment-of-relapsed-follicular-lymphoma-and-chronic-lymphocytic-leukemia-a-comparison-of-treatment-outcomes-in-clinical-trial-participants-vs-medicare-beneficiaries/2024-10-31T15:39:11+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-relapsed-and-refractory-mycosis-fungoides-and-sezary-syndrome-a-multicenter-phase-ii-study/2024-10-31T15:33:06+00:00https://lymphoma-stg.clarovantdigital.com/library/amount-and-intensity-of-leisure-time-physical-activity-and-lower-cancer-risk/2024-10-31T15:30:15+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-blockade-for-diffuse-large-b-cell-lymphoma-after-autologous-stem-cell-transplantation/2025-12-10T18:19:41+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-older-patients-with-mantle-cell-lymphoma-mcl-long-term-follow-up-of-the-randomized-european-mcl-elderly-trial/2024-10-31T15:23:21+00:00https://lymphoma-stg.clarovantdigital.com/library/how-durable-are-responses-to-targeted-therapies-across-single-arm-cancer-trials/2024-10-29T18:33:00+00:00https://lymphoma-stg.clarovantdigital.com/library/gemcitabine-and-bendamustine-is-a-safe-and-effective-salvage-regimen-for-patients-with-recurrent-refractory-hodgkin-lymphoma/2024-10-29T18:09:35+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-of-disease-progression-in-patients-with-chronic-lymphocytic-leukemia-acute-myeloid-leukemia-and-nona%c2%80%c2%90hodgkins-lymphoma/2025-12-19T18:46:40+00:00https://lymphoma-stg.clarovantdigital.com/library/major-cardiac-events-for-adult-survivors-of-childhood-cancer-diagnosed-between-1970-and-1999-report-from-the-childhood-cancer-survivor-study-cohort/2024-10-29T18:03:29+00:00https://lymphoma-stg.clarovantdigital.com/library/apatinib-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-phase-ii-open-label-single-arm-prospective-study/2024-10-29T17:58:34+00:00https://lymphoma-stg.clarovantdigital.com/library/global-burden-of-cancer-attributable-to-infections-in-2018-a-worldwide-incidence-analysis/2026-09-02T16:08:47+00:00https://lymphoma-stg.clarovantdigital.com/library/infectious-complications-in-aggressive-b-cell-non-hodgkin-lymphoma-after-cd-19-chimeric-antigen-receptor-t-cell-therapy/2024-10-31T15:21:09+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-patients-with-cll-after-venetoclax-discontinuation/2024-10-29T17:48:10+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-and-clinicopathological-characteristics-of-pd-l1-overexpression-in-non-hodgkin-lymphoma-a-meta-analysis/2024-10-29T15:49:37+00:00https://lymphoma-stg.clarovantdigital.com/library/patterns-of-transplants-and-survival-outcomes-for-mantle-cell-lymphoma-over-last-17-years-single-center-experience/2026-01-15T17:09:13+00:00https://lymphoma-stg.clarovantdigital.com/library/use-of-car-transduced-natural-killer-cells-in-cd19-positive-lymphoid-tumors/2026-01-15T16:58:36+00:00https://lymphoma-stg.clarovantdigital.com/library/microsatellite-instability-and-its-associations-with-the-clinicopathologic-characteristics-of-diffuse-large-ba%c2%80%c2%90cell-lymphoma/2024-10-29T15:40:59+00:00https://lymphoma-stg.clarovantdigital.com/library/identification-of-gene-modules-associated-with-survival-of-diffuse-large-b-cell-lymphoma-treated-with-chop-based-chemotherapy/2024-10-29T15:30:21+00:00https://lymphoma-stg.clarovantdigital.com/library/cancer-incidence-and-risk-factors-in-dialysis-patients-with-human-immunodeficiency-virus-a-cohort-study/2024-10-29T15:28:34+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-with-chemotherapy-for-stage-iii-iv-classical-hodgkin-lymphoma/2024-10-29T15:27:13+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-rituximaba%c2%80%c2%90beam-versus-beam-conditioning-regimen-in-patients-with-diffuse-large-b-cell-lymphoma-undergoing-autologous-transplantation/2025-12-19T15:20:44+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-alterations-in-epigenetic-modifiers-and-jak-stat-signaling-are-frequent-in-breast-implanta%c2%80%c2%93associated-alcl/2024-10-08T20:45:08+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma-after-autologous-stem-cell-transplantation/2026-01-15T14:22:15+00:00https://lymphoma-stg.clarovantdigital.com/library/begev-salvage-regimen-linked-to-high-complete-remission-rates/2026-01-15T14:03:31+00:00https://lymphoma-stg.clarovantdigital.com/library/higher-total-body-irradiation-dose-fails-to-improve-transplant-outcomes-in-non-hodgkin-lymphoma/2025-12-19T15:19:30+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-long-term-quality-of-life-after-tisagenlecleucel-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-10-29T15:36:11+00:00https://lymphoma-stg.clarovantdigital.com/library/marginal-zone-lymphoma-biology-and-treatment/2024-10-08T17:27:04+00:00https://lymphoma-stg.clarovantdigital.com/library/the-immune-landscape-and-response-to-immune-checkpoint-blockade-therapy-in-lymphoma/2024-10-08T17:21:03+00:00https://lymphoma-stg.clarovantdigital.com/library/new-vte-incidence-a%c2%80%c2%98significanta%c2%80%c2%99-after-car-t-cell-therapy-for-lymphoma/2024-10-29T15:33:57+00:00https://lymphoma-stg.clarovantdigital.com/library/impaired-immune-health-in-survivors-of-diffuse-large-b-cell-lymphoma/2024-10-08T17:16:37+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-and-rituximab-as-induction-therapy-in-both-transplant-eligible-and-ineligible-patients-with-mantle-cell-lymphoma/2024-10-08T17:14:54+00:00https://lymphoma-stg.clarovantdigital.com/library/best-practices-for-diagnosing-breast-implant-associated-anaplastic-large-cell-lymphoma/2024-10-08T17:12:13+00:00https://lymphoma-stg.clarovantdigital.com/library/integrative-oncology-using-evidence-informed-medicine-to-improve-patient-outcomes-and-quality-of-life/2025-12-15T19:18:11+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-treatment-with-the-combination-obinutuzumaba%c2%b1chlorambucil-for-chronic-lymphocytic-leukemia-outside-clinical-trials-results-of-a-multinational-multicenter-study-by-eric-and-the-israeli/2024-10-08T17:09:14+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-values-of-baseline-18f-fdg-pet-ct-in-patients-with-peripheral-t-cell-lymphoma/2024-10-08T17:02:33+00:00https://lymphoma-stg.clarovantdigital.com/library/noninvasive-candidiasis-viral-infections-common-after-car-t-cell-therapy/2024-10-29T15:32:07+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-and-secondary-hematological-malignancies-a-nationa%c2%80%c2%90wide-cancer-registry-study/2024-10-08T16:53:40+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-2020-cytopenia-in-cart-the-prolonged-threat-of-infection/2024-10-08T16:50:39+00:00https://lymphoma-stg.clarovantdigital.com/library/undetectable-peripheral-blood-mrd-should-be-the-goal-of-venetoclax-in-cll-but-attainment-plateaus-after-24-months/2024-10-08T16:44:56+00:00https://lymphoma-stg.clarovantdigital.com/library/despite-benefits-of-stem-cell-transplant-in-mcl-best-practices-remain-elusive/2024-10-08T14:48:34+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-bendamustine-and-rituximab-cytarabine-induction-therapy-for-transplant-eligible-mantle-cell-lymphoma/2024-10-08T14:45:19+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-with-chemotherapy-for-stage-iii-iv-classical-hodgkin-lymphoma-3-year-update-of-the-echelon-1-study/2024-10-08T14:42:29+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-early-disease-progression-and-very-poor-survival-in-the-gallium-study-in-follicular-lymphoma-benefit-of-obinutuzumab-in-reducing-the-rate-of-early-progression/2023-08-23T17:56:00+00:00https://lymphoma-stg.clarovantdigital.com/library/the-phase-3-duo-trial-duvelisib-versus-ofatumumab-in-relapsed-and-refractory-cll-sll/2026-01-15T13:46:03+00:00https://lymphoma-stg.clarovantdigital.com/library/controversies-in-the-treatment-of-classical-hodgkin-lymphoma/2023-08-23T17:52:53+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-relapsed-refractory-double-expressor-b-cell-lymphoma-treated-with-ibrutinib-monotherapy/2025-12-15T21:53:11+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-testicular-lymphoma/2023-08-23T17:47:58+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-epstein-barr-virus-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma-a-case-report-and-review-of-the-literature/2023-08-23T17:46:05+00:00https://lymphoma-stg.clarovantdigital.com/library/a-high-definition-picture-of-key-genes-and-pathways-mutated-in-pediatric-follicular-lymphoma/2022-03-01T22:23:56+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-toxicity-current-management-and-future-directions/2026-01-14T22:05:37+00:00https://lymphoma-stg.clarovantdigital.com/library/mucosal-lymphoid-proliferation-extra-nodal-marginal-zone-lymphoma/2023-08-23T17:45:05+00:00https://lymphoma-stg.clarovantdigital.com/library/proteomics-insights-into-the-pathology-and-prognosis-of-chronic-lymphocytic-leukemia/2023-08-23T17:43:10+00:00https://lymphoma-stg.clarovantdigital.com/library/the-retrospective-evaluation-of-hodgkin-lymphoma-cases-and-the-effects-of-prognostic-factors-on-survival-a-seven-year-experience/2023-08-23T17:41:10+00:00https://lymphoma-stg.clarovantdigital.com/library/turning-point-in-the-treatment-of-mantle-cell-lymphoma/2023-08-23T17:39:57+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-in-diffuse-large-b-cell-lymphoma-hype-and-hope/2026-01-14T22:06:24+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cells-future-perspectives/2022-08-15T19:47:51+00:00https://lymphoma-stg.clarovantdigital.com/library/from-biology-to-therapy-the-cll-success-story/2023-08-23T17:29:49+00:00https://lymphoma-stg.clarovantdigital.com/library/in-the-eye-of-the-storm-immune-mediated-toxicities-associated-with-car-t-cell-therapy-2/2026-01-14T22:01:58+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-blockade-as-bridge-to-allogenic-stem-cell-transplantation-in-relapsed-refractory-hodgkin-lymphoma-patients/2023-08-23T17:23:03+00:00https://lymphoma-stg.clarovantdigital.com/library/suicide-in-european-hodgkin-lymphoma-patients/2022-03-01T22:06:36+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-presentation-determines-selection-of-patients-for-initial-observation-in-mantle-cell-lymphoma/2023-08-23T17:21:09+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnostic-value-of-cd49d-expression-in-patients-with-chronic-lymphocytic-leukemia/2022-03-01T22:03:24+00:00https://lymphoma-stg.clarovantdigital.com/library/the-incidence-of-non-hodgkin-lymphoma-in-iran-a-systematic-review-and-meta-analysis/2022-03-01T22:01:57+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-access-to-essential-medicines-for-treating-childhood-cancers-a-medicines-availability-price-and-affordability-study-in-new-delhi-india/2023-08-23T17:18:08+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-insights-of-lymphomagenesis-of-helicobacter-pylori-dependent-gastric-mucosa-associated-lymphoid-tissue-lymphoma/2023-08-23T17:16:48+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-costing-analysis-for-diffuse-large-b-cell-lymphoma-in-british-columbia/2022-03-01T21:57:55+00:00https://lymphoma-stg.clarovantdigital.com/library/review-of-bruton-tyrosine-kinase-inhibitors-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma/2023-08-23T17:14:55+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-rituximab-or-obinutuzumab-after-allogeneic-hematopoietic-stem-cell-transplantation-in-chronic-lymphocytic-leukemia/2023-08-23T17:13:35+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-1-trial-of-alisertib-and-romidepsin-for-relapsed-refractory-aggressive-b-cell-and-t-cell-lymphomas/2023-08-23T17:12:09+00:00https://lymphoma-stg.clarovantdigital.com/library/detection-of-cancer-stem-cells-in-the-most-common-head-and-neck-non-hodgkina%c2%80%c2%99s-lymphoma-using-cd34-in-vitro-study/2022-03-01T21:51:33+00:00https://lymphoma-stg.clarovantdigital.com/library/differential-effects-of-btk-inhibitors-ibrutinib-and-zanubrutinib-on-nk-cell-effector-function-in-patients-with-mantle-cell-lymphoma/2025-12-15T22:07:42+00:00https://lymphoma-stg.clarovantdigital.com/library/mechanisms-of-resistance-to-targeted-therapies-in-chronic-lymphocytic-leukemia/2023-08-23T17:07:09+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-assessment-in-cll-ready-for-use-in-clinical-routine/2026-01-14T20:56:51+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-in-relapsed-refractory-classical-hodgkin-lymphoma-a%c2%80%c2%93-extended-follow-up-of-30-patients-treated-within-the-checkmate-205-trial-in-a-single-center/2022-03-01T21:36:29+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-increases-the-risk-of-hepatitis-b-virus-reactivation-in-non-hodgkinlymphoma-patients-who-are-hepatitis-b-surface-antigen-positive-or-have-resolved-hepatitis-b-virus-infection-in-a-real-world/2023-08-23T17:00:31+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prognostic-significance-of-pfs24-in-follicular-lymphoma-following-firstline-immunotherapy-a-combined-analysis-of-3-calgb-trials/2022-03-01T21:31:22+00:00https://lymphoma-stg.clarovantdigital.com/library/biological-approaches-to-aggressive-cutaneous-t-cell-lymphoma/2023-08-23T16:56:56+00:00https://lymphoma-stg.clarovantdigital.com/library/high-prognostic-value-of-measurable-residual-disease-detection-by-flow-cytometry-in-chronic-lymphocytic-leukemia-patients-treated-with-front-line-fludarabine-cyclophosphamide-and-rituximab-followed/2026-01-14T20:56:25+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-tp53-gene-promoter-methylation-on-chronic-lymphocytic-leukemia-pathogenesis-and-progression/2023-08-23T16:51:08+00:00https://lymphoma-stg.clarovantdigital.com/library/myd88-in-the-drivera%c2%80%c2%99s-seat-of-b-cell-lymphomagenesis-from-molecular-mechanisms-to-clinical-implications/2023-08-23T16:50:31+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-autologous-stem-cell-transplantation-in-the-treatment-of-diffuse-large-b-cell-lymphoma-in-the-era-of-car-t-cell-therapy/2026-01-15T14:11:06+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-results-from-the-phase-3-helios-study-of-ibrutinib-bendamustine-and-rituximab-in-relapsed-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-2/2025-06-09T20:41:25+00:00https://lymphoma-stg.clarovantdigital.com/library/controversies-in-the-treatment-of-follicular-lymphoma/2023-09-07T19:06:18+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnostic-accuracy-of-stool-tests-for-colorectal-cancer-surveillance-in-hodgkin-lymphoma-survivors/2022-03-01T19:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-and-intricacies-of-bone-marrow-microenvironment-in-b-cell-lymphomas/2023-08-23T16:06:26+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-data-and-health-related-quality-of-life-in-frontline-therapy-of-fit-patients-treated-with-fcr-versus-br/2026-01-14T20:55:29+00:00https://lymphoma-stg.clarovantdigital.com/library/malnutrition-in-older-patients-with-hematological-malignancies-at-initial-diagnosis/2023-08-23T16:03:25+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-of-mucosa-associated-lymphoid-tissue/2023-08-23T16:02:29+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-and-response-adapted-treatment-guidelines-for-managing-first-relapsed-and-refractory-classical-hodgkin-lymphoma-in-children-and-young-people/2023-08-28T18:55:55+00:00https://lymphoma-stg.clarovantdigital.com/library/test-article-jun-24/2020-06-24T16:02:17+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-18f-fdg-pet-in-detecting-richtera%c2%80%c2%99s-transformation-of-chronic-lymphocytic-leukemia-in-patients-receiving-therapy-with-a-b-cell-receptor-inhibitor-2/2023-08-23T15:58:42+00:00https://lymphoma-stg.clarovantdigital.com/library/autoimmune-complications-in-chronic-lymphocytic-leukemia-in-the-era-of-targeted-drugs-2/2023-08-23T16:42:40+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-3-study-of-rituximab-biosimilar-hlx01-in-patients-with-diffuse-large-b-cell-lymphoma/2024-05-10T18:40:08+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-baseline-serum-lactate-dehydrogenase-level-in-patients-with-hairy-cell-leukemia/2024-05-10T18:36:40+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-challenges-in-peripheral-t-cell-lymphoma/2024-05-10T18:35:52+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-bexarotene-combined-with-photochemotherapy-for-cutaneous-tcell-lymphoma/2024-05-10T18:34:23+00:00https://lymphoma-stg.clarovantdigital.com/library/ema-review-of-axicabtagene-ciloleucel-yescarta-for-the-treatment-of-diffuse-large-bcell-lymphoma/2026-01-15T16:56:26+00:00https://lymphoma-stg.clarovantdigital.com/library/positive-safety-profile-reported-for-atezolizumab-axi-cel-combo-in-dlbcl/2024-05-10T18:31:25+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-fdg-pet-ct-detects-bone-marrow-involvement-in-follicular-lymphoma-and-provides-relevant-prognostic-information/2024-05-10T18:26:24+00:00https://lymphoma-stg.clarovantdigital.com/library/prediagnostic-serum-concentrations-of-organochlorine-pesticides-and-non-hodgkin-lymphoma-a-nested-casei%c2%bdcontrol-study-in-the-norwegian-janus-serum-bank-cohort/2024-05-10T18:23:30+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-in-persons-with-haematological-cancers/2023-11-01T00:00:00+00:00https://lymphoma-stg.clarovantdigital.com/library/geptanolimab-shows-efficacy-in-relapsed-refractory-peripheral-t-cell-lymphoma/2024-05-10T18:21:21+00:00https://lymphoma-stg.clarovantdigital.com/library/lipid-trait-variants-and-the-risk-of-non-hodgkin-lymphoma-subtypes-a-mendelian-randomization-study/2024-05-10T18:09:57+00:00https://lymphoma-stg.clarovantdigital.com/library/temozolomide-demonstrates-high-response-in-older-patients-with-primary-vitreoretinal-lymphoma/2024-05-10T18:08:15+00:00https://lymphoma-stg.clarovantdigital.com/library/residual-site-radiotherapy-after-immunochemotherapy-in-primary-mediastinal-b-cell-lymphoma-a-monoinstitutional-retrospective-study/2024-05-10T18:02:54+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-with-or-without-obinutuzumab-versus-chlorambucil-and-obinutuzmab-for-treatment-naive-chronic-lymphocytic-leukaemia-elevate-tn-a-randomised-controlled-phase-3-trial/2026-01-15T16:55:39+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-nivolumab-and-avd-in-early-stage-unfavorable-classic-hodgkin-lymphoma-the-randomized-phase-2-german-hodgkin-study-group-nivahl-trial/2024-05-10T17:59:35+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicenter-phase-ii-study-of-venetoclax-plus-dose-adjusted-r-epoch-vr-epoch-for-richteri%c2%bds-syndrome/2024-04-23T19:39:33+00:00https://lymphoma-stg.clarovantdigital.com/library/a-populationbased-study-on-serious-inpatient-bacterial-infections-in-patients-with-chronic-lymphocytic-leukemia-and-their-impact-on-survival/2024-04-23T19:38:09+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-in-patients-with-hodgkin-lymphoma-a-longitudinal-analysis-of-the-german-hodgkin-study-group/2020-12-07T12:46:09+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-efficacy-of-mogamulizumab-for-relapsed-refractory-aggressive-adult-tcell-leukemia-lymphoma-a-retrospective-analysis/2024-04-23T19:07:42+00:00https://lymphoma-stg.clarovantdigital.com/library/successful-use-of-covid-19-convalescent-plasma-in-a-patient-recently-treated-for-follicular-lymphoma/2024-04-23T16:43:19+00:00https://lymphoma-stg.clarovantdigital.com/library/axi-cel-retreatment-demonstrates-clinical-efficacy-in-large-b-cell-lymphoma/2024-04-23T16:42:24+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-consolidation-therapy-after-autologous-stem-cell-transplantation-in-patients-with-high-risk-hodgkins-lymphoma-multi-center-real-life-experience/2026-01-15T14:20:58+00:00https://lymphoma-stg.clarovantdigital.com/library/biomarker-identification-in-relapsed-refractory-non-germinal-center-b-celli%c2%bdlike-diffuse-large-b-cell-lymphoma-treated-with-zanubrutinib/2024-04-23T16:38:36+00:00https://lymphoma-stg.clarovantdigital.com/library/extranodal-site-of-diffuse-large-bcell-lymphoma-and-the-risk-of-rchop-chemotherapy-resistance-and-early-relapse/2024-04-23T16:37:20+00:00https://lymphoma-stg.clarovantdigital.com/library/liso-cel-maintains-efficacy-in-outpatient-setting-for-patients-with-large-b-cell-lymphomas/2024-04-23T16:36:07+00:00https://lymphoma-stg.clarovantdigital.com/library/update-the-investigation-and-management-of-follicular-lymphoma/2024-04-23T16:31:16+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-bgb-3111-in-combination-with-rituximab-in-patients-with-relapsed-refractory-non-hodgkin-lymphoma/2024-04-23T16:30:18+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-and-venetoclax-in-untreated-unfit-patients-with-chronic-lymphocytic-leukemia/2026-01-15T16:54:36+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-mutations-and-features-of-mantle-cell-lymphoma-a-systematic-review-and-meta-analysis/2020-12-07T12:46:12+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-with-chemotherapy-for-stage-iii-iv-classical-hodgkin-lymphoma-4-year-update-of-the-echelon-1-study/2024-04-23T16:25:59+00:00https://lymphoma-stg.clarovantdigital.com/library/international-prognostic-score-for-asymptomatic-early-stage-chronic-lymphocytic-leukemia/2020-12-07T12:46:12+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-trial-of-coadministration-of-cd19-and-cd20targeted-chimeric-antigen-receptor-t-cells-for-relapsed-and-refractory-diffuse-large-b-cell-lymphoma/2026-01-15T14:00:27+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-therapy-in-cutaneous-t-cell-lymphoma-after-total-skin-electron-irradiation-evidence-for-improved-overall-survival-with-ultraviolet-therapy/2024-04-23T16:22:01+00:00https://lymphoma-stg.clarovantdigital.com/library/seasonal-variation-in-the-incidence-of-primary-central-nervous-system-lymphoma/2024-04-23T16:17:11+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-cancer-immunotherapies-require-radical-car-overhaul/2022-08-15T14:48:50+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-results-of-a-phase-i-ib-study-of-ibrutinib-in-combination-with-umbralisib-in-patients-with-relapsed-refractory-cll-or-mcl/2024-04-23T16:10:44+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-analysis-of-allogeneic-stem-cell-transplantation-for-peripheral-t-cell-lymphoma/2024-04-23T16:08:37+00:00https://lymphoma-stg.clarovantdigital.com/library/influence-of-rurality-race-and-ethnicity-on-non-hodgkin-lymphoma-incidence/2024-04-25T20:29:08+00:00https://lymphoma-stg.clarovantdigital.com/library/positron-emission-tomographyi%c2%bddirected-therapy-for-patients-with-limited-stage-diffuse-large-b-cell-lymphoma-results-of-intergroup-national-clinical-trials-network-study-s1001/2024-04-23T16:04:06+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-severity-and-mortality-in-patients-with-chronic-lymphocytic-leukemia-a-joint-study-by-eric-the-european-research-initiative-on-cll-and-cll-campus/2024-04-23T16:02:34+00:00https://lymphoma-stg.clarovantdigital.com/library/two-cases-of-spindle-cell-variant-diffuse-large-b-cell-lymphoma-of-the-uterine-cervix/2024-04-23T16:01:46+00:00https://lymphoma-stg.clarovantdigital.com/library/bone-marrow-infiltration-pattern-in-patients-with-intravascular-large-bcell-lymphoma-diagnosed-by-random-skin-biopsy/2024-04-23T15:59:48+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-access-to-novel-drugs-for-lymphoma-and-chronic-lymphocytic-leukemia-between-india-and-the-united-states/2025-12-19T18:44:51+00:00https://lymphoma-stg.clarovantdigital.com/library/end-user-perceptions-of-a-patient-and-family-centred-intervention-to-improve-nutrition-intake-among-oncology-patients-a-descriptive-qualitative-analysis/2024-04-23T15:51:06+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-rituximab-induces-high-molecular-response-in-untreated-follicular-lymphoma-lysa-ancillary-relevance-study/2024-04-23T14:40:23+00:00https://lymphoma-stg.clarovantdigital.com/library/extra-copies-of-myc-bcl2-and-bcl6-and-outcome-in-patients-with-diffuse-large-b-cell-lymphoma/2024-04-22T21:37:15+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-cd30-car-t-cell-therapy-in-relapsed-and-refractory-hodgkin-lymphoma/2024-04-22T21:36:09+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-treatment-for-first-line-and-relapsed-refractory-chronic-lymphocytic-leukemia-final-analysis-of-the-pivotal-phase-ib-ii-pcyc-1102-study/2026-01-15T16:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-for-improved-chimeric-antigen-receptor-tcell-production-for-chronic-lymphocytic-leukemia-patients/2024-04-22T21:32:43+00:00https://lymphoma-stg.clarovantdigital.com/library/insecticide-use-and-risk-of-nonhodgkin-lymphoma-subtypes-a-subset-metaanalysis-of-the-north-american-pooled-project/2021-03-01T19:52:10+00:00https://lymphoma-stg.clarovantdigital.com/library/p53-is-associated-with-highrisk-and-pinpoints-tp53-missense-mutations-in-mantle-cell-lymphoma/2024-04-22T21:15:01+00:00https://lymphoma-stg.clarovantdigital.com/library/durability-of-complete-response-after-blinatumomab-therapy-for-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-04-22T21:13:54+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-for-primary-breast-diffuse-large-b-cell-lymphoma-using-immunochemotherapy-and-central-nervous-system-prophylaxis/2024-04-22T21:09:28+00:00https://lymphoma-stg.clarovantdigital.com/library/gender-disparity-in-cardiovascular-mortality-following-radiation-therapy-for-hodgkini%c2%bds-lymphoma-a-systematic-review/2021-03-01T19:51:43+00:00https://lymphoma-stg.clarovantdigital.com/library/managing-cancer-patients-during-the-covid-19-pandemic-an-esmo-interdisciplinary-expert-consensus/2024-04-22T21:03:52+00:00https://lymphoma-stg.clarovantdigital.com/library/asian-race-and-origin-have-no-clinically-meaningful-effects-on-polatuzumab-vedotin-pharmacokinetics-in-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma/2026-01-15T13:59:46+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-front-line-treatments-for-advanced-hodgkin-lymphoma-a-systematic-literature-review/2024-04-22T21:00:12+00:00https://lymphoma-stg.clarovantdigital.com/library/belinostat-in-patients-with-r-r-angioimmunoblastic-t-cell-lymphoma/2024-04-22T20:59:18+00:00https://lymphoma-stg.clarovantdigital.com/library/dlbcl-patients-treated-with-cd19-car-t-cells-experience-a-high-burden-of-organ-toxicities-but-low-nonrelapse-mortality/2026-01-15T17:08:44+00:00https://lymphoma-stg.clarovantdigital.com/library/how-patients-lose-their-own-voices-disparities-in-patient-reported-outcome-capture-in-clinical-trials/2020-12-07T12:46:17+00:00https://lymphoma-stg.clarovantdigital.com/library/rchop-immunochemotherapy-plus-surgery-is-associated-with-a-superior-prognosis-in-chinese-primary-intestinal-diffuse-large-bcell-lymphoma/2024-04-16T18:41:43+00:00https://lymphoma-stg.clarovantdigital.com/library/stem-cell-transplantation-and-vinblastine-monotherapy-for-relapsed-pediatric-anaplastic-large-cell-lymphoma-results-of-the-international-prospective-alcl-relapse-trial/2025-12-15T21:06:50+00:00https://lymphoma-stg.clarovantdigital.com/library/reflect-real-world-evidence-rwe-prospective-study-update-efficacy-and-safety-results-of-sandoz-biosimilar-rituximab-sdz-rtx-for-the-treatment-of-diffuse-large-b-cell-lymphoma-dlbcl/2024-04-16T18:37:26+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-background-delineates-outcome-of-double-protein-expressor-diffuse-large-b-cell-lymphoma/2024-04-16T18:32:56+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-chop-with-early-rituximab-intensification-for-diffuse-large-b-cell-lymphoma-a-randomized-phase-iii-trial-of-the-hovon-and-the-nordic-lymphoma-group-hovon-84/2024-04-16T18:08:58+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-rituximab-bendamustine-vs-bendamustine-rituximab-in-relapsed-refractory-follicular-lymphoma-contralto/2024-04-16T18:07:52+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-with-zanubrutinib-a-selective-inhibitor-of-brutons-tyrosine-kinase/2026-01-15T16:53:04+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-combination-obinutuzumab-ibrutinib-and-venetoclax-in-treatment-naive-and-relapsed-or-refractory-chronic-lymphocytic-leukemia/2024-04-16T17:56:49+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-plus-avd-as-first-line-treatment-for-high-risk-classic-hodgkin-lymphoma/2024-04-16T17:52:20+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-in-the-modern-era-survival-treatment-outcomes-and-identification-of-high-risk-subgroups/2024-04-16T17:51:19+00:00https://lymphoma-stg.clarovantdigital.com/library/researchers-develop-tool-to-predict-car-t-cell-therapy-associated-neurotoxicity/2024-04-16T17:38:58+00:00https://lymphoma-stg.clarovantdigital.com/library/improving-survival-in-younger-patients-with-waldenstrom-macroglobulinemia/2025-12-15T21:20:27+00:00https://lymphoma-stg.clarovantdigital.com/library/g-csf-appears-safe-in-car-ti%c2%bdtreated-patients-with-refractory-relapsed-b-cell-lymphoma/2024-04-16T17:17:33+00:00https://lymphoma-stg.clarovantdigital.com/library/fda-updates-analysis-of-medical-device-reports-of-breast-implant-illness-and-breast-implant-associated-lymphoma/2024-04-16T17:14:38+00:00https://lymphoma-stg.clarovantdigital.com/library/a-pilot-study-of-lenalidomide-maintenance-therapy-after-autologous-transplantation-in-relapsed-or-refractory-classical-hodgkin-lymphoma/2024-04-16T16:38:26+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphomai%c2%bds-new-genomics-the-bridge-and-the-chasm/2024-04-16T16:37:23+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-and-covid-19-outcomes-in-patients-with-cancer/2024-04-16T16:35:26+00:00https://lymphoma-stg.clarovantdigital.com/library/ixazomib-dexamethasone-and-rituximab-in-treatment-naive-patients-with-waldenstrom-macroglobulinemia-long-term-follow-up/2024-04-16T16:34:42+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-3-randomized-study-homer-of-ofatumumab-vs-rituximab-in-inhl-relapsed-after-rituximab-containing-therapy/2024-04-16T16:33:16+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-prevalence-and-mortality-in-patients-with-cancer-and-the-effect-of-primary-tumour-subtype-and-patient-demographics-a-prospective-cohort-study/2024-04-16T16:32:05+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-of-dlbcl-may-predict-outcomes-for-patients-receiving-car-t-cells/2024-04-16T16:31:11+00:00https://lymphoma-stg.clarovantdigital.com/library/persistent-covid-19-pneumonia-and-failure-to-develop-anti-sars-cov-2-antibodies-during-rituximab-maintenance-therapy-for-follicular-lymphoma/2026-01-06T21:15:37+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-improves-progression-free-survival-vs-idelalisib-plus-rituximab-or-bendamustine-plus-rituximab-in-relapsed-or-refractory-cll/2025-12-10T20:13:42+00:00https://lymphoma-stg.clarovantdigital.com/library/systematic-review-with-metaanalysis-comparative-risk-of-lymphoma-with-antitumour-necrosis-factor-agents-and-or-thiopurines-in-patients-with-inflammatory-bowel-disease/2024-04-16T16:24:55+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-stem-cell-transplantation-for-chronic-lymphocytic-leukemia-in-the-era-of-novel-agents/2024-04-16T16:12:02+00:00https://lymphoma-stg.clarovantdigital.com/library/five-decades-of-low-intensity-and-low-survival-adapting-intensified-regimens-to-cure-pediatric-burkitt-lymphoma-in-africa/2026-03-13T19:44:26+00:00https://lymphoma-stg.clarovantdigital.com/library/a-three-arm-randomized-phase-ii-study-of-bendamustine-rituximab-with-bortezomib-induction-or-lenalidomide-continuation-in-untreated-follicular-lymphoma-ecog-acrin-e2408/2024-04-16T16:04:42+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-cd83-in-mantle-cell-lymphoma-with-antihuman-cd83-antibody/2024-04-16T14:56:37+00:00https://lymphoma-stg.clarovantdigital.com/library/final-5-year-findings-from-the-phase-3-helios-study-of-ibrutinib-plus-bendamustine-and-rituximab-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2026-01-15T13:59:03+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-the-discussion-of-late-effects-and-screening-recommendations-in-survivors-of-adolescent-and-young-adult-aya-lymphoma/2024-04-16T14:53:39+00:00https://lymphoma-stg.clarovantdigital.com/library/analysis-of-the-response-time-to-involved-field-radiotherapy-in-primary-gastrointestinal-low-grade-b-cell-lymphoma/2024-04-16T14:50:37+00:00https://lymphoma-stg.clarovantdigital.com/library/a-high-tp53-mutation-burden-is-a-strong-predictor-of-primary-refractory-mantle-cell-lymphoma/2024-04-16T14:48:19+00:00https://lymphoma-stg.clarovantdigital.com/library/doctors-debate-should-asymptomatic-patients-with-follicular-lymphoma-be-actively-monitored-with-watch-and-wait-strategy-or-immediately-treated/2024-04-16T14:12:17+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-for-patients-with-relapsed-or-refractory-large-b-cell-lymphomas-transcend-nhl-001-a-multicentre-seamless-design-study/2024-04-16T14:11:10+00:00https://lymphoma-stg.clarovantdigital.com/library/mirna-based-therapies-in-b-cell-non-hodgkin-lymphoma/2024-04-16T14:09:50+00:00https://lymphoma-stg.clarovantdigital.com/library/bridging-therapy-prior-to-axicabtagene-ciloleucel-for-relapsed-refractory-large-b-cell-lymphoma/2024-04-16T14:05:40+00:00https://lymphoma-stg.clarovantdigital.com/library/the-efficacy-and-safety-of-geptanolimab-gb226-in-patients-with-relapsed-refractory-peripheral-t-cell-lymphoma-ptcl-a-multicenter-open-label-single-arm-phase-2-trial/2024-04-16T14:01:49+00:00https://lymphoma-stg.clarovantdigital.com/library/declines-in-health-related-quality-of-life-among-older-patients-diagnosed-with-hematologic-malignancies/2024-04-16T13:57:23+00:00https://lymphoma-stg.clarovantdigital.com/library/mogamulizumab-plus-epoch-therapy-for-patients-with-newly-diagnosed-aggressive-adult-t-cell-leukemia-lymphoma/2024-04-16T13:55:21+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-obinutuzumab-versus-chlorambucil-plus-obinutuzumab-for-previously-untreated-chronic-lymphocytic-leukaemia-cll14-follow-up-results-from-a-multicentre-open-label-randomised-phase-3/2024-04-16T13:53:47+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-disease-risks-in-younger-and-older-b-cell-non-hodgkins-lymphoma-survivors/2024-04-16T13:56:07+00:00https://lymphoma-stg.clarovantdigital.com/library/vaccination-history-and-risk-of-lymphoma-and-its-major-subtypes/2024-04-16T13:50:44+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-cd30-car-t-cell-therapy-in-patients-with-heavily-pretreated-r-r-hl/2024-04-16T13:47:59+00:00https://lymphoma-stg.clarovantdigital.com/library/whole-body-mri-versus-an-fdg-pet-ct-based-reference-standard-for-staging-of-paediatric-hodgkin-lymphoma/2024-04-16T13:44:15+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-in-the-non-trial-setting-outcomes-and-correlates-of-response-resistance-and-toxicity/2024-04-16T13:43:02+00:00https://lymphoma-stg.clarovantdigital.com/library/recent-progress-of-prognostic-biomarkers-and-risk-scoring-systems-in-chronic-lymphocytic-leukemia/2024-04-16T13:40:55+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-prophylaxis-with-g-csf-may-improve-outcomes-in-patients-with-newly-diagnosed-stage-iii-iv-hodgkin-lymphoma-treated-with-brentuximab-vedotin-plus-chemotherapy/2024-04-16T13:39:10+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-cell-transplantation-after-prior-targeted-therapy-for-high-risk-chronic-lymphocytic-leukemia/2024-04-15T21:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-immunophenotypic-markers-and-clinico-hematological-profile-in-chronic-lymphocytic-leukemia-implications-for-prognosis/2024-04-15T21:23:27+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-radiologic-correlates-of-neurotoxicity-after-axicabtagene-ciloleucel-in-large-b-cell-lymphoma/2024-04-15T21:22:39+00:00https://lymphoma-stg.clarovantdigital.com/library/consensus-statement-on-the-management-of-waldenstrom-macroglobulinemia-patients-during-the-covid-19-pandemic/2024-04-15T21:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/the-relationship-between-oxidative-stress-and-cytogenetic-abnormalities-in-b-cell-chronic-lymphocytic-leukemia/2024-04-15T21:18:43+00:00https://lymphoma-stg.clarovantdigital.com/library/2021-update-on-diagnosis-risk-stratification-and-management-of-cutaneous-b-cell-lymphomas/2026-06-25T16:52:53+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-treatment-followed-by-consolidation-with-allo-hsct-is-associated-with-favorable-outcomes-in-patients-with-relapsed-refractory-hodgkin-lymphoma/2026-01-15T16:57:34+00:00https://lymphoma-stg.clarovantdigital.com/library/checkpoint-inhibition-before-haploidentical-transplantation-with-posttransplant-cyclophosphamide-in-hodgkin-lymphoma/2024-05-14T16:19:01+00:00https://lymphoma-stg.clarovantdigital.com/library/kte-x19-car-t-cell-therapy-in-relapsed-or-refractory-mantle-cell-lymphoma/2024-05-14T15:06:58+00:00https://lymphoma-stg.clarovantdigital.com/library/early-treatment-with-fcr-versus-watch-and-wait-in-patients-with-stage-binet-a-high-risk-chronic-lymphocytic-leukemia-cll-a-randomized-phase-3-trial/2024-05-14T14:56:55+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-and-predictive-impact-of-genetic-markers-in-patients-with-cll-treated-with-obinutuzumab-and-venetoclax/2024-05-14T14:13:09+00:00https://lymphoma-stg.clarovantdigital.com/library/requirements-for-better-outcomes-for-patients-with-non-hodgkin-lymphoma-in-sub-saharan-africa/2026-03-13T19:44:58+00:00https://lymphoma-stg.clarovantdigital.com/library/longterm-exposure-to-air-pollution-and-risk-of-nonhodgkin-lymphoma-in-denmark-a-populationbased-casei%c2%bdcontrol-study/2024-05-14T14:02:14+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-risk-stratification-in-aggressive-b-cell-lymphomas/2020-12-07T12:46:27+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-suvmax-did-not-predict-histological-transformation-in-follicular-lymphoma-in-the-phase-3-gallium-study/2024-05-14T13:57:16+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-monotherapy-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-updated-phase-2-results/2026-01-15T16:57:00+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-in-a-patient-with-chronic-lymphocytic-leukaemia/2024-05-10T18:50:00+00:00https://lymphoma-stg.clarovantdigital.com/library/a-probabilistic-classification-tool-for-genetic-subtypes-of-diffuse-large-b-cell-lymphoma-with-therapeutic-implications/2024-05-10T18:44:23+00:00https://lymphoma-stg.clarovantdigital.com/library/bortezomib-maintenance-after-rchop-cytarabine-and-autologous-stem-cell-transplantation-in-newly-diagnosed-patients-with-mantle-cell-lymphoma-results-of-a-randomised-phase-ii-hovon-trial/2024-05-10T18:42:45+00:00https://lymphoma-stg.clarovantdigital.com/library/practical-insights-into-managing-follicular-lymphoma-whats-best-for-patients/2024-05-10T17:58:20+00:00https://lymphoma-stg.clarovantdigital.com/library/head-to-head-comparison-of-in-house-produced-cd19-car-t-cell-in-all-and-nhl-patients/2024-05-10T17:56:12+00:00https://lymphoma-stg.clarovantdigital.com/library/sgx301-for-cutaneous-t-cell-lymphoma-positive-results-from-phase-iii-flash-study/2024-05-10T17:54:15+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-with-high-risk-dlbcl-benefit-from-dose-dense-immunochemotherapy-combined-with-early-systemic-cns-prophylaxis/2024-04-25T20:50:48+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-and-efficacy-of-cd19-targeted-car-t-cells-with-concurrent-ibrutinib-for-cll-after-ibrutinib-failure/2024-04-25T20:49:03+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-from-a-randomized-dose-optimization-study-of-chimeric-antigen-receptor-modified-t-cells-in-relapsed-chronic-lymphocytic-leukemia/2024-04-25T20:44:13+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-with-the-btk-inhibitor-zanubrutinib-phase-2-single-arm-multicenter-study/2025-03-03T21:32:07+00:00https://lymphoma-stg.clarovantdigital.com/library/academic-centers-compared-with-nonacademic-centers-for-patients-with-international-prognostic-index-risk-stratified-diffuse-large-b-cell-lymphoma-a-survival-outcomes-analysis/2025-12-19T18:46:03+00:00https://lymphoma-stg.clarovantdigital.com/library/realworld-data-on-efficacy-and-safety-of-obinutuzumab-plus-chlorambucil-rituximab-plus-chlorambucil-and-rituximab-plus-bendamustine-in-the-frontline-treatment-of-chronic-lymphocytic-leukemia-the-go/2024-04-25T20:35:47+00:00https://lymphoma-stg.clarovantdigital.com/library/two-distinct-prognostic-groups-in-advanced-stage-hodgkin-lymphoma-revealed-by-the-presence-and-site-of-bulky-disease/2024-04-25T20:33:13+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-receiving-palliative-intent-therapies/2026-01-15T14:02:00+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-activity-of-ibrutinib-in-classical-hodgkin-lymphoma-relapsing-after-allogeneic-stem-cell-transplantation-is-independent-of-tumor-btk-expression/2024-04-25T20:27:15+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-composite-and-sequential-bcell-lymphomas-with-features-intermediate-between-dlbcl-pmbcl-and-classical-hodgkin-lymphoma-from-the-seer-database/2024-04-25T20:21:26+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-alemtuzumab-improves-responses-in-elderly-patients-with-peripheral-t-cell-lymphomas/2024-04-25T19:55:06+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-stem-cell-transplantation-for-peripheral-t-cell-lymphomas-a-retrospective-study-in-285-patients-from-the-socii%c2%bdti%c2%bd-francophone-de-greffe-de-moelle-et-de-thi/2024-04-25T19:50:52+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-gdpt-gemcitabine-cisplatin-prednisone-thalidomide-versus-chop-in-newly-diagnosed-peripheral-t-cell-lymphoma-patients/2024-04-25T19:49:16+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-plus-rituximab-vs-rituximab-alone-in-relapsed-or-refractory-indolent-lymphoma-a-costeffectiveness-analysis/2024-04-25T19:46:36+00:00https://lymphoma-stg.clarovantdigital.com/library/close-monitoring-full-time-caregiver-recommended-for-30-days-after-car-t-therapy/2024-04-25T19:42:51+00:00https://lymphoma-stg.clarovantdigital.com/library/optimized-tandem-car-t-cell-therapy-targeted-cd19-cd20-appears-feasible-in-b-nhl/2024-04-25T19:41:23+00:00https://lymphoma-stg.clarovantdigital.com/library/off-the-shelf-car-t-cell-therapy-shows-promise-in-relapsed-refractory-b-cell-lymphomas/2024-04-25T19:38:45+00:00https://lymphoma-stg.clarovantdigital.com/library/head-to-head-zanubrutinib-vs-ibrutinib-in-waldenstrom-macroglobulinemia/2024-04-25T19:35:32+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-for-high-risk-mature-b-cell-non-hodgkini%c2%bds-lymphoma-in-children/2024-04-25T19:20:10+00:00https://lymphoma-stg.clarovantdigital.com/library/racial-disparities-in-hiv-associated-lymphoma/2024-04-25T19:18:57+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-study-of-risk-adapted-therapy-with-dose-adjusted-epoch-r-in-adults-with-untreated-burkitt-lymphoma/2024-04-25T19:16:31+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-shows-superior-pfs-in-relapsed-refractory-classical-hodgkin-lymphoma/2024-04-25T19:15:20+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-activity-of-cirmtuzumab-an-anti-ror1-antibody-in-combination-with-ibrutinib-interim-results-of-a-phase-ib-ii-study-in-mantle-cell-lymphoma-mcl-or-chronic-lymphocytic-leukemia-cll/2024-04-25T19:13:41+00:00https://lymphoma-stg.clarovantdigital.com/library/platelet-function-and-bleeding-in-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-patients-on-ibrutinib/2024-04-25T19:11:50+00:00https://lymphoma-stg.clarovantdigital.com/library/ascend-phase-iii-randomized-trial-of-acalabrutinib-versus-idelalisib-plus-rituximab-or-bendamustine-plus-rituximab-in-relapsed-or-refractory-chronic-lymphocytic-leukemia/2025-12-10T20:14:33+00:00https://lymphoma-stg.clarovantdigital.com/library/the-incremental-prognostic-value-of-baseline-18f-fdg-pet-ct-imaging-in-angioimmunoblastic-t-cell-lymphoma/2024-04-25T19:05:23+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-elderly-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-treated-with-chimeric-antigen-receptor-t-cell-car-t-therapy/2024-04-25T18:44:29+00:00https://lymphoma-stg.clarovantdigital.com/library/a-randomized-open-label-phase-iii-study-of-obinutuzumab-or-rituximab-plus-chop-in-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma-final-analysis-of-goya/2024-04-25T18:39:28+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-treatments-in-extremely-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-population-based-study-in-taiwan-2010i%c2%bd2015/2024-04-25T18:37:30+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-plus-lenalidomide-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-l-mind-a-multicentre-prospective-single-arm-phase-2-study/2024-04-25T18:11:53+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-dose-modifications-in-the-management-of-cll/2024-04-25T18:07:00+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-expression-profiling-of-gray-zone-lymphoma/2026-09-02T16:08:02+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-therapy-may-benefit-patients-with-early-extranodal-nasal-type-nk-t-cell-lymphoma/2024-04-25T18:03:59+00:00https://lymphoma-stg.clarovantdigital.com/library/sintilimab-for-relapsed-refractory-classical-hodgkini%c2%bds-lymphoma-long-term-follow-up-on-the-multicenter-single-arm-phase-ii-orient-1-study/2024-12-02T18:43:10+00:00https://lymphoma-stg.clarovantdigital.com/library/abstract-b092-epstein-barr-virus-prevalence-in-classical-hodgkin-lymphoma-tumors-by-race-ethnicity-in-a-multiethnic-u-s-population/2026-09-02T16:07:20+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-adding-ublituximab-to-ibrutinib-on-pfs-orr-and-mrd-negativity-in-previously-treated-high-risk-chronic-lymphocytic-leukemia-final-results-of-the-genuine-phase-iii-study/2024-04-25T17:38:17+00:00https://lymphoma-stg.clarovantdigital.com/library/changes-in-long-term-survival-after-diagnosis-with-common-hematologic-malignancies-in-the-early-21st-century/2025-12-19T18:45:17+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-concurrent-expression-of-c-myc-and-bcl2-in-intravascular-large-b-cell-lymphoma-a-10-year-retrospective-study/2024-04-25T17:35:48+00:00https://lymphoma-stg.clarovantdigital.com/library/older-patients-with-mantle-cell-lymphoma-mcl-practice-patterns-and-predictors-of-survival-in-the-rituximab-era/2024-04-25T17:33:37+00:00https://lymphoma-stg.clarovantdigital.com/library/biomarker-driven-management-strategies-for-peripheral-t-cell-lymphoma/2024-04-25T17:32:25+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tisagenlecleucel-in-japanese-adult-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-04-25T17:28:50+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-pathological-characteristics-of-peripheral-tcell-lymphomas-in-a-spanish-population-a-retrospective-study/2026-09-02T16:06:46+00:00https://lymphoma-stg.clarovantdigital.com/library/standard-of-care-axicabtagene-ciloleucel-for-relapsed-or-refractory-large-b-cell-lymphoma-results-from-the-us-lymphoma-car-t-consortium/2024-04-25T17:24:57+00:00https://lymphoma-stg.clarovantdigital.com/library/abvd-vs-beacopp-escalated-in-advancedstage-hodgkins-lymphoma-results-from-a-multicenter-european-study/2024-04-25T17:23:45+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-inhibitor-effective-in-patients-with-progressive-high-risk-cll/2026-01-16T15:06:53+00:00https://lymphoma-stg.clarovantdigital.com/library/sandoz-r-chop-combination-confirms-findings-in-reflect/2024-04-25T17:16:22+00:00https://lymphoma-stg.clarovantdigital.com/library/timing-of-md-mtx-prophylaxis-for-dlbcl-cns-relapse-evaluated/2024-04-25T17:11:39+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort-study/2024-04-25T17:09:44+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-modifications-common-among-older-patients-with-chl/2024-04-25T17:08:58+00:00https://lymphoma-stg.clarovantdigital.com/library/cll2-give-a-prospective-open-label-multicenter-phase-ii-trial-of-obinutuzumab-ga101-g-ibrutinib-i-plus-venetoclax-ve-in-untreated-patients-with-cll-with-17p-deletion-tp53-mutation/2024-04-25T17:06:24+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-risk-of-tumor-lysis-syndrome-in-patients-with-relapsed-chronic-lymphocytic-leukemia-cll-treated-with-venetoclax-in-routine-clinical-practice/2024-04-25T17:04:18+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-may-play-role-as-salvage-therapy-in-multiply-relapsed-mcl/2026-01-15T14:21:25+00:00https://lymphoma-stg.clarovantdigital.com/library/inotuzumab-ozogamicin-plus-r-cvp-for-patients-with-dlbcl-who-are-ineligible-for-r-chop/2024-04-25T16:57:50+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-among-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-treated-with-single-agent-oral-selinexor-in-the-sadal-study/2024-04-25T16:39:35+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-single-agent-oral-selinexor-in-patients-with-primary-refractory-diffuse-large-b-cell-lymphoma-dlbcl-a-post-hoc-analysis-of-the-sadal-study/2024-04-25T16:37:56+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-treatment-naive-chronic-lymphocytic-leukemia-mature-results-from-phase-2-study-demonstrating-durable-remissions-and-long-term-tolerability/2024-04-25T16:35:04+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-quality-of-life-in-patients-with-relapsed-refractory-cutaneous-t-cell-lymphoma-results-from-the-randomised-phase-iii-alcanza-study/2024-04-25T16:32:26+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-plus-lenalidomide-demonstrates-long-term-efficacy-in-r-r-dlbcl/2024-04-25T18:34:43+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-vs-idelalisib-plus-rituximab-idr-or-bendamustine-plus-rituximab-br-in-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-cll-ascend-final-results/2024-04-25T16:27:54+00:00https://lymphoma-stg.clarovantdigital.com/library/positron-emission-tomography-guided-omission-of-radiotherapy-in-early-stage-unfavorable-hodgkin-lymphoma-final-results-of-the-international-randomized-phase-iii-hd17-trial-by-the-ghsg/2024-04-25T16:18:55+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-results-of-a-phase-2-study-of-loncastuximab-tesirine-a-novel-pyrrolobenzodiazepine-based-antibody-drug-conjugate-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2024-04-25T16:17:29+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-release-syndrome-underlies-cardiovascular-effects-of-car-t-cell/2024-04-25T16:15:09+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-premature-venetoclax-ven-discontinuation-interruption-on-outcomes-in-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-cll-phase-iii-murano-study-results/2024-04-25T16:11:20+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1-2-study-of-single-agent-zanubrutinib-in-patients-with-relapsed-refractory-marginal-zone-lymphoma/2026-01-15T14:00:56+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-of-treatment-naive-and-previously-treated-patients-with-waldenstri%c2%bdm-macroglobulinemia-wm-receiving-single-agent-zanubrutinib/2024-04-25T15:20:30+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-relapsed-refractory-mcl-patients-treated-with-zanubrutinib-monotherapy-in-the-second-line-and-in-later-lines-a-pooled-analysis-from-2-studies/2024-04-25T15:19:31+00:00https://lymphoma-stg.clarovantdigital.com/library/tislelizumab-bgb-a317-for-relapsed-refractory-peripheral-t-cell-lymphomas-safety-and-efficacy-results-from-a-phase-2-study/2024-04-25T15:18:29+00:00https://lymphoma-stg.clarovantdigital.com/library/tislelizumab-bgb-a317-for-relapsed-refractory-extranodal-nk-t-cell-lymphoma-preliminary-efficacy-and-safety-results-from-a-phase-2-study/2024-04-25T15:17:01+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-i-alexander-study-of-auto3-the-first-cd19-22-dual-targeting-car-t-cell-therapy-with-pembrolizumab-in-patients-with-relapsed-refractory-r-r-dlbcl/2024-04-23T19:58:17+00:00https://lymphoma-stg.clarovantdigital.com/library/retreatment-of-patients-with-refractory-large-b-cell-lymphoma-with-axicabtagene-ciloleucel-axi-cel-in-zuma-1/2024-04-23T19:56:30+00:00https://lymphoma-stg.clarovantdigital.com/library/recent-survival-trends-in-diffuse-large-bcell-lymphomai%c2%bdi%c2%bdhave-we-made-any-progress-beyond-rituximab/2024-04-23T19:54:55+00:00https://lymphoma-stg.clarovantdigital.com/library/when-covid-19-meets-cll-limited-evidence-offers-some-hope-for-good-outcomes/2023-11-01T00:01:55+00:00https://lymphoma-stg.clarovantdigital.com/library/overall-survival-improved-after-fewer-chemotherapy-cycles-in-advanced-hodgkin-lymphoma-long-term-follow-up-of-ghsg-hd18-trial/2024-04-23T19:42:24+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-remain-favorable-with-venetoclax-obinutuzumab/2026-01-15T16:55:12+00:00https://lymphoma-stg.clarovantdigital.com/library/alectinib-for-relapsed-or-refractory-alkpositive-anaplastic-large-cell-lymphoma-an-open-label-phase-2-trial/2024-04-15T18:40:17+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-of-anthracyclineinduced-cardiotoxicity-in-patients-with-malignant-lymphoma-who-received-a-chop-regimen-with-or-without-rituximab-a-singlecenter-retrospective-observational-study/2024-04-15T18:37:42+00:00https://lymphoma-stg.clarovantdigital.com/library/a-systematic-review-of-the-clinical-efficacy-of-treatments-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2024-04-15T18:35:03+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-plus-nivolumab-as-first-line-therapy-in-older-or-chemotherapy-ineligible-patients-with-hodgkin-lymphoma-accru-a-multicentre-single-arm-phase-2-trial/2024-04-15T18:33:58+00:00https://lymphoma-stg.clarovantdigital.com/library/studies-must-refine-genomic-classification-tools-to-improve-use-of-targeted-therapies-in-dlbcl-subgroups/2024-04-15T18:24:59+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-bgb-3111-plus-obinutuzumab-in-patients-with-chronic-lymphocytic-leukemia-and-follicular-lymphoma/2024-04-15T18:20:00+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-anti-cd19-chimeric-antigen-receptor-t-cell-therapy/2024-04-15T18:18:35+00:00https://lymphoma-stg.clarovantdigital.com/library/managing-the-frontline-treatment-for-diffuse-large-b-cell-lymphoma-and-highgrade-b-cell-lymphoma-during-the-covid19-outbreak/2024-04-15T18:17:37+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-and-consolidative-radiotherapy-in-patients-living-with-hiv-and-treated-for-diffuse-large-b-cell-lymphoma/2024-04-15T18:15:43+00:00https://lymphoma-stg.clarovantdigital.com/library/us-cost-effectiveness-of-polatuzumab-vedotin-bendamustine-and-rituximab-in-diffuse-large-b-cell-lymphoma/2025-12-19T18:42:49+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-combined-with-radiotherapy-for-successful-treatment-of-angioimmunoblastic-t-cell-lymphoma-a-case-report/2024-04-12T19:01:49+00:00https://lymphoma-stg.clarovantdigital.com/library/visible-and-near-infrared-hyperspectral-imaging-techniques-allow-the-reliable-quantification-of-prognostic-markers-in-lymphomas-a-pilot-study-using-the-ki67-proliferation-index-as-an-example/2024-04-12T19:00:13+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-vs-sequential-ddgp-and-radiotherapy-in-newly-diagnosed-early-nk-t-cell-lymphoma-a-randomized-controlled-openlabel-multicenter-study/2024-04-12T18:58:18+00:00https://lymphoma-stg.clarovantdigital.com/library/determinants-of-outcome-in-covid-19-hospitalized-patients-with-lymphoma-a-retrospective-multicentric-cohort-study/2024-04-12T18:47:43+00:00https://lymphoma-stg.clarovantdigital.com/library/educational-theme-mutational-profile-and-treatment-of-waldenstromi%c2%bds-macroglobulinemia/2024-04-12T18:46:56+00:00https://lymphoma-stg.clarovantdigital.com/library/health-technology-assessment-and-reimbursement-policy-for-oncology-orphan-drugs-in-central-and-eastern-europe/2024-04-12T18:45:35+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-recovery-in-patients-with-mantle-cell-lymphoma-receiving-long-term-ibrutinib-and-venetoclax-combination-therapy/2024-04-12T18:43:52+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-of-venetoclax-rapid-dose-escalation-in-cll-patients-previously-treated-with-b-cell-receptor-signaling-antagonists/2024-04-12T18:42:26+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-of-axicabtagene-ciloleucel-for-the-treatment-of-relapsed-or-refractory-large-b-cell-lymphoma-2/2024-04-12T18:41:14+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-hematologic-malignancy-and-type-of-cancer-therapy-on-covid-19-severity-and-mortality-lessons-from-a-large-population-based-registry-study/2023-11-01T00:16:04+00:00https://lymphoma-stg.clarovantdigital.com/library/the-relationship-between-physical-activity-and-lymphoma-a-systematic-review-and-meta-analysis/2024-04-12T18:39:43+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-brentuximab-vedotin-in-advanced-stage-hodgkini%c2%bds-lymphoma-a-probabilistic-analysis/2024-04-12T18:38:48+00:00https://lymphoma-stg.clarovantdigital.com/library/a-case-of-irreversible-bradycardia-after-rituximab-therapy-for-diffuse-large-b-cell-lymphoma/2024-04-12T18:37:06+00:00https://lymphoma-stg.clarovantdigital.com/library/maternal-fetal-considerations-for-the-treatment-and-management-of-lymphoma-during-pregnancy/2024-04-12T18:02:53+00:00https://lymphoma-stg.clarovantdigital.com/library/copanlisib-rituximab-prolongs-pfs-in-relapsed-indolent-non-hodgkin-lymphoma/2024-04-12T17:54:49+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-patient-pathway-of-care-for-diffuse-large-b-cell-lymphoma-dlbcl/2024-04-12T17:46:08+00:00https://lymphoma-stg.clarovantdigital.com/library/defining-the-optimal-treatment-of-first-relapse-of-pediatric-relapsed-anaplastic-large-cell-lymphoma-clinical-trial-challenges-for-rare-diagnoses/2024-04-12T17:44:31+00:00https://lymphoma-stg.clarovantdigital.com/library/prediction-of-outcome-in-patients-with-chronic-lymphocytic-leukemia-treated-with-ibrutinib-development-and-validation-of-a-four-factor-prognostic-model/2020-12-07T12:46:44+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-doseadjusted-gemcitabine-dexamethasone-cisplatin-and-rituximab-in-elderly-relapsed-diffuse-large-bcell-lymphoma-patients/2024-04-12T17:42:57+00:00https://lymphoma-stg.clarovantdigital.com/library/evidence-grows-for-acupuncture-treatment-in-cancer-survivors/2024-04-12T17:41:26+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-vorinostat-plus-sirolimus-or-everolimus-in-patients-with-relapsed-refractory-hodgkin-lymphoma/2020-12-07T12:46:44+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-low-muscle-mass-and-low-muscle-density-in-patients-with-diffuse-large-b-cell-lymphoma/2024-10-08T14:40:16+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii%c2%bdii-clinical-trial-with-car-nk-cells-against-cd19-positive-non-hodgkin-lymphoma-or-chronic-lymphocytic-leukemia/2024-10-08T14:38:22+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-adverse-events-from-the-combination-of-rituximab-and-lenalidomide-r2-in-the-treatment-of-patients-with-follicular-and-low-grade-non-hodgkin-lymphomas/2024-10-08T14:32:04+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-dose-modification-and-temporary-interruption-of-ibrutinib-on-outcomes-of-chronic-lymphocytic-leukemia-patients-in-routine-clinical-practice/2024-10-08T14:24:15+00:00https://lymphoma-stg.clarovantdigital.com/library/the-combination-of-ibrutinib-and-rituximab-demonstrates-activity-in-firstline-follicular-lymphoma/2024-10-08T14:22:32+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-malt-lymphoma-of-the-conjunctiva-with-intralesional-rituximab-supplemented-with-autologous-serum/2024-10-08T14:20:41+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-mantle-cell-lymphoma-in-asia-a-consensus-paper-from-the-asian-lymphoma-study-group/2024-10-08T14:19:08+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-the-zuma-1-study-assessing-axicabtagene-ciloleucel-for-the-treatment-of-refractory-b-cell-lymphoma/2026-01-15T14:02:49+00:00https://lymphoma-stg.clarovantdigital.com/library/biomarker-impact-on-survival-in-diffuse-large-b-cell-lymphoma/2024-10-08T14:09:14+00:00https://lymphoma-stg.clarovantdigital.com/library/a-clinico-genotypic-prognostic-index-for-de-novo-composite-diffuse-large-b-cell-lymphoma-arising-from-follicular-lymphoma-in-asian-patients-treated-in-the-rituximab-era/2024-10-08T13:56:16+00:00https://lymphoma-stg.clarovantdigital.com/library/what-physicians-should-know-about-breast-implant-associated-anaplastic-large-cell-lymphoma/2024-10-08T13:53:46+00:00https://lymphoma-stg.clarovantdigital.com/library/an-early-look-at-when-car-t-therapy-fails-patients-with-cll/2025-12-16T14:43:08+00:00https://lymphoma-stg.clarovantdigital.com/library/genome-and-exome-wide-studies-reveal-potential-predictive-efficacy-markers-for-venetoclax-and-rituximab-venr-in-relapsed-refractory-chronic-lymphocytic-leukemia-r-r-cll-subgroup-analyses-of-the-m/2026-01-15T16:58:06+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-duvelisib-following-disease-progression-on-ofatumumab-in-patients-with-relapsed-refractory-cll-or-sll-in-the-duo-crossover-extension-study-2/2025-03-03T21:32:53+00:00https://lymphoma-stg.clarovantdigital.com/library/dlbcl-type-richter-transformation-associated-with-worse-prognosis-vs-dlbcl/2024-07-30T17:11:42+00:00https://lymphoma-stg.clarovantdigital.com/library/ipilimumab-nivolumab-and-brentuximab-vedotin-combination-therapies-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma-phase-1-results-of-an-open-label-multicentre-phase-1-2-trial-2/2024-04-15T21:16:00+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-identifying-patients-with-indolent-disease/2024-04-15T21:12:57+00:00https://lymphoma-stg.clarovantdigital.com/library/stable-improvement-in-classical-bcell-chronic-lymphocytic-leukemia-with-dietary-interventions-a-personal-experience/2024-04-15T21:10:48+00:00https://lymphoma-stg.clarovantdigital.com/library/tumor-microenvironment-composition-and-severe-cytokine-release-syndrome-crs-influence-toxicity-in-patients-with-large-b-cell-lymphoma-treated-with-axicabtagene-ciloleucel/2025-12-15T19:40:53+00:00https://lymphoma-stg.clarovantdigital.com/library/abstract-po-088-covid-19-pandemic-slows-launch-of-oncology-clinical-trials/2024-04-15T21:04:48+00:00https://lymphoma-stg.clarovantdigital.com/library/abstract-s12-01-high-mortality-among-hospital-acquired-covid-19-infection-in-patients-with-cancer-an-observational-cohort-study-from-quebec-and-british-columbia/2024-04-15T21:03:44+00:00https://lymphoma-stg.clarovantdigital.com/library/abstract-s12-02-risk-of-morbidity-and-mortality-in-covid-19-patients-with-cancer/2023-11-01T00:11:28+00:00https://lymphoma-stg.clarovantdigital.com/library/fractures-are-common-within-18-months-following-first-line-r-chop-in-older-patients-with-diffuse-large-b-cell-lymphoma/2020-12-07T12:46:47+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-venetoclax-under-investigation-as-first-line-combo-in-mcl/2024-04-15T21:01:37+00:00https://lymphoma-stg.clarovantdigital.com/library/steroids-may-improve-mogamulizumab-efficacy-for-cutaneous-t-cell-lymphoma/2024-04-15T20:59:15+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-results-from-checkmate-140-a-phase-2-study-of-nivolumab-for-relapsed-refractory-follicular-lymphoma/2024-04-15T20:53:35+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-for-chronic-lymphocytic-leukemia-in-the-setting-of-respiratory-failure-from-severe-covid19-infection-case-report-and-literature-review/2023-11-01T00:13:12+00:00https://lymphoma-stg.clarovantdigital.com/library/quality-of-life-impact-of-the-anti-ccr4-monoclonal-antibody-mogamulizumab-versus-vorinostat-in-patients-with-cutaneous-t-cell-lymphoma/2024-04-15T20:51:25+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-venetoclax-plus-r-chop-as-first-line-treatment-for-patients-with-diffuse-large-b-cell-lymphoma/2024-04-15T20:47:30+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-response-after-obinutuzumab-plus-high-dose-cytarabine-induction-for-transplant-eligible-patients-with-untreated-mantle-cell-lymphoma-lyma-101-a-phase-2-trial-of-the-lysa-group/2024-04-15T20:45:44+00:00https://lymphoma-stg.clarovantdigital.com/library/can-next-generation-pi3k-inhibitors-unlock-the-full-potential-of-the-class-in-patients-with-b-cell-lymphoma/2025-12-28T13:47:36+00:00https://lymphoma-stg.clarovantdigital.com/library/neurotoxicity-after-car-t-cell-therapy-has-no-effect-on-survival-in-lymphoma-subset/2024-04-15T20:25:12+00:00https://lymphoma-stg.clarovantdigital.com/library/pegaspargase-combined-with-concurrent-radiotherapy-for-earlystage-extranodal-natural-killer-tcell-lymphoma-nasal-type-a-twocenter-phase-ii-study/2024-04-15T20:22:24+00:00https://lymphoma-stg.clarovantdigital.com/library/study-finds-qol-lags-in-patients-with-cll-even-before-treatment/2026-03-13T19:40:40+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-hbv-hcv-and-hiv-seroprevalence-in-patients-with-plasma-cell-disorders/2024-04-15T20:20:10+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-bendamustine-and-rituximab-in-unfit-patients-with-previously-untreated-chronic-lymphocytic-leukemia-indirect-comparison-with-ibrutinib-in-a-realworld-setting-a-gimemaeric-and-us-study/2024-04-15T20:14:55+00:00https://lymphoma-stg.clarovantdigital.com/library/bidirectional-relationship-between-primary-sjogren-syndrome-and-non-hodgkin-lymphoma-a-nationwide-taiwanese-population-based-study/2020-12-07T12:46:49+00:00https://lymphoma-stg.clarovantdigital.com/library/cause-specific-mortality-following-initial-chemotherapy-in-a-population-based-cohort-of-patients-with-classical-hodgkin-lymphoma-2000-2016/2025-12-19T18:43:28+00:00https://lymphoma-stg.clarovantdigital.com/library/auto3-car-t-cell-product-plus-pembrolizumab-shows-clinical-activity-tolerability-in-relapsed-refractory-dlbcl/2024-04-15T19:54:21+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-ibrutinib-and-shortcourse-fludarabine-in-previously-untreated-patients-with-chronic-lymphocytic-leukemia/2024-04-15T19:52:08+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-upfront-high-dose-consolidation-after-r-chop-for-follicular-lymphoma-by-clinical-and-genetic-risk-models/2024-04-15T19:50:32+00:00https://lymphoma-stg.clarovantdigital.com/library/low-dose-continuous-lenalidomide-in-heavily-pretreated-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-a-retrospective-case-series/2024-04-15T19:09:43+00:00https://lymphoma-stg.clarovantdigital.com/library/artificial-intelligence-to-detect-myc-translocation-in-slides-of-diffuse-large-b-cell-lymphoma/2024-04-15T19:08:50+00:00https://lymphoma-stg.clarovantdigital.com/library/ofatumumab-and-complement-replacement-in-relapsed-refractory-chronic-lymphocytic-leukemia/2024-04-15T19:07:59+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-the-assessment-of-minimal-residual-disease-in-mantle-cell-lymphoma/2024-04-15T19:05:28+00:00https://lymphoma-stg.clarovantdigital.com/library/outdoor-artificial-light-at-night-and-risk-of-non-hodgkin-lymphoma-among-women-in-the-california-teachers-study-cohort/2024-04-15T19:04:36+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-rituximab-in-relapsed-chronic-lymphocytic-leukemia-4-year-results-and-evaluation-of-impact-of-genomic-complexity-and-gene-mutations-from-the-murano-phase-iii-study/2024-04-15T19:03:40+00:00https://lymphoma-stg.clarovantdigital.com/library/new-analysis-of-the-tumor-microenvironment-reveals-3-subtypes-in-large-b-cell-lymphoma-of-the-brain/2024-04-15T19:01:21+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-iii-study-of-zanubrutinib-plus-rituximab-versus-bendamustine-plus-rituximab-in-transplant-ineligible-untreated-mantle-cell-lymphoma/2024-04-15T18:58:09+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-i-ib-study-of-tenalisib-rp6530-a-dual-pi3k-inhibitor-in-patients-with-relapsed-refractory-t-cell-lymphoma/2024-04-15T18:56:29+00:00https://lymphoma-stg.clarovantdigital.com/library/hiv-status-does-not-affect-outcomes-in-advanced-classical-hodgkin-lymphoma/2024-04-15T18:49:59+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-plus-obinutuzumab-in-treatment-naive-and-relapsed-refractory-chronic-lymphocytic-leukemia-2/2026-01-15T13:45:37+00:00https://lymphoma-stg.clarovantdigital.com/library/precision-medicine-challenges-deepen-in-dlbcl-as-subtypes-emerge/2024-04-15T18:42:56+00:00https://lymphoma-stg.clarovantdigital.com/library/is-autologous-transplant-in-relapsed-dlbcl-patients-achieving-only-a-pet-pr-appropriate-in-the-car-t-cell-era/2021-03-04T19:01:45+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-supports-fixed-course-treatment-with-obinutuzumab-ibrutinib-based-therapy-in-treatment-naive-cll/2024-04-04T18:01:22+00:00https://lymphoma-stg.clarovantdigital.com/library/relapse-after-early-stage-favorable-hodgkin-lymphoma-disease-characteristics-and-outcomes-with-conventional-or-high-dose-chemotherapy/2022-01-21T22:08:20+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-radiation-doses-delivered-to-organs-at-risk-among-patients-with-early-stage-favorable-hodgkin-lymphoma-treated-with-contemporary-radiation-therapy/2025-05-27T12:15:47+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-and-second-primary-non-lymphoid-malignancies-cytopathologic-study-of-seventeen-cases/2024-04-04T21:09:30+00:00https://lymphoma-stg.clarovantdigital.com/library/doxorubicin-and-subsequent-risk-of-cardiovascular-diseases-among-survivors-of-diffuse-large-b-cell-lymphoma-in-hong-kong/2024-04-04T20:59:45+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukaemia-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up/2024-04-04T20:58:40+00:00https://lymphoma-stg.clarovantdigital.com/library/early-intervention-with-lenalidomide-in-patients-with-high-risk-chronic-lymphocytic-leukemia/2022-02-01T20:05:53+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-personalized-survival-prediction-of-patients-with-diffuse-large-b-cell-lymphoma-using-gene-expression-profiling/2024-04-04T20:55:09+00:00https://lymphoma-stg.clarovantdigital.com/library/886mo-health-related-quality-of-life-hrqol-from-keynote-204-a-phase-iii-randomized-open-label-study-of-pembrolizumab-pembro-vs-brentuximab-vedotin-bv-in-relapsed-or-refractory-classical-hodgk/2024-04-04T20:46:21+00:00https://lymphoma-stg.clarovantdigital.com/library/893mo-an-open-label-single-center-phase-ii-single-arm-trial-of-camrelizumab-combined-with-apatinib-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma/2024-04-04T20:44:12+00:00https://lymphoma-stg.clarovantdigital.com/library/903p-combination-of-nivolumab-with-brentuximab-vedotin-in-therapy-of-relapsed-and-refractory-hodgkin-lymphoma/2024-04-04T20:41:06+00:00https://lymphoma-stg.clarovantdigital.com/library/an-integrative-microenvironment-approach-for-follicular-lymphoma-roles-of-inflammatory-cell-subsets-and-immune-response-polymorphisms-on-disease-clinical-course/2024-04-04T20:37:54+00:00https://lymphoma-stg.clarovantdigital.com/library/multivariate-mortality-analyses-in-covid19-comparing-patients-with-cancer-and-patients-without-cancer-in-louisiana/2025-12-19T18:42:25+00:00https://lymphoma-stg.clarovantdigital.com/library/radiation-may-be-a-useful-bridging-therapy-to-car-t-treatment-in-relapsed-refractory-non-hodgkin-lymphoma/2024-04-04T20:04:17+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-prior-malignancies-on-the-development-of-second-malignancies-and-survival-in-follicular-lymphoma-a-populationbased-study/2024-04-04T20:03:02+00:00https://lymphoma-stg.clarovantdigital.com/library/hepatosplenic-t-cell-lymphoma/2024-04-04T20:01:22+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-practice-management-and-outcomes-in-veterans-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-04-04T19:57:50+00:00https://lymphoma-stg.clarovantdigital.com/library/overexpression-of-oct-1-gene-is-a-biomarker-of-adverse-prognosis-for-diffuse-large-b-cell-lymphoma-dlbcl-data-from-a-retrospective-cohort-of-77-brazilian-patients/2024-04-04T19:56:50+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-between-venetoclax-based-and-bruton-tyrosine-kinase-inhibitors-based-therapy-as-upfront-treatment-of-chronic-lymphocytic-leukemia-cll-a-systematic-review-and-network-meta-analysis/2024-04-04T19:55:19+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-with-rituximab-for-previously-treated-follicular-lymphoma-and-marginal-zone-lymphoma-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal/2024-04-04T19:53:56+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-parsaclisib-incb050465-a-highly-selective-next-generation-pi3k-inhibitor-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-citadel-202/2024-04-04T19:52:11+00:00https://lymphoma-stg.clarovantdigital.com/library/standard-of-care-setting-results-of-axi-cel-in-r-r-large-b-cell-lymphoma/2024-04-04T19:50:58+00:00https://lymphoma-stg.clarovantdigital.com/library/tazemetostat-for-patients-with-relapsed-or-refractory-follicular-lymphoma-an-open-label-single-arm-multicentre-phase-2-trial/2024-04-04T19:09:57+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-relapsed-mantle-cell-lymphoma-treated-with-venetoclax-a-multicenter-retrospective-analysis/2024-04-04T19:09:06+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-incidence-of-gastrointestinal-involvement-and-correlation-with-overall-response-retrospective-review-of-multiple-multicenter-trials/2024-04-04T19:07:34+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-management-of-patients-with-mantle-cell-lymphoma-after-progression-on-brexucabtagene-autoleucel-therapy/2024-04-04T19:06:37+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-lenalidomide-rituximab-combined-with-second-line-chemotherapy-r2-chemo-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2026-01-06T21:14:43+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-treatments-and-outcomes-of-hiv-associated-diffuse-large-b-cell-lymphoma-a-single-center-experience/2025-12-15T19:17:08+00:00https://lymphoma-stg.clarovantdigital.com/library/proteomic-markers-with-prognostic-impact-on-outcome-of-chronic-lymphocytic-leukemia-patients-under-chemo-immunotherapy-results-from-the-hovon-109-study/2024-04-04T19:01:08+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-the-patient-journey/2024-04-04T19:00:02+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-lymphoma-of-the-breast-a-case-report-and-review-of-the-literature/2024-04-04T18:59:01+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-outcomes-of-treatments-for-double-relapsed-refractory-follicular-lymphoma-r-r-fl-a-systematic-literature-review/2024-04-04T18:57:38+00:00https://lymphoma-stg.clarovantdigital.com/library/hypogammaglobulinemia-and-infection-risk-in-chronic-lymphocytic-leukemia-cll-patients-treated-with-cd19-directed-chimeric-antigen-receptor-t-car-t-cells/2024-04-04T18:53:33+00:00https://lymphoma-stg.clarovantdigital.com/library/improving-outcomes-after-autologous-transplantation-in-relapsed-refractory-hodgkin-lymphoma-a-european-expert-perspective/2026-01-15T14:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/bcl2-expression-in-first-line-diffuse-large-b-cell-lymphoma-identifies-a-patient-population-with-poor-prognosis/2024-04-04T18:33:00+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-chemotherapeutic-regimens-for-mantle-cell-lymphoma-a-systematic-review-of-phase-iii-trials/2024-04-04T18:32:06+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-sequential-immunochemotherapy-plus-lenalidomide-for-mantle-cell-lymphoma-incorporating-mrd-evaluation-phase-ii-investigator-initiated-single-center-study/2024-04-04T18:27:42+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-factors-of-early-progression-after-car-t-cell-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-04-04T18:26:26+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-found-superior-in-grade-3a-1-2-3a-follicular-lymphoma/2024-04-04T18:24:30+00:00https://lymphoma-stg.clarovantdigital.com/library/biomarker-for-immune-response-identified-in-relapsed-refractory-dlbcl/2024-04-04T18:12:59+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-relapsed-or-refractory-transplant-eligible-patients-with-diffuse-large-b-cell-lymphoma-following-second-line-salvage-chemotherapy-the-gustave-roussy-experience/2026-01-15T14:19:58+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-associated-with-outcomes-after-a-second-cd19-targeted-car-t-cell-infusion-for-refractory-b-cell-malignancies/2026-01-15T16:51:38+00:00https://lymphoma-stg.clarovantdigital.com/library/900p-the-emerging-treatment-options-of-plasmablastic-lymphoma-analysis-of-173-individual-patients-outcomes/2024-04-04T20:42:32+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cell-therapy-associated-cardiomyopathy-in-patients-with-refractory-or-relapsed-non-hodgkin-lymphoma/2024-04-04T20:39:09+00:00https://lymphoma-stg.clarovantdigital.com/library/why-its-been-so-hard-to-conclusively-link-environmental-factors-to-non-hodgkin-lymphoma/2024-04-04T20:35:19+00:00https://lymphoma-stg.clarovantdigital.com/library/nationwide-claims-database-analysis-of-treatment-patterns-costs-and-survival-of-japanese-patients-with-diffuse-large-b-cell-lymphoma/2024-04-04T17:54:55+00:00https://lymphoma-stg.clarovantdigital.com/library/intercontinental-asian-study-compiles-the-relative-incidence-of-non-hodgkin-t-cell-lymphoma-subtypes/2026-04-24T19:53:51+00:00https://lymphoma-stg.clarovantdigital.com/library/consolidation-radiotherapy-could-be-safely-omitted-in-advanced-hodgkin-lymphoma-with-large-nodal-mass-in-complete-metabolic-response-after-abvd-final-analysis-of-the-randomized-gitil-fil-hd0607-trial/2024-04-04T17:48:33+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-a-real-game-changer-in-treatment-of-chronic-lymphocytic-leukemia/2024-04-04T17:25:16+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-refractory-cll-following-treatment-with-venetoclax-plus-rituximab-what-to-do-next/2024-04-04T17:22:52+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-free-combination-therapy-targeted-to-the-epigenome-in-ptcl/2026-01-15T16:50:48+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-pembrolizumab-plus-gvd-as-second-line-therapy-for-relapsed-or-refractory-classical-hodgkin-lymphoma/2026-01-15T14:19:39+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-ibrutinib-with-rituximab-ir-in-previously-untreated-older-patients-with-mantle-cell-lymphoma-mcl-a-phase-ii-clinical-trial/2024-04-04T16:58:19+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-rituximab-ir-followed-by-short-course-r-hypercvad-mtx-in-patients-age-65-years-with-previously-untreated-mantle-cell-lymphoma-phase-ii-window-1-clinical-trial/2024-04-04T16:56:47+00:00https://lymphoma-stg.clarovantdigital.com/library/retrospective-review-of-prognostic-and-predictors-markers-in-newly-diagnosed-angioimmunoblastic-t-cell-lymphoma-at-ut-md-anderson-cancer-center/2026-01-15T16:50:21+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-acalabrutinib-failures-in-relapsed-mantle-cell-lymphoma/2024-04-04T15:28:01+00:00https://lymphoma-stg.clarovantdigital.com/library/newly-diagnosed-and-relapsed-follicular-lymphoma-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up/2026-01-02T14:46:07+00:00https://lymphoma-stg.clarovantdigital.com/library/ifrt-appears-safe-effective-standard-of-care-for-some-pediatric-patients-with-high-risk-chl/2024-04-04T15:24:41+00:00https://lymphoma-stg.clarovantdigital.com/library/current-treatment-options-for-nodular-lymphocyte-predominant-hodgkin-lymphoma/2024-04-04T15:22:29+00:00https://lymphoma-stg.clarovantdigital.com/library/additional-possibilities-of-chimeric-antigen-receptor-t-cells-in-b-cell-lymphoma-combination-therapy/2024-04-04T15:21:11+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-infusion-product-characteristics-influencing-the-outcomes-and-toxicity-of-car-t-cell-treatment-with-axicabtagene-ciloleucel-for-lbcl/2024-04-04T15:18:04+00:00https://lymphoma-stg.clarovantdigital.com/library/da-repoch-versus-r-chop-for-the-treatment-of-activated-b-cell-subtype-diffuse-large-b-cell-lymphoma-a-community-center-experience/2024-04-04T15:15:24+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-analysis-from-a-prospective-multicenter-study-of-next-generation-sequencing-minimal-residual-disease-assessment-and-ct-monitoring-for-surveillance-after-frontline-treatment-in-diffuse-large-b/2024-04-04T15:01:37+00:00https://lymphoma-stg.clarovantdigital.com/library/complex-karyotype-is-a-significant-predictor-for-worst-outcomes-in-patients-with-mantle-cell-lymphoma-mcl-treated-with-btk-inhibitors-comprehensive-analysis-of-396-patients/2024-04-04T15:00:09+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-pembrolizumab-in-combination-with-romidepsin-demonstrates-durable-responses-in-relapsed-or-refractory-t-cell-lymphoma-tcl/2025-12-15T19:56:49+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-smoking-with-advanced-stage-and-survival-outcomes-in-classic-hodgkins-lymphoma/2024-04-04T14:56:41+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-epstein-barr-virus-with-advanced-stage-and-survival-outcomes-in-classic-hodgkins-lymphoma/2026-09-02T16:06:07+00:00https://lymphoma-stg.clarovantdigital.com/library/comprehensive-analysis-of-factors-predictive-for-time-to-transformation-and-risk-of-transformation-in-patients-pts-with-mantle-cell-lymphoma/2024-04-11T13:58:42+00:00https://lymphoma-stg.clarovantdigital.com/library/gut-bacterial-diversity-associates-with-efficacy-of-anti-cd19-car-t-cell-therapy-in-patients-with-large-b-cell-lymphoma/2024-04-04T14:50:38+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-vitamin-d-deficiency-with-inferior-treatment-outcomes-in-patients-with-newly-diagnosed-classic-hodgkin-lymphoma-md-anderson-cancer-center-experience/2024-04-04T14:48:43+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-versus-r-bendamustine-with-or-without-rituximab-maintenance-in-newly-diagnosed-follicular-lymphoma-patients-with-high-suv-at-baseline-pet/2024-04-04T14:47:38+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-versus-rituximab-in-young-patients-with-advanced-dlbcl-a-pet-guided-and-randomized-phase-3-study-by-lysa/2024-04-04T14:45:17+00:00https://lymphoma-stg.clarovantdigital.com/library/severe-infections-in-patients-with-chronic-lymphocytic-leukemia-treated-with-immunochemotherapy-a-pooled-analysis-of-gcllsg-trials/2024-04-04T14:42:33+00:00https://lymphoma-stg.clarovantdigital.com/library/combined-ibrutinib-and-venetoclax-for-first-line-treatment-for-patients-with-chronic-lymphocytic-leukemia-cll-focus-on-mrd-results/2024-04-04T14:41:01+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-patients-treated-with-single-agent-ibrutinib-for-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-a-systematic-review-and-meta-analysis/2025-03-03T21:29:08+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-front-line-venetoclax-and-rituximab-venr-for-the-treatment-of-young-patients-with-chronic-lymphocytic-leukemia-and-an-unfavorable-biologic-profile-preliminary-results-of-the/2024-04-04T14:36:16+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-followed-by-obinutuzumab-and-idelalisib-in-patients-with-chronic-lymphocytic-leukemia-cll-cll2-bcg-trial-of-the-german-cll-study-group-gcllsg/2024-04-04T14:34:14+00:00https://lymphoma-stg.clarovantdigital.com/library/severity-of-sars-cov-2-infection-in-patients-with-hematologic-malignancies-a-covid-19-and-cancer-consortium-ccc19-registry-analysis/2024-04-04T14:31:13+00:00https://lymphoma-stg.clarovantdigital.com/library/how-do-progression-free-survival-and-toxicity-risks-influence-oncologist-and-patient-preferences-for-novel-agents-in-chronic-lymphocytic-leukemia/2024-04-04T14:19:39+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-on-mental-health-disease-management-and-socioeconomic-modifications-in-hematological-patients-during-covid-19-pandemia-in-italy/2024-04-04T14:04:49+00:00https://lymphoma-stg.clarovantdigital.com/library/examination-of-clinical-and-molecular-characteristics-and-treatment-patterns-of-adolescent-and-young-adult-aya-patients-with-chronic-lymphocytic-leukemia/2024-04-04T14:03:13+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-analysis-of-murano-study-demonstrates-enduring-undetectable-minimal-residual-disease-umrd-in-a-subset-of-relapsed-refractory-chronic-lymphocytic-leukemia-r-r-cll-patients-pts-following/2024-04-03T21:38:45+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-first-line-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-and-high-risk-genomic-features-with-up-to-6-5-years-follow-up-integrated-analysis-o/2025-03-03T21:27:25+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-of-first-line-ibrutinib-treatment-for-chronic-lymphocytic-leukemia-cll-with-4-years-of-follow-up-in-patients-with-tp53-aberrations-del17p-or-tp53-mutation-a-pooled-analysis-f/2024-04-03T21:36:06+00:00https://lymphoma-stg.clarovantdigital.com/library/single-agent-ibrutinib-as-first-line-treatment-for-patients-with-chronic-lymphocytic-leukemia-cll-in-routine-clinical-practice-in-spain/2024-04-03T21:34:35+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-characterization-of-ibrutinib-therapy-for-chronic-lymphocytic-leukemia-cll-and-small-lymphocytic-lymphoma-sll-patients-in-british-columbia/2025-03-03T21:17:43+00:00https://lymphoma-stg.clarovantdigital.com/library/frailty-is-associated-with-increased-one-year-mortality-in-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-a-population-based-study/2024-04-03T21:32:11+00:00https://lymphoma-stg.clarovantdigital.com/library/waldenstrom-macroglobulinemia-in-the-very-elderly-75-yearsclinical-characteristics-and-outcomes/2024-04-03T21:30:33+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-preliminary-efficacy-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-receiving-lisocabtagene-maraleucel-in-transcend-nhl-001/2024-04-03T21:27:38+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-preliminary-efficacy-of-sintilimab-plus-p-gemox-pegaspargase-gemcitabine-and-oxaliplatin-regimen-as-first-line-treatment-for-patients-with-advanced-extranodal-natural-killer-t-cell-lymph/2025-12-15T22:04:00+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-plus-venetoclax-with-rituximab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-primary-efficacy-analysis-of-a-phase-ib-ii-study/2024-04-03T21:16:23+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-safety-and-efficacy-results-from-a-phase-2-study-of-acalabrutinib-venetoclax-and-obinutuzumab-avo-for-frontline-treatment-of-chronic-lymphocytic-leukemia-cll/2024-04-03T21:14:58+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-single-arm-window-of-opportunity-study-of-a-combination-of-obinutuzumab-and-venetoclax-in-early-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl-first-results-of-the-agmt-nhl1/2024-04-03T21:13:21+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-idasanutlin-venetoclax-and-obinutuzumab-in-patients-with-relapsed-or-refractory-r-r-non-hodgkin-lymphoma-nhl-results-from-a-phase-i-ii-study/2024-04-03T21:11:52+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-from-a-phase-2-study-of-combination-obinutuzumab-ibrutinib-and-venetoclax-in-chronic-lymphocytic-leukemia/2024-04-03T21:10:19+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-between-time-limitedvenetoclax-based-and-continuous-bruton-thyrosine-kinase-inhibitors-based-therapy-in-the-upfront-treatment-of-chronic-lymphocytic-leukemia-clla-systematic-review-and/2024-04-03T21:04:51+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1b-2-study-of-vipor-venetoclax-ibrutinib-prednisone-obinutuzumab-and-lenalidomide-in-relapsed-refractory-b-cell-lymphoma-safety-efficacy-and-molecular-analysis/2024-04-03T21:03:34+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-in-combination-with-venetoclax-for-patients-with-treatment-naive-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-del17p-arm-d-of-the-sequoia-bgb-3111-304-trial/2025-03-03T21:16:52+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-outcomes-of-newly-diagnosed-patients-with-chronic-lymphocytic-leukemia-who-are-80-years-of-age-or-older/2024-04-03T20:59:05+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-efficacy-of-first-line-chemotherapy-free-combinations-in-chronic-lymphocytic-leukemia-cll-a-network-meta-analysis/2024-04-03T20:57:56+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-induces-durable-remissions-in-treatment-naive-cll-patients-with-17p-deletion-tp53-mutations-five-year-follow-up-from-a-phase-2-study/2024-04-03T20:56:04+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-cd19-car-t-cells-in-richters-transformation-after-targeted-therapy-for-chronic-lymphocytic-leukemia/2024-04-03T20:54:10+00:00https://lymphoma-stg.clarovantdigital.com/library/utility-of-an-online-cll-treatment-decision-support-tool-as-a-resource-for-patients-and-caregivers/2024-04-03T20:52:31+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-the-bruton-tyrosine-kinase-inhibitor-zanubrutinib-bgb-3111-in-patients-with-waldenstrom-macroglobulinemia-from-a-phase-2-trial/2024-04-03T20:51:37+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-zanubrutinib-in-patients-with-treatment-naive-tn-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll-with-del17p-follow-up-results-from-arm-c-of-the-sequ/2025-03-03T21:16:04+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-zanubrutinib-in-patients-with-relapsed-refractory-marginal-zone-lymphoma-initial-results-of-the-magnolia-bgb-3111-214-trial/2024-04-03T20:47:21+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-btk-inhibitor-associated-adverse-events-current-practice-trends-among-healthcare-providers-and-concordance-with-expert-recommendations/2024-04-03T20:45:48+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-long-term-follow-up-in-hairy-cell-leukemia-patients-treated-with-cladribine-a-thirty-year-experience/2024-04-03T20:44:33+00:00https://lymphoma-stg.clarovantdigital.com/library/antibiotic-therapy-and-low-gut-microbiome-diversity-is-associated-with-decreased-response-and-high-toxicity-in-bcp-all-and-dlbcl-patients-after-treatment-with-cd19-car-t-cells/2024-04-03T20:41:32+00:00https://lymphoma-stg.clarovantdigital.com/library/lines-of-therapy-before-autologous-stem-cell-transplant-asct-and-car-t-infusion-affect-outcomes-in-aggressive-non-hodgkins-lymphoma-nhl/2026-01-15T16:49:44+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-a-real-world-analysis-of-patterns-of-failure-and-role-of-bridging-therapy/2024-04-03T20:37:40+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-cd22-dual-targeted-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-refractory-aggressive-b-cell-lymphoma-a-safety-and-efficacy-study/2024-04-03T20:34:38+00:00https://lymphoma-stg.clarovantdigital.com/library/steroid-use-advanced-stage-disease-and-3-lines-of-prior-chemotherapy-are-associated-with-a-higher-risk-of-infection-following-cd19-car-t-cell-therapy-for-b-nhl-real-world-data-from-a-large-uk-cente/2024-04-03T20:33:06+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-therapy-for-lymphoma-with-prophylactic-tocilizumab-decreased-rates-of-severe-cytokine-release-syndrome-without-excessive-neurologic-toxicity/2024-04-03T20:30:42+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-at-time-of-car-t-cell-therapy/2024-04-03T20:08:08+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-splenic-non-hodgkin-lymphoma-of-diffuse-large-b-cell-type-a-case-report-and-review-of-the-literature/2024-04-03T20:05:49+00:00https://lymphoma-stg.clarovantdigital.com/library/retreatment-with-axicabtagene-ciloleucel-axi-cel-in-patients-with-relapsed-refractory-indolent-non-hodgkin-lymphoma-in-zuma-5/2024-04-03T20:04:12+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-of-zuma-5-a-phase-2-study-of-axicabtagene-ciloleucel-axi-cel-in-patients-with-relapsed-refractory-r-r-indolent-non-hodgkin-lymphoma-inhl/2024-04-03T20:01:38+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-pts-in-zuma-9-a-multicenter-open-label-study-of-axicabtagene-ciloleucel-axi-cel-in-relapsed-refractory-large-b-cell-lymphoma-r-r-lbcl-for-expanded-access-and-commercial-ou/2024-04-03T20:00:20+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-analysis-of-zuma-12-a-phase-2-study-of-axicabtagene-ciloleucel-axi-cel-as-first-line-therapy-in-patients-pts-with-high-risk-large-b-cell-lymphoma-lbcl/2024-04-03T19:59:28+00:00https://lymphoma-stg.clarovantdigital.com/library/matching-adjusted-indirect-comparison-maic-of-lisocabtagene-maraleucel-liso-cel-vs-axicabtagene-ciloleucel-axi-cel-and-tisagenlecleucel-in-relapsed-refractory-r-r-large-b-cell-lymphoma-lbcl/2024-04-03T19:58:15+00:00https://lymphoma-stg.clarovantdigital.com/library/one-year-follow-up-of-zuma-2-the-multicenter-registrational-study-of-kte-x19-in-patients-with-relapsed-refractory-mantle-cell-lymphoma/2024-04-03T19:54:54+00:00https://lymphoma-stg.clarovantdigital.com/library/pharmacological-profile-and-clinical-outcomes-of-kte-x19-by-prior-bruton-tyrosine-kinase-inhibitor-btki-exposure-or-mantle-cell-lymphoma-mcl-morphology-in-patients-with-relapsed-refractory-r-r-m/2024-04-03T19:52:07+00:00https://lymphoma-stg.clarovantdigital.com/library/time-to-change-direction-in-the-treatment-of-relapsed-hodgkin-lymphoma/2024-04-03T19:49:32+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-survival-and-gradual-recovery-of-b-cells-in-patients-with-refractory-large-b-cell-lymphoma-treated-with-axicabtagene-ciloleucel-axi-cel/2024-04-03T19:47:19+00:00https://lymphoma-stg.clarovantdigital.com/library/loxo-305-a-next-generation-highly-selective-non-covalent-btk-inhibitor-in-previously-treated-mantle-cell-lymphoma-waldenstroms-macroglobulinemia-and-other-non-hodgkin-lymphomas-results-from-the/2024-04-03T19:44:53+00:00https://lymphoma-stg.clarovantdigital.com/library/loxo-305-a-next-generation-highly-selective-non-covalent-btk-inhibitor-in-previously-treated-cll-sll-results-from-the-phase-1-2-bruin-study/2025-03-03T21:15:23+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-inhibitor-loxo-305-shows-promise-in-previously-treated-mantle-cell-lymphoma/2024-04-03T19:41:08+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-treatment-with-lenalidomide-plus-rituximab-for-mantle-cell-lymphoma-mcl-7-year-analysis-from-a-multi-center-phase-ii-study/2024-04-03T19:38:26+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-analysis-of-ibrutinib-containing-therapy-for-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-results-from-a-real-world-study-in-china/2026-01-15T13:58:40+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-ibr-plus-venetoclax-ven-for-first-line-treatment-of-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-1-year-disease-free-survival-dfs-results-from-the-mrd-cohort-of/2025-03-03T21:39:05+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostication-survival-and-treatment-related-outcomes-in-hiv-associated-burkitt-lymphoma-hiv-bl-a-us-and-uk-collaborative-analysis/2024-04-03T19:27:32+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-power-of-early-sequential-mrd-monitoring-in-peripheral-blood-and-bone-marrow-in-patients-with-mantle-cell-lymphoma-following-autologous-stem-cell-transplantation-with-or-without-rituximab/2026-03-13T13:27:56+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-i-ii-trial-of-da-epoch-r-plus-ixazomib-as-frontline-therapy-for-patients-with-myc-aberrant-lymphoid-malignancies-the-daciphor-regimen/2024-04-03T19:25:20+00:00https://lymphoma-stg.clarovantdigital.com/library/ixazomib-rituximab-in-untreated-indolent-b-nhl-an-effective-very-low-toxicity-regimen/2024-04-03T19:23:57+00:00https://lymphoma-stg.clarovantdigital.com/library/ixazomib-with-or-without-rituximab-following-immunochemotherapy-and-autologous-stem-cell-transplant-in-mantle-cell-lymphoma/2024-04-03T19:06:42+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-waldenstrom-macroglobulinemia-in-2020/2024-04-03T19:04:13+00:00https://lymphoma-stg.clarovantdigital.com/library/pigmentary-traits-sun-exposure-and-risk-of-non-hodgkins-lymphoma-chronic-lymphocytic-leukemia-a-study-within-the-french-e3n-prospective-cohort/2024-04-04T17:03:11+00:00https://lymphoma-stg.clarovantdigital.com/library/age-dependent-increase-of-treatment-related-mortality-in-older-patients-with-aggressive-b-cell-lymphoma-analysis-of-outcome-treatment-feasibility-and-toxicity-in-1171-elderly-patients-with-aggressi/2024-04-04T15:07:03+00:00https://lymphoma-stg.clarovantdigital.com/library/new-community-setting-data-affirm-ibrutinibs-efficacy-in-r-r-mcl/2026-01-16T15:06:13+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-waldenstrom-macroglobulinemia-3/2024-04-03T19:03:22+00:00https://lymphoma-stg.clarovantdigital.com/library/umbralisib-the-once-daily-dual-inhibitor-of-pi3k-and-casein-kinase-1-demonstrates-clinical-activity-in-patients-with-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-results-from-the-phase-2-glo/2024-04-03T19:01:44+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-1-2-study-of-umbralisib-ublituximab-and-venetoclax-u2-ven-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll/2024-04-03T19:00:11+00:00https://lymphoma-stg.clarovantdigital.com/library/umbralisib-plus-ublituximab-u2-is-superior-to-obinutuzumab-plus-chlorambucil-ochl-in-patients-with-treatment-naive-tn-and-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-cll-results-f/2024-04-03T18:57:56+00:00https://lymphoma-stg.clarovantdigital.com/library/chlormethine-gel-for-mycosis-fungoides-t-cell-lymphoma-recent-real-world-data/2024-04-15T20:58:48+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-loncastuximab-tesirine-adct-402-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-04-03T18:55:12+00:00https://lymphoma-stg.clarovantdigital.com/library/multi-center-phase-ii-study-of-oral-azacitidine-cc-486-plus-chop-as-initial-treatment-for-peripheral-t-cell-lymphoma-ptcl/2024-04-03T18:52:54+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-results-of-a-phase-2-study-of-camidanlumab-tesirine-cami-a-novel-pyrrolobenzodiazepine-based-antibody-drug-conjugate-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma/2024-04-03T18:51:31+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-with-chemotherapy-for-patients-with-previously-untreated-stage-iii-iv-classical-hodgkin-lymphoma-5-year-update-of-the-echelon-1-study/2024-04-03T18:50:06+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-dense-brentuximab-vedotin-plus-ifosfamide-carboplatin-and-etoposide-ice-is-highly-active-for-second-line-treatment-in-relapsed-refractory-classical-hodgkin-lymphoma-final-results-of-a-phase/2024-04-03T18:49:02+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-characteristics-of-patients-with-classical-hodgkin-lymphoma-receiving-frontline-brentuximab-vedotin-with-chemotherapy-a-retrospective-analysis-with-propensity-score-matching/2024-04-03T18:47:48+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-pembrolizumab-pembro-monotherapy-versus-brentuximab-vedotin-bv-on-patients-pts-with-relapsed-refractory-classical-hodgkin-lymphoma-r-r-chl-exploratory-analysis-of-the-randomized-ph/2024-04-03T18:46:06+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-brentuximab-vedotin-to-gemcitabine-in-relapsed-or-refractory-t-cell-lymphoma-results-of-a-lysa-multicenter-phase-ii-study-the-total-trial/2025-04-14T20:35:04+00:00https://lymphoma-stg.clarovantdigital.com/library/the-echelon-2-trial-5-year-results-of-a-randomized-double-blind-phase-3-study-of-brentuximab-vedotin-and-chp-achp-versus-chop-in-frontline-treatment-of-patients-with-cd30-positive-peripheral-t-c/2025-04-14T20:36:02+00:00https://lymphoma-stg.clarovantdigital.com/library/a-pilot-study-of-brentuximab-vedotin-rituximab-and-dose-attenuated-chp-in-patients-75-years-and-older-with-diffuse-large-b-cell-lymphoma/2024-04-03T18:37:44+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-combined-with-brentuximab-vedotin-for-relapsed-refractory-mediastinal-gray-zone-lymphoma-primary-efficacy-and-safety-analysis-of-the-phase-2-checkmate-436-study/2025-12-15T22:09:16+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-pembrolizumab-monotherapy-versus-brentuximab-vedotin-bv-on-symptoms-associated-with-health-related-quality-of-life-hrqol-in-relapsed-refractory-r-r-classical-hodgkin-lymphoma-chl-in/2024-04-03T18:34:30+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-analysis-of-brentuximab-vedotin-and-pembrolizumab-combination-as-salvage-treatment-for-patients-with-relapsed-or-refractory-hodgkin-lymphoma/2026-01-15T14:18:51+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-strategies-and-outcomes-for-patients-with-peripheral-t-cell-lymphoma-and-its-subtypes/2024-04-03T18:29:40+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-laboratory-validation-of-the-mcl35-assay-for-molecular-risk-stratification-of-mantle-cell-lymphoma/2022-02-02T18:54:45+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-omission-reduction-of-vincristine-from-r-chop-in-treatment-of-dlbcl/2024-04-03T18:26:19+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-evaluating-the-efficacy-and-safety-of-parsaclisib-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-not-previously-treated-with-a-btk-inhibitor-citadel-205/2024-04-03T18:25:15+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-evaluating-the-efficacy-and-safety-of-parsaclisib-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-previously-treated-with-ibrutinib-citadel-205/2024-04-03T18:23:43+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-evaluating-the-efficacy-and-safety-of-parsaclisib-in-patients-with-relapsed-or-refractory-marginal-zone-lymphoma-citadel-204/2026-01-15T13:57:37+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-evaluating-the-efficacy-and-safety-of-parsaclisib-in-patients-with-relapsed-or-refractory-follicular-lymphoma-citadel-203/2026-01-15T13:57:14+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-dynamics-after-venetoclax-obinutuzumab-therapy-novel-insights-from-the-randomized-phase-3-cll14-trial/2024-04-03T18:17:09+00:00https://lymphoma-stg.clarovantdigital.com/library/uk-guidelines-on-the-diagnosis-and-treatment-of-breast-implantassociated-anaplastic-large-cell-lymphoma-on-behalf-of-the-medicines-and-healthcare-products-regulatory-agency-plastic-reconstructive-an/2024-04-03T18:13:03+00:00https://lymphoma-stg.clarovantdigital.com/library/burkitt-lymphoma-clinical-pathologic-and-genomic-features-in-adults/2024-04-03T18:09:08+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-brentuximab-vedotin-as-monotherapy-or-in-combination-for-older-hodgkin-lymphoma-patients/2026-01-15T16:49:10+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-with-chemotherapy-in-frontline-treatment-of-classic-hodgkin-lymphoma-nodular-sclerosis-syncytial-variant/2024-04-03T18:02:00+00:00https://lymphoma-stg.clarovantdigital.com/library/consolidation-with-nivolumab-and-brentuximab-vedotin-after-autologous-hematopoietic-cell-transplantation-in-patients-with-high-risk-hodgkin-lymphoma/2026-01-15T14:18:35+00:00https://lymphoma-stg.clarovantdigital.com/library/transcend-cll-004-phase-1-cohort-of-lisocabtagene-maraleucel-liso-cel-in-combination-with-ibrutinib-for-patients-with-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-small-lymphocytic-lympho/2025-03-03T21:14:15+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-follow-up-of-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-treated-with-lisocabtagene-maraleucel-in-the-phase-1-monotherapy-cohort-of-transcend-cll/2025-03-03T21:11:46+00:00https://lymphoma-stg.clarovantdigital.com/library/noninvasive-monitoring-of-mantle-cell-lymphoma-by-immunoglobulin-gene-next-generation-sequencing-in-a-phase-2-study-of-sequential-chemo-radioimmunotherapy-followed-by-autologous-stem-cell-rescue/2024-04-03T17:54:09+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-regn1979-a-human-cd20-x-cd3-bispecific-antibody-induces-durable-complete-responses-in-patients-with-highly-refractory-b-cell-non-hodgkin-lymphoma-including-patients-refractory-to-ca/2024-04-03T17:52:02+00:00https://lymphoma-stg.clarovantdigital.com/library/long-lasting-remission-with-dual-targeting-car-t-therapy-for-r-r-dlbcl/2024-04-03T17:47:45+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-profile-of-brentuximab-vedotin-in-japanese-patients-with-relapsed-refractory-hodgkin-lymphoma-or-systemic-anaplastic-large-cell-lymphoma-a-post-marketing-surveillance-study/2024-04-03T17:45:03+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-of-tisagenlecleucel-for-pediatric-acute-lymphoblastic-leukemia-and-non-hodgkin-lymphoma/2024-04-03T17:43:02+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-with-relapsed-refractory-marginal-zone-lymphoma-in-the-magnify-phase-iiib-interim-analysis-of-induction-r2-followed-by-maintenance/2024-04-03T17:39:44+00:00https://lymphoma-stg.clarovantdigital.com/library/subgroup-analyses-of-elderly-patients-aged-70-years-in-magnify-a-phase-iiib-interim-analysis-of-induction-r2-followed-by-maintenance-in-relapsed-refractory-indolent-non-hodgkin-lymphoma/2026-01-15T13:56:54+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-re-treatment-of-chronic-lymphocytic-leukemia-cll-patients-after-a-previous-venetoclax-based-regimen/2024-04-03T17:30:57+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-results-from-zuma-12-axi-cel-as-frontline-treatment-for-high-risk-lbcl/2024-04-03T17:29:48+00:00https://lymphoma-stg.clarovantdigital.com/library/the-clinicopathological-relevance-of-uniform-cd56-expression-in-anaplastic-large-cell-lymphoma-a-retrospective-analysis-of-18-cases/2024-04-03T17:28:23+00:00https://lymphoma-stg.clarovantdigital.com/library/new-agents-and-regimens-for-diffuse-large-b-cell-lymphoma/2024-03-06T22:38:40+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-subsequent-novel-targeted-therapies-including-repeated-venetoclax-rituximab-venr-in-patients-pts-with-relapsed-refractory-chronic-lymphocytic-leukemia-r-r-cll-previously-treated-wi/2024-03-06T22:37:20+00:00https://lymphoma-stg.clarovantdigital.com/library/network-meta-analysis-of-targeted-therapies-for-diffuse-large-b-cell-lymphoma/2024-03-06T22:36:01+00:00https://lymphoma-stg.clarovantdigital.com/library/single-agent-mosunetuzumab-is-a-promising-safe-and-efficacious-chemotherapy-free-regimen-for-elderly-unfit-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma/2024-03-06T22:34:54+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-shows-promising-efficacy-in-patients-with-multiply-relapsed-follicular-lymphoma-updated-clinical-experience-from-a-phase-i-dose-escalation-trial/2024-03-06T22:33:37+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-a-novel-cd20-cd3-bispecific-antibody-in-combination-with-chop-confers-high-response-rates-in-patients-with-diffuse-large-b-cell-lymphoma/2024-03-06T22:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-and-outcomes-of-primary-mediastinal-b-cell-lymphoma-a-three-decade-monocentric-experience-with-151-patients/2024-03-06T22:31:43+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-primary-mediastinal-large-b-cell-lymphoma-using-r-chop-impact-of-a-pet-adapted-approach/2024-03-06T22:30:18+00:00https://lymphoma-stg.clarovantdigital.com/library/mogamulizumab-for-adult-t-cell-leukemia-lymphoma-a-multicenter-prospective-observational-study/2024-03-06T22:27:43+00:00https://lymphoma-stg.clarovantdigital.com/library/investigational-drugs-for-the-treatment-of-diffuse-large-b-cell-lymphoma/2024-03-06T22:25:37+00:00https://lymphoma-stg.clarovantdigital.com/library/selinexor-efficacy-and-safety-are-independent-of-renal-function-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-a-post-hoc-analysis-from-the-pivotal-phase-2b-sadal-study/2024-03-06T22:22:31+00:00https://lymphoma-stg.clarovantdigital.com/library/what-are-the-challenges-faced-when-selecting-frontline-treatment-for-cll/2024-03-06T22:20:34+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-tumor-lysis-syndrome-in-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-in-the-clinical-trial-and-post-marketing-settings/2024-03-06T22:19:51+00:00https://lymphoma-stg.clarovantdigital.com/library/what-factors-guide-treatment-decisions-in-the-frontline-treatment-of-follicular-lymphoma/2022-02-02T18:54:52+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-rituximab-maintenance-in-follicular-lymphoma-patients-long-term-results-of-the-sakk-35-03-randomized-trial/2024-03-06T22:18:21+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-maintenance-after-autologous-haematopoietic-stem-cell-transplantation-in-mantle-cell-lymphoma-results-of-a-fondazione-italiana-linfomi-fil-multicentre-randomised-phase-3-trial/2024-03-06T22:14:34+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-outcomes-of-extranodal-stage-i-diffuse-large-b-cell-lymphoma-in-the-rituximab-era/2024-03-06T22:13:17+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-and-survival-outcomes-in-patients-with-mantle-cell-lymphoma-a-systematic-review-and-meta-analysis/2024-03-06T22:09:57+00:00https://lymphoma-stg.clarovantdigital.com/library/nk-cell-based-cancer-immunotherapy-from-basic-biology-to-clinical-development/2024-04-02T17:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-multicenter-gibb-study-of-obinutuzumab-plus-bendamustine-in-previously-untreated-patients-with-chronic-lymphocytic-leukemia/2024-03-06T21:52:37+00:00https://lymphoma-stg.clarovantdigital.com/library/the-stagespecific-roles-of-radiotherapy-and-chemotherapy-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-patients-a-propensity-scorematched-analysis-of-the-seer-database/2024-03-06T21:51:38+00:00https://lymphoma-stg.clarovantdigital.com/library/pooled-analysis-of-cardiovascular-events-from-clinical-trials-evaluating-acalabrutinib-monotherapy-in-patients-with-chronic-lymphocytic-leukemia-cll/2024-03-06T21:50:11+00:00https://lymphoma-stg.clarovantdigital.com/library/prevalence-and-predictors-of-neurocognitive-impairment-in-long-term-survivors-of-childhood-hodgkin-lymphoma-a-report-from-the-childhood-cancer-survivor-study/2024-03-06T21:49:12+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-effectiveness-of-bendamustine-plus-rituximab-br-and-rituximab-plus-gemcitabine-and-oxaliplatin-r-gemox-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-03-06T21:46:47+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-combination-with-rituximab-cyclophosphamide-doxorubicin-vincristine-and-prednisolone-r-chop-as-first-line-therapy-for-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-the-acc/2024-03-06T21:45:25+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-subgroup-analyses-from-l-mind-a-phase-ii-study-of-tafasitamab-mor208-combined-with-lenalidomide-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2024-03-06T21:44:11+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-tafasitamab-mor208-combined-with-lenalidomide-in-patients-with-high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-the-l-mind-study/2024-03-06T21:41:41+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-lenalidomide-based-regimens-in-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis-of-clinical-trials/2024-03-06T21:40:39+00:00https://lymphoma-stg.clarovantdigital.com/library/final-results-of-a-phase-ii-study-of-fc-engineered-cd19-antibody-tafasitamab-in-combination-with-lenalidomide-or-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-cll/2024-03-06T21:38:06+00:00https://lymphoma-stg.clarovantdigital.com/library/lack-of-effectiveness-of-intravenous-high-dose-methotrexate-for-prevention-of-cns-relapse-in-patients-with-high-risk-dlbcl-a-retrospective-analysis-from-alberta-canada/2025-12-15T21:48:47+00:00https://lymphoma-stg.clarovantdigital.com/library/beyond-mortality-health-related-quality-of-life-in-adolescent-and-young-adult-patients-with-lymphoma-a-longitudinal-study/2024-03-05T22:29:09+00:00https://lymphoma-stg.clarovantdigital.com/library/quality-of-life-after-diagnosis-in-survivors-of-aggressive-lymphomas/2024-03-05T22:27:43+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-among-patients-with-high-risk-untreated-follicular-lymphoma-fl-randomized-to-bendamustine-rituximab-br-or-bendamustine-rituximab-with-bortezomib-bvr-therapy-results-fr/2024-03-05T22:26:32+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-treatment-vs-watch-and-wait-in-advanced-stage-follicular-lymphoma-in-the-rituximab-era-an-analysis-of-the-national-cancer-database-ncdb/2024-03-05T22:23:40+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-monotherapy-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-long-term-efficacy-and-safety-results-from-a-phase-2-study/2024-03-05T22:22:23+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-rchop-r2chop-produces-high-response-rates-and-overall-survival-in-new-untreated-diffuse-large-b-cell-lymphoma-transformed-from-follicular-lymphoma-results-from-mc078e/2024-03-05T22:21:24+00:00https://lymphoma-stg.clarovantdigital.com/library/successful-treatment-of-mature-t-cell-lymphoma-with-allogeneic-stem-cell-transplantation-the-largest-multicenter-retrospective-analysis/2024-03-05T22:20:10+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-of-the-ro-chop-phase-iii-study-conducted-by-lysa-romidepsin-plus-chop-in-patients-with-peripheral-t-cell-lymphoma/2024-03-05T22:18:54+00:00https://lymphoma-stg.clarovantdigital.com/library/cd58-aberrations-limit-durable-responses-to-cd19-car-in-large-b-cell-lymphoma-patients-treated-with-axicabtagene-ciloleucel-but-can-be-overcome-through-novel-car-engineering/2024-03-05T22:17:58+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-lenalidomide-rituximab-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-final-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial/2024-03-05T22:15:40+00:00https://lymphoma-stg.clarovantdigital.com/library/checkpoint-inhibition-therapy-in-transplant-ineligible-relapsed-or-refractory-classic-hodgkin-lymphoma/2024-03-05T22:14:01+00:00https://lymphoma-stg.clarovantdigital.com/library/overcoming-resistance-to-targeted-therapies-in-chronic-lymphocytic-leukemia/2024-03-05T22:11:36+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-geptanolimab-gb226-for-relapsed-or-refractory-peripheral-t-cell-lymphoma-an-open-label-phase-2-study-gxplore-002/2024-03-05T22:10:32+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-venetoclax-in-relapsed-and-refractory-follicular-lymphoma/2024-02-26T22:29:38+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-outcomes-of-covid-19-in-haematopoietic-stem-cell-transplantation-recipients-an-observational-cohort-study/2024-02-26T22:28:15+00:00https://lymphoma-stg.clarovantdigital.com/library/myc-expression-and-tumor-infiltrating-t-cells-are-associated-with-response-in-patients-pts-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-treated-with-tisagenlecleucel-in-the-jul/2024-02-26T22:26:13+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-adverse-events-associated-with-tisagenlecleucel-in-acute-lymphoblastic-leukemia-and-large-b-cell-lymphoma/2024-02-26T22:22:49+00:00https://lymphoma-stg.clarovantdigital.com/library/resource-utilization-and-factors-prolonging-hospitalization-for-patients-with-relapsed-and-refractory-large-b-cell-lymphoma-receiving-tisagenlecleucel-versus-axicabtagene-ciloleucel/2024-02-26T22:09:17+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tisagenlecleucel-in-adult-patients-with-relapsed-refractory-follicular-lymphoma-interim-analysis-of-the-phase-2-elara-trial/2024-02-26T22:07:57+00:00https://lymphoma-stg.clarovantdigital.com/library/a-clinical-practice-comparison-of-overall-survival-time-to-next-treatment-and-time-to-treatment-discontinuation-among-cll-sll-patients-receiving-first-line-ibrutinib-with-and-without-a-del17p-muta/2025-03-03T21:10:45+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-the-treatment-patterns-of-chlormethine-mechlorethamine-gel-in-patients-with-stage-i-iia-mycosis-fungoides-by-time-reanalysis-of-a-randomized-controlled-phase-2-study/2024-02-26T22:04:41+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-ibrutinib-responses-in-relapsed-refractory-marginal-zone-lymphoma-long-term-follow-up-and-biomarker-analysis/2024-02-26T22:00:56+00:00https://lymphoma-stg.clarovantdigital.com/library/development-of-molecular-intervention-strategies-for-b-cell-lymphoma/2024-02-26T21:29:01+00:00https://lymphoma-stg.clarovantdigital.com/library/blood-cancers-and-covid-19-a-medically-vulnerable-group/2024-02-26T21:24:50+00:00https://lymphoma-stg.clarovantdigital.com/library/continued-long-term-responses-to-ibrutinib-venetoclax-treatment-for-relapsed-refractory-cll-in-the-blood-cancer-uk-tap-clarity-trial/2024-02-26T21:19:07+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-follow-up-of-ibrutinib-plus-rituximab-vs-placebo-plus-rituximab-for-waldenstroms-macroglobulinemia-final-analysis-from-the-randomized-phase-3-innovate-study/2024-02-26T21:15:21+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-genotyping-of-circulating-tumor-dna-for-classical-hodgkin-lymphoma-monitoring-a-prospective-study/2024-02-26T20:56:53+00:00https://lymphoma-stg.clarovantdigital.com/library/nonhodgkin-lymphoma-after-treatment-for-classical-hodgkin-lymphoma-a-report-from-the-german-hodgkin-study-group/2025-12-15T21:48:03+00:00https://lymphoma-stg.clarovantdigital.com/library/rcomp-versus-rchop-as-firstline-therapy-for-diffuse-large-bcell-lymphoma-in-patients-60-years-results-of-a-randomized-phase-2-study-from-the-spanish-geltamo-group/2024-02-26T20:26:49+00:00https://lymphoma-stg.clarovantdigital.com/library/everolimus-plus-itacitinib-in-relapsed-refractory-classical-hodgkin-lymphoma-results-of-a-phase-i-ii-investigator-initiated-trial-evita-study/2024-02-26T20:24:15+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-circulating-tumor-dna-ctdna-in-autologous-stem-cell-graft-and-post-transplant-plasma-samples-among-patients-with-diffuse-large-b-cell-lymphoma/2024-02-26T20:18:46+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-induction-and-maintenance-avelumab-plus-r-chop-in-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-analysis-of-the-phase-ii-avr-chop-study/2024-02-16T21:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-pd-1-antibody-sintilimab-plus-histone-deacetylase-inhibitor-chidamide-for-the-treatment-of-refractory-or-relapsed-extranodal-natural-killer-t-cell-lymphoma-nasal-type-r-r-enktl-preliminar/2024-02-16T21:40:44+00:00https://lymphoma-stg.clarovantdigital.com/library/matrix-rice-therapy-and-autologous-haematopoietic-stem-cell-transplantation-in-diffuse-large-b-cell-lymphoma-with-secondary-cns-involvement-marietta-an-international-single-arm-phase-2-trial/2024-02-16T21:37:44+00:00https://lymphoma-stg.clarovantdigital.com/library/associations-between-race-and-survival-in-pediatric-patients-with-diffuse-large-bcell-lymphoma/2022-02-03T15:12:03+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-outcomes-of-primary-versus-secondary-gastrointestinal-mantle-cell-lymphoma/2022-02-02T22:38:43+00:00https://lymphoma-stg.clarovantdigital.com/library/umbralisib-and-ublituximab-combination-is-superior-to-current-standard-of-care-for-patients-with-untreated-relapsed-or-refractory-cll/2024-02-16T21:34:42+00:00https://lymphoma-stg.clarovantdigital.com/library/burkitt-lymphoma-international-prognostic-index/2022-02-02T22:38:43+00:00https://lymphoma-stg.clarovantdigital.com/library/considerations-for-secondary-primary-malignancy-development-in-follicular-lymphoma/2024-02-16T21:31:02+00:00https://lymphoma-stg.clarovantdigital.com/library/adding-lenalidomide-to-r-minichop-does-not-improve-os-in-older-adults-with-dlbcl/2024-02-16T21:29:23+00:00https://lymphoma-stg.clarovantdigital.com/library/how-should-we-manage-toxicities-associated-with-btk-inhibitors-in-cll/2022-02-02T22:38:44+00:00https://lymphoma-stg.clarovantdigital.com/library/4-gy-versus-24-gy-radiotherapy-for-follicular-and-marginal-zone-lymphoma-fort-long-term-follow-up-of-a-multicentre-randomised-phase-3-non-inferiority-trial/2022-02-02T22:38:44+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-landscape-of-cutaneous-follicular-lymphomas-reveals-2-subgroups-with-clinically-predictive-molecular-features/2024-02-16T21:27:03+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-rituximab-with-or-without-bendamustine-vs-bendamustine-rituximab-in-relapsed-refractory-follicular-lymphoma/2024-02-16T21:25:07+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-dysregulation-can-affect-the-efficacy-of-car-t-therapy-in-some-lymphoma-patients/2026-01-15T16:48:39+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-and-utility-outcomes-with-selinexor-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-02-16T21:13:48+00:00https://lymphoma-stg.clarovantdigital.com/library/influence-of-severe-gastrointestinal-complications-in-primary-gastrointestinal-diffuse-large-b-cell-lymphoma/2022-02-02T22:38:45+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-venetoclax-plus-r-chop-as-first-line-treatment-for-patients-with-diffuse-large-b-cell-lymphoma/2024-02-16T21:11:32+00:00https://lymphoma-stg.clarovantdigital.com/library/ki67-proliferation-index-in-germinal-and-non-germinal-subtypes-of-diffuse-large-b-cell-lymphoma/2024-02-16T21:10:22+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-with-lymphoma-treated-with-b-cell-depleting-therapies-may-have-worse-outcomes-from-covid-19-infection/2024-02-16T20:25:15+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-lenalidomide-to-r-chop-improves-outcomes-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-in-a-randomized-phase-ii-us-intergroup-study-ecog-acrin-e1412/2024-02-16T20:22:40+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-for-significant-kidney-function-decline-after-acute-kidney-injury-in-adults-with-hematologic-malignancy/2024-02-16T20:20:12+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-continue-to-be-inadequately-informed-of-risk-for-breast-implant-associated-alcl/2024-02-16T20:11:45+00:00https://lymphoma-stg.clarovantdigital.com/library/cd30-positive-anaplastic-variant-of-diffuse-large-b-cell-lymphoma-frequency-and-association-with-clinicopathological-parameters/2026-01-20T19:17:24+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-hematological-malignancies-in-the-families-of-patients-treated-for-nodular-lymphocyte-predominant-hodgkin-lymphoma/2024-02-16T20:08:14+00:00https://lymphoma-stg.clarovantdigital.com/library/when-is-a-second-car-t-cell-infusion-feasible-for-patients-who-failed-prior-car-t-cell-therapy/2024-02-16T20:06:58+00:00https://lymphoma-stg.clarovantdigital.com/library/axi-cel-treatment-outcomes-correlate-with-response-to-prior-therapy-in-refractory-large-b-cell-lymphoma/2025-05-26T19:02:22+00:00https://lymphoma-stg.clarovantdigital.com/library/challenges-and-opportunities-in-the-management-of-diffuse-large-bcell-lymphoma-in-older-patients/2024-02-16T19:56:08+00:00https://lymphoma-stg.clarovantdigital.com/library/therapeutic-options-for-patients-with-tp53-deficient-chronic-lymphocytic-leukemia-narrative-review/2024-02-16T19:54:31+00:00https://lymphoma-stg.clarovantdigital.com/library/daratumumab-monotherapy-for-patients-with-relapsed-or-refractory-natural-killer-t-cell-lymphoma-nasal-type-an-open-label-single-arm-multicenter-phase-2-study/2026-01-15T16:48:10+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-histopathological-patterns-of-hodgkin-lymphoma-and-treatment-outcomes-at-a-tertiary-cancer-center-in-ethiopia/2024-02-16T19:49:41+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-pet-ct-imaging-parameters-for-prediction-of-treatment-outcome-in-hodgkin-and-diffuse-large-b-cell-lymphoma-a-systematic-review/2022-02-02T22:38:47+00:00https://lymphoma-stg.clarovantdigital.com/library/adverse-events-and-economic-burden-among-patients-receiving-systemic-treatment-for-mantle-cell-lymphoma-a-real-world-retrospective-cohort-study/2024-02-16T19:41:01+00:00https://lymphoma-stg.clarovantdigital.com/library/promising-5-year-outcomes-shown-with-car-t-cell-therapy-in-r-r-b-cell-lymphoma/2024-02-16T19:38:26+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-infertility-in-female-adolescents-and-young-adults-with-cancer-a-population-based-cohort-study/2024-02-16T19:32:27+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-including-cns-relapse-in-a-population-based-cohort-of-4243-patients-in-sweden/2022-02-02T22:38:48+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-l1-and-ido1-are-potential-targets-for-treatment-in-patients-with-primary-diffuse-large-b-cell-lymphoma-of-the-cns/2024-02-16T19:27:39+00:00https://lymphoma-stg.clarovantdigital.com/library/hematopoietic-stem-cell-transplantation-in-waldenstroms-macroglobulinemia/2024-02-16T19:26:12+00:00https://lymphoma-stg.clarovantdigital.com/library/genome-wide-association-study-identifies-risk-loci-for-progressive-chronic-lymphocytic-leukemia/2025-12-15T21:47:22+00:00https://lymphoma-stg.clarovantdigital.com/library/robust-a-phase-iii-study-of-lenalidomide-plus-r-chop-versus-placebo-plus-r-chop-in-previously-untreated-patients-with-abc-type-diffuse-large-b-cell-lymphoma/2024-02-16T01:02:58+00:00https://lymphoma-stg.clarovantdigital.com/library/final-genuine-data-support-addition-of-ublituximab-to-btk-inhibitors-in-relapsed-refractory-high-risk-cll/2026-01-06T21:13:37+00:00https://lymphoma-stg.clarovantdigital.com/library/building-on-btk-inhibition-in-mcl/2024-02-15T22:18:22+00:00https://lymphoma-stg.clarovantdigital.com/library/eradication-therapy-may-be-effective-for-helicobacter-pylori-negative-gastric-malt-lymphoma/2026-01-15T16:47:38+00:00https://lymphoma-stg.clarovantdigital.com/library/simplified-geriatric-assessment-in-older-patients-with-diffuse-large-b-cell-lymphoma-the-prospective-elderly-project-of-the-fondazione-italiana-linfomi/2024-02-15T22:04:20+00:00https://lymphoma-stg.clarovantdigital.com/library/richter-syndrome/2024-02-15T22:03:17+00:00https://lymphoma-stg.clarovantdigital.com/library/ascorbic-acid-vitamin-c-synergistically-enhances-the-therapeutic-effect-of-targeted-therapy-in-chronic-lymphocytic-leukemia/2022-02-02T22:38:50+00:00https://lymphoma-stg.clarovantdigital.com/library/the-patient-experience-of-abvd-treatment-in-hodgkin-lymphoma-a-retrospective-cohort-study-of-patient-reported-distress/2024-02-15T22:01:04+00:00https://lymphoma-stg.clarovantdigital.com/library/moxetumomab-pasudotox-in-heavily-pre-treated-patients-with-relapsed-refractory-hairy-cell-leukemia-hcl-long-term-follow-up-from-the-pivotal-trial/2026-01-14T21:33:00+00:00https://lymphoma-stg.clarovantdigital.com/library/5-hydroxymethylcytosine-profiles-of-cfdna-are-highly-predictive-of-r-chop-treatment-response-in-diffuse-large-b-cell-lymphoma-patients/2026-01-15T16:47:07+00:00https://lymphoma-stg.clarovantdigital.com/library/icu-admissions-after-car-t-therapy-likely-to-due-to-crs-and-neurotoxicity/2024-02-15T21:30:11+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-rituximab-minichop-compared-with-subcutaneous-rituximab-minichop-plus-lenalidomide-in-diffuse-large-b-cell-lymphoma-for-patients-age-80-years-or-older/2024-02-15T21:29:06+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-for-mantle-cell-lymphoma-at-first-relapse-a-united-kingdom-realworld-analysis-of-outcomes-in-211-patients/2024-02-15T21:28:02+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-risk-adapted-therapy-for-pediatric-hodgkin-lymphoma-on-risk-of-long-term-morbidity-a-report-from-the-childhood-cancer-survivor-study/2024-02-15T21:26:22+00:00https://lymphoma-stg.clarovantdigital.com/library/delayed-covid-19-respiratory-failure-in-lymphoma-patients-on-rituximab-based-chemoimmunotherapy/2024-01-29T22:37:23+00:00https://lymphoma-stg.clarovantdigital.com/library/outpatient-car-t-cell-therapy-safe-effective-for-advanced-large-b-cell-lymphoma/2024-01-29T22:36:32+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-primary-mediastinal-b-cell-lymphoma-treated-with-dose-adjusted-r-epoch-regimen-a-single-centre-experience/2024-01-29T22:35:01+00:00https://lymphoma-stg.clarovantdigital.com/library/r-chop-resistance-in-diffuse-large-b-cell-lymphoma-biological-and-molecular-mechanisms/2025-06-12T19:28:50+00:00https://lymphoma-stg.clarovantdigital.com/library/current-opinion-on-pixantrone-in-the-treatment-of-non-hodgkin-b-cell-lymphoma/2026-01-15T14:18:01+00:00https://lymphoma-stg.clarovantdigital.com/library/inhibitor-of-b-rafv600e-mutation-as-a-treatment-option-for-hairy-cell-leukemia-with-deep-neutropenia-and-infectious-complications/2022-02-02T22:38:53+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-plus-high-dose-chemotherapy-megachoep-or-conventional-chemotherapy-choep-14-in-young-high-risk-patients-with-aggressive-b-cell-lymphoma-10-year-follow-up-of-a-randomised-open-label-p/2024-01-29T22:27:36+00:00https://lymphoma-stg.clarovantdigital.com/library/frederick-locke-md-and-michael-jain-md-phd-on-why-some-patients-with-lymphoma-do-not-respond-to-cellular-immunotherapy/2024-01-29T22:26:50+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-in-relapsed-or-refractory-b-cell-malignancies-bruin-a-phase-1-2-study/2024-01-29T22:19:33+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-obinutuzumab-alone-or-with-chemotherapy-in-previously-untreated-or-relapsed-refractory-chronic-lymphocytic-leukaemia-patients-final-analysis-of-the-phase-iiib-green-study/2024-01-29T22:18:42+00:00https://lymphoma-stg.clarovantdigital.com/library/dermatological-considerations-in-the-diagnosis-and-treatment-of-marginal-zone-lymphomas/2022-02-02T22:38:54+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-cell-constitution-in-the-tumor-microenvironment-predicts-the-outcome-in-diffuse-large-b-cell-lymphoma/2024-01-29T22:16:08+00:00https://lymphoma-stg.clarovantdigital.com/library/current-and-emerging-therapeutic-options-for-hairy-cell-leukemia-variant/2024-01-29T22:15:04+00:00https://lymphoma-stg.clarovantdigital.com/library/umbralisib-a-dual-pi3k-ck1-inhibitor-in-patients-with-relapsed-or-refractory-indolent-lymphoma/2024-01-29T22:13:54+00:00https://lymphoma-stg.clarovantdigital.com/library/pathogenesis-of-follicular-lymphoma-genetics-to-the-microenvironment-to-clinical-translation/2024-01-29T22:05:46+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-r-ceop-show-curative-potential-in-patients-with-dlbcl-and-a-contraindication-to-anthracyclines/2024-01-29T22:04:48+00:00https://lymphoma-stg.clarovantdigital.com/library/copanlisib-for-the-treatment-of-malignant-lymphoma-clinical-experience-and-future-perspectives/2024-01-29T22:04:14+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-shows-benefits-in-patients-with-r-r-indolent-non-hodgkin-lymphoma/2024-01-29T22:01:19+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-followed-by-avd-in-untreated-early-unfavorable-and-advanced-stage-classical-hodgkin-lymphoma-2/2024-01-29T21:56:59+00:00https://lymphoma-stg.clarovantdigital.com/library/double-expressor-phenotype-bcl-2-c-myc-co-expression-of-diffuse-large-b-cell-lymphoma-and-its-clinicopathological-correlation/2025-12-15T21:46:36+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-ibrutinib-dose-reductions-discontinuations-in-cll/2024-01-29T21:45:44+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-guided-omission-of-radiotherapy-in-early-stage-unfavourable-hodgkin-lymphoma-ghsg-hd17-a-multicentre-open-label-randomised-phase-3-trial/2024-01-29T21:43:09+00:00https://lymphoma-stg.clarovantdigital.com/library/unmarried-or-less-educated-patients-with-mantle-cell-lymphoma-are-less-likely-to-undergo-a-transplant-leading-to-lower-survival/2024-01-29T21:41:38+00:00https://lymphoma-stg.clarovantdigital.com/library/double-hit-signature-with-tp53-abnormalities-predicts-poor-survival-in-patients-with-germinal-center-type-diffuse-large-b-cell-lymphoma-treated-with-r-chop/2024-01-29T21:40:44+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-prognostic-biomarker-testing-treatment-patterns-and-dosing-among-1461-patients-pts-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-from-the-informcll-prospective-o/2025-03-03T21:09:10+00:00https://lymphoma-stg.clarovantdigital.com/library/evolving-management-strategies-for-lymphomas-during-the-covid-19-pandemic/2024-01-29T21:37:20+00:00https://lymphoma-stg.clarovantdigital.com/library/the-pi3k-selective-inhibitor-idelalisib-induces-t-and-nk-cell-dysfunction-independently-of-b-cell-malignancy-associated-immunosuppression/2024-01-29T21:36:33+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-results-from-zuma-2-trial-investigating-kte-x19-in-r-r-mantle-cell-lymphoma/2024-01-29T21:25:29+00:00https://lymphoma-stg.clarovantdigital.com/library/liso-cel-administration-in-relapsed-refractory-lbcl-successful-in-inpatient-outpatient-settings-at-nonuniversity-centers/2024-01-29T21:23:27+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-aspects-of-primary-mucosaassociated-lymphoid-tissue-lymphoma-of-the-salivary-gland-a-retrospective-singlecenter-analysis-of-72-cases/2024-01-29T21:22:02+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-transplantation-after-pd-1-blockade-for-classic-hodgkin-lymphoma/2024-01-29T21:20:29+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-showcase-favorable-outcomes-and-less-toxicity-with-axi-cel-in-large-b-cell-lymphoma/2024-01-29T21:18:17+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-bruton-tyrosine-kinase-inhibitor-on-efficacy-of-adjuvanted-recombinant-hepatitis-b-and-zoster-vaccines/2024-01-29T21:17:19+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-older-patients-with-follicular-lymphoma-using-individual-data-from-5922-patients-in-18-randomized-controlled-trials/2024-01-29T21:15:51+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-axi-cel-elicits-74-cr-rate-in-high-risk-large-b-cell-lymphoma/2024-01-29T21:15:03+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-anaplastic-large-cell-lymphoma-alcl-in-cases-of-late-seroma-formation-after-breast-implant-insertion/2024-01-29T21:12:02+00:00https://lymphoma-stg.clarovantdigital.com/library/concurrent-chronic-lymphocytic-leukemia-and-covid-19-a-comprehensive-review-of-epidemiological-diagnostic-and-therapeutic-challenges/2024-01-29T21:10:43+00:00https://lymphoma-stg.clarovantdigital.com/library/early-progression-of-disease-in-follicular-lymphoma-is-a-robust-correlate-but-not-a-surrogate-for-overall-survival/2024-01-29T21:09:50+00:00https://lymphoma-stg.clarovantdigital.com/library/what-are-the-options-for-cell-based-therapies-in-mantle-cell-lymphoma/2024-01-29T21:04:01+00:00https://lymphoma-stg.clarovantdigital.com/library/oral-pi3k-inhibitor-for-the-management-of-people-with-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-a-narrative-review-on-duvelisib/2025-03-03T21:08:12+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-obinutuzumab-and-venetoclax-to-ibrutinib-overcomes-resistance-in-r-r-mcl-shows-activity-in-newly-diagnosed-mcl/2024-01-29T19:38:43+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-plus-gemcitabine-and-oxaliplatin-r-gemox-in-refractory-relapsed-diffuse-large-b-cell-lymphoma-a-real-life-study-in-patients-ineligible-for-autologous-stem-cell-transplantation/2024-01-29T19:33:40+00:00https://lymphoma-stg.clarovantdigital.com/library/a-review-of-chimeric-antigen-receptor-t-cell-therapy-for-myeloma-and-lymphoma/2024-01-29T19:27:06+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-in-germany-with-standard-of-care-axi-cel-and-tisa-cel-in-patients-with-large-b-cell-lymphoma/2026-01-14T22:36:34+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-advances-in-molecular-biology-prognostication-and-treatment-approaches/2024-01-29T19:24:05+00:00https://lymphoma-stg.clarovantdigital.com/library/maternal-and-neonatal-outcomes-in-80-patients-diagnosedwith-non-hodgkin-lymphoma-during-pregnancy-results-fromthe-international-network-of-cancer-infertility-and-pregnancy/2024-01-29T19:21:53+00:00https://lymphoma-stg.clarovantdigital.com/library/chn1-is-a-novel-prognostic-marker-for-diffuse-large-b-cell-lymphoma/2022-02-02T22:39:00+00:00https://lymphoma-stg.clarovantdigital.com/library/low-dose-aspirin-associated-with-reduced-likelihood-of-non-hodgkin-lymphoma-diagnosis/2024-01-29T19:19:44+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-vaccines-for-patients-with-haematological-conditions/2024-01-29T19:13:24+00:00https://lymphoma-stg.clarovantdigital.com/library/excellent-outcome-for-pediatric-patients-with-high-risk-hodgkin-lymphoma-treated-with-brentuximab-vedotin-and-risk-adapted-residual-node-radiation/2024-01-29T19:11:31+00:00https://lymphoma-stg.clarovantdigital.com/library/upfront-low-dose-chemo-immunotherapy-safe-effective-for-elderly-with-cll/2024-01-29T19:04:23+00:00https://lymphoma-stg.clarovantdigital.com/library/mitigating-peripheral-neuropathy-is-still-focus-of-ongoing-research-in-hodgkin-lymphoma/2024-01-29T19:02:31+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-new-targets-and-novel-therapies/2024-01-29T18:57:54+00:00https://lymphoma-stg.clarovantdigital.com/library/pediatric-classical-hodgkin-lymphoma/2022-02-02T22:39:01+00:00https://lymphoma-stg.clarovantdigital.com/library/checkpoint-blockade-treatment-may-sensitize-hodgkin-lymphoma-to-subsequent-therapy/2025-05-30T13:45:46+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-of-hairy-cell-leukemia-with-cladribine-followed-by-rituximab-consolidation-significantly-improves-leukemia-free-survival/2024-01-24T01:02:03+00:00https://lymphoma-stg.clarovantdigital.com/library/gut-microbiota-in-untreated-diffuse-large-b-cell-lymphoma-patients/2024-01-24T01:00:26+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-versus-brentuximab-vedotin-in-relapsed-or-refractory-classical-hodgkin-lymphoma-keynote-204-an-interim-analysis-of-a-multicentre-randomised-open-label-phase-3-study/2026-01-15T13:55:55+00:00https://lymphoma-stg.clarovantdigital.com/library/product-composition-immune-biomarkers-linked-to-car-t-efficacy/2026-01-15T16:46:35+00:00https://lymphoma-stg.clarovantdigital.com/library/the-association-between-deaths-from-infection-and-mutations-of-the-braf-fbxw7-nras-and-xpo1-genes-a-report-from-the-lrf-cll4-trial/2024-01-23T22:46:56+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiology-pathology-and-clinical-features-of-dlbcl/2024-01-23T22:45:34+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-the-bnt162b2-mrna-covid-19-vaccine-in-patients-with-chronic-lymphocytic-leukemia/2024-01-23T22:43:23+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-agents-and-regimens-for-hematological-malignancies-recent-updates-from-2020-ash-annual-meeting/2024-01-23T22:40:25+00:00https://lymphoma-stg.clarovantdigital.com/library/are-we-nearer-to-effective-management-of-elderly-patients-with-lymphoma/2022-02-02T22:39:03+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiology-treatment-patterns-and-survival-of-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-in-taiwan-20062015/2025-03-03T21:07:22+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-treatment-naive-chronic-lymphocytic-leukemia/2024-01-23T22:32:12+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-with-ublituximab-plus-ibrutinib-versus-ibrutinib-alone-a-phase-iii-randomised-trial-genuine-for-patients-with-relapsed-or-refractory-high-risk-cll/2024-01-23T22:22:56+00:00https://lymphoma-stg.clarovantdigital.com/library/current-and-future-treatment-strategies-in-chronic-lymphocytic-leukemia/2025-05-13T13:48:27+00:00https://lymphoma-stg.clarovantdigital.com/library/hypomagnesemia-at-the-time-of-autologous-stem-cell-transplantation-for-patients-with-diffuse-large-b-cell-lymphoma-is-associated-with-an-increased-risk-of-failure/2024-01-23T22:19:55+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-combined-with-chemotherapy-in-patients-with-newly-diagnosed-early-stage-unfavorable-risk-hodgkin-lymphoma/2024-01-23T22:15:15+00:00https://lymphoma-stg.clarovantdigital.com/library/short-diagnosis-to-treatment-interval-is-associated-with-higher-circulating-tumor-dna-levels-in-diffuse-large-b-cell-lymphoma/2024-01-23T22:14:09+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-inhospital-stay-and-higher-mortality-after-covid19-among-patients-with-nonhodgkin-lymphoma-treated-with-bcell-depleting-immunotherapy/2024-01-15T23:21:11+00:00https://lymphoma-stg.clarovantdigital.com/library/change-in-health-behaviors-affect-quality-of-life-in-lymphoma-survivors/2022-02-02T22:39:04+00:00https://lymphoma-stg.clarovantdigital.com/library/antibiotic-treatment-is-associated-with-decreased-response-to-car-t-cell-therapy/2024-01-15T23:18:52+00:00https://lymphoma-stg.clarovantdigital.com/library/educational-theme-efficacy-and-safety-of-car-t-cell-therapy-in-older-patients-a-multicenter-matched-control-cohort-study/2024-01-15T23:17:32+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-clinical-outcome-in-a-randomized-phase-ii-study-of-anti-pd-1-camrelizumab-plus-decitabine-in-relapsed-refractory-hodgkin-lymphoma/2026-01-15T16:46:06+00:00https://lymphoma-stg.clarovantdigital.com/library/realworld-evidence-of-tisagenlecleucel-for-the-treatment-of-relapsed-or-refractory-large-bcell-lymphoma/2024-02-26T22:23:56+00:00https://lymphoma-stg.clarovantdigital.com/library/epigenetics-of-indolent-lymphoma-and-how-it-drives-novel-therapeutic-approaches-focus-on-ezh2-targeted-drugs/2024-01-15T23:13:47+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-pancreatic-lymphoma-recommendations-for-diagnosis-and-management/2024-01-15T23:12:11+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-benefit-of-rituximab-maintenance-post-autograft-in-patients-with-relapsed-follicular-lymphoma-12-year-follow-up-of-the-ebmt-lymphoma-working-party-lym1-trial/2024-01-15T23:11:09+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-or-r-bac-prolong-pfs2-in-relapsed-refractory-mantle-cell-lymphoma/2024-01-15T23:10:09+00:00https://lymphoma-stg.clarovantdigital.com/library/low-risk-of-lymphoma-but-not-other-cancers-with-topical-calcineurin-inhibitors/2024-01-15T23:08:21+00:00https://lymphoma-stg.clarovantdigital.com/library/the-value-of-complete-remission-according-to-positron-emission-tomography-prior-to-autologous-stem-cell-transplantation-in-lymphoma-a-population-based-study-showing-improved-outcome/2024-01-15T23:04:19+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-3-randomized-study-of-ofatumumab-combined-with-bendamustine-in-rituximabrefractory-inhl-complement-a-b-study/2025-12-15T20:17:21+00:00https://lymphoma-stg.clarovantdigital.com/library/vemurafenib-plus-rituximab-in-refractory-or-relapsed-hairy-cell-leukemia/2025-07-03T17:24:50+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-recognition-of-markers-for-targeted-therapy/2024-01-15T22:59:25+00:00